Page last updated: 2024-11-04

imipramine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Imipramine is a tricyclic antidepressant (TCA) that was first synthesized in 1957. Its mechanism of action involves inhibiting the reuptake of serotonin and norepinephrine in the brain, leading to increased levels of these neurotransmitters in the synaptic cleft. Imipramine has been shown to be effective in treating major depressive disorder, generalized anxiety disorder, and panic disorder. It is also used off-label for the treatment of obsessive-compulsive disorder, enuresis, and chronic pain. The importance of imipramine lies in its pioneering role in the development of antidepressants. It was one of the first drugs shown to be effective in treating depression, paving the way for the development of other antidepressants. However, imipramine is associated with several side effects, including dry mouth, constipation, blurred vision, and drowsiness. It can also cause serious adverse effects, such as cardiac arrhythmias and seizures, especially at high doses. Imipramine remains a valuable tool in the treatment of depression, particularly in patients who have not responded to other antidepressants. However, its use is typically reserved for severe cases due to its potential for serious side effects. Extensive research has been conducted on imipramine to understand its mechanism of action, its effectiveness in treating various conditions, and its potential risks. Studies have examined its pharmacokinetic properties, its effects on neurotransmitter levels, and its clinical efficacy in different populations. Research is ongoing to explore new uses for imipramine and to develop safer and more effective antidepressants.'

Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3696
CHEMBL ID11
CHEBI ID47499
SCHEMBL ID34282
MeSH IDM0011056

Synonyms (210)

Synonym
janimine
BIDD:GT0116
AB00053486-15
BRD-K38436528-003-05-5
gtpl357
2,2'-(3-dimethylaminopropylimino)bibenzyl
n-(3-dimethylaminopropyl)-o-iminodibenzyl
5h-dibenz(b, 5-(3-(dimethylamino)propyl)-10,11-dihydro-
2,2'-(3-dimethylaminopropylimino)dibenzyl
1-(3-dimethylaminopropyl)-4,3,6,7-dibenzazepine
timolet
n-(.gamma.-dimethylaminopropyl)iminodibenzyl
dynaprin
imizine
imizin
5-(3-(dimethylamino)propyl)-10,f)azepine
psychoforin
melipramin
nsc-169866
intalpram
promiben
imiprin
tofranil, base
nelipramin
antideprin
5,e)azepine
berkomine
censtin
imidobenzyle
wln: t c676 bn&t&j b3n1&1
5h-dibenz[b, 5-[3-(dimethylamino)propyl]-10,11-dihydro-
5h-dibenz[b, 10,11-dihydro-n,n-dimethyl-
censtim
5,e]azepine
dpid
impramine
imizinum
iramil
eupramin
irmin
tofranil (free base)
sk-pramine
surplix
dimipressin
5h-dibenz(b, 10,11-dihydro-5-(3-(dimethylamino)propyl)-
nsc169866
5-(3-dimethylaminopropyl)-10,f)azepine
imavate
melipramine
dyna-zina
5h-dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-n,n-dimethyl-
DIVK1C_000559
KBIO1_000559
einecs 200-042-1
5-(3-(dimethylamino)propyl)-10,11-dihydro-5h-dibenz(b,f)azepine
hsdb 3100
5h-dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)propyl)-
imipramina [inn-spanish]
ccris 9173
brn 0256892
5-(3-dimethylaminopropyl)-10,11-dihydro-5h-dibenzo(b,f)azepine
5h-dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-n,n-dimethyl-
nsc 169866
5,6-dihydro-n-(3-(dimethylamino)propyl)-11h-dibenz(b,e)azepine
imipraminum [inn-latin]
imipramina [italian]
5h-dibenz(b,f)azepine, 5-(3-(dimethylamino)propyl)-10,11-dihydro-
imipramine [inn:ban]
1-(3-dimethylaminopropyl)-4,5-dihydro-2,3,6,7-dibenzazepine
SPECTRUM_000915
NCGC00015563-01
lopac-i-7379
NCGC00015563-02
cas-113-52-0
BPBIO1_000313
BSPBIO_000283
IDI1_000559
PRESTWICK2_000072
BSPBIO_002172
PRESTWICK3_000072
LOPAC0_000702
SPECTRUM5_000864
AB00053486
C07049
50-49-7
imipramine
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-n,n-dimethyl-propan-1-amine
10,11-dihydro-n,n-dimethyl-5h-dibenz[b,f]azepine-5-propanamine
tofranil (hydrochloride)
janimine (hydrochloride)
DB00458
tofranil (tn)
10,11-dihydro-5-(3-(dimethylamino)propyl)-5h-dibenz[b,f]azepine
OPREA1_200908
imipraminum
CHEBI:47499 ,
NCGC00024253-04
imipramin
3-(10,11-dihydro-5h-dibenzo[b,f]azepin-5-yl)-n,n-dimethylpropan-1-amine
n-(gamma-dimethylaminopropyl)iminodibenzyl
3-(5h-dibenzo[b,f]azepin-5-yl)-n,n-dimethylpropan-1-amine
5-[3-(dimethylamino)propyl]-10,11-dihydro-5h-dibenz[b,f]azepine
KBIO3_001392
KBIO2_003963
KBIO2_006531
KBIO2_001395
KBIOGR_000391
KBIOSS_001395
SPBIO_002204
SPBIO_001059
PRESTWICK1_000072
PRESTWICK0_000072
NINDS_000559
SPECTRUM3_000466
SPECTRUM2_000990
SPECTRUM4_000016
NCGC00015563-03
NCGC00024253-03
inchi=1/c19h24n2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11h,7,12-15h2,1-2h
HMS2089G08
NCGC00015563-09
L000739
sermonil
trimipramine maleate impurity, imipramine-
cristalia
org-2463
CHEMBL11 ,
D08070
imipramine (inn)
bdbm50010859
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-n,n-dimethylpropan-1-amine
NCGC00015563-07
ixx ,
tox21_110174
cas-50-49-7
dtxsid1043881 ,
dtxcid9023881
declomipramine
AKOS016010320
CCG-36485
NCGC00015563-11
NCGC00015563-08
NCGC00015563-06
NCGC00015563-04
NCGC00015563-05
NCGC00015563-10
FT-0670319
unii-ogg85sx4e4
imipramina
ogg85sx4e4 ,
3-(10,11-dihydro-5h-dibenzo[b,f]azepin-5-yl)-n,n-dimethyl-1-propanamine
imipramine [mart.]
trimipramine maleate impurity, imipramine- [usp impurity]
imipramine [vandf]
imipramine [who-dd]
imipramine [mi]
clomipramine hydrochloride impurity b [ep impurity]
imipramine [hsdb]
imipramine [inn]
trimipramine maleate impurity d [ep impurity]
SCHEMBL34282
NCGC00015563-13
tox21_110174_1
surplix (salt/mix)
5h-dibenz[b,f]azepine, 5-[3-(dimethylamino)propyl]-10,11-dihydro-
imizinum (salt/mix)
tofranil (salt/mix)
eupramin (salt/mix)
imizine (salt/mix)
imavate (salt/mix)
imizin (salt/mix)
psychoforin (salt/mix)
sk-pramine (salt/mix)
3-(10,11-dihydro-5h-dibenzo[b,f]azepin-5-yl)-n,n-dimethyl-1-propanamine #
g-22355 (salt/mix)
W-109253
STL416211
AB00053486_17
AB00053486_16
FT-0697093
(3-{2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl}propyl)dimethylamine
tofranil base
MRF-0000592
SBI-0050680.P004
3-(10,11-dihydro-5h-dibenz[b,f]azepin-5-yl)propyldimethylamine
3-(10,11-dihydro-5h-dibenzo[b,f]azepin-5-yl)-n,n-dimethylpropan-1-amine;3-(10,11-dihydro-5h-dibenzo[b,f]azepin-5-yl)-n,n-dimethylpropan-1-amine
112898-42-7
SY246340
2241983-10-6
mfcd31699979
n,n-dimethyl-10,11-dihydro-5h-dibenzo[b,f]azepine-5-propanamine-2,8-d2
clomipramine ep impurity b; 10,11-dihydro-n,n-dimethyl-5h-dibenz[b,f]azepine-5-propanamine
Q58396
BRD-K38436528-003-15-4
SDCCGSBI-0050680.P005
NCGC00015563-25
EN300-708790
(3-{2-azatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl}propyl)dimethylamine
HY-B1490A
CS-0013621
imipramine-d3 hydrochloride 98 atom % d
3-(5h-dibenzo(b,f)azepin-5-yl)-n,n-dimethylpropan-1-amine
trimipramine maleate impurity, imipramine-(usp impurity)
10,11-dihydro-n,n-dimethyl-5h-dibenz(b,f)azepine-5-propanamine
imipramina (inn-spanish)
imipraminum (inn-latin)
trimipramine maleate impurity d (ep impurity)
3-(10,11-dihydro-5h-dibenzo(b,f)azepin-5-yl)-n,n-dimethylpropan-1-amine
imipramine (mart.)
n06aa02

Research Excerpts

Overview

Imipramine (IMI) is a tricyclic synthetic antidepressant that is used to treat chronic psychiatric disorders, including depression and neuropathic pain. It has been reported to inhibit the progression of highly metastatic non-small cell lung cancer.

ExcerptReferenceRelevance
"Imipramine is a tricyclic antidepressant that possesses anti-inflammatory activity and has been reported to inhibit the progression of highly metastatic non-small cell lung cancer."( Imipramine Induces Apoptosis and Inhibits the Metastatic Potential of Triple-negative Breast Cancer Cells.
Chen, SK; Chen, WT; Hsu, FT; Lee, W; Li, YC, 2023
)
3.07
"Imipramine (IMI), which is a tricyclic antidepressant, has also been shown to has antineoplastic effect."( Effect of Imipramine on radiosensitivity of Prostate Cancer: An In Vitro Study.
Barlaz Us, S; Comelekoglu, U; Sogut, F; Yalin, S; Yetkin, D; Yildirim, M; Yilmaz, SN, 2019
)
1.64
"Imipramine (IMI) is a frequently prescribed tricyclic antidepressant and widely detected in the natural waters, while the environmental fate of IMI is yet poorly understood. "( Mechanistic investigation of humic substances assisted photodegradation of imipramine under simulated sunlight.
Chen, Y; Fang, Y; Grivin, VP; Liu, L; Luo, F; Parkhats, MV; Pozdnyakov, IP; Tyutereva, YE; Wan, D, 2020
)
2.23
"Imipramine (IMI) is a tricyclic synthetic antidepressant that is used to treat chronic psychiatric disorders, including depression and neuropathic pain. "( Imipramine Inhibits Migration and Invasion in Metastatic Castration-Resistant Prostate Cancer PC-3 Cells via AKT-Mediated NF-κB Signaling Pathway.
Kim, MJ; Kim, YT; Lim, EY; Park, J, 2020
)
3.44
"Imipramine is an antidepressant that increases the release of neurotransmitters."( Co-administration of imipramine and doxorubicin reduces the survival rate and body weight of mice.
Aldubayan, M; Alhowail, A; Chigurupati, S; Elgharabawy, R, 2020
)
1.6
"Imipramine is a tricyclic antidepressant used to treat enuresis with initial success rates are high as 50% but some studies record a high relapse rate and it has a cardiotoxic effect when overdosed."( Can the combined treatment of solifenacin and imipramine has a role in desmopressin refractory monosymptomatic nocturnal enuresis? A prospective double-blind randomized placebo-controlled study.
Elawady, H; Mahmoud, MA; Samir, M, 2021
)
1.6
"Imipramine is a kind of tricyclic antidepressant with reported anti-inflammatory and anti-oxidant effects in the brain."( Imipramine alleviates memory impairment and hippocampal apoptosis in STZ-induced sporadic Alzheimer's rat model: Possible contribution of MAPKs and insulin signaling.
Ahmadiani, A; Askari, S; Dargahi, L; Ghasemi, R; Javadpour, P; Rashidi, FS, 2021
)
2.79
"Imipramine is a tricyclic antidepressant (TCA) drug that is sometimes used to treat neuropathic pain. "( Synergistic effect between imipramine and citicoline upon induction of analgesic and antidepressant effects in mice.
Khakpai, F; Ramezanikhah, M; Valizadegan, F; Zarrindast, MR, 2021
)
2.36
"Imipramine (IMP) is a FDA approved tricyclic antidepressant drug with lysosomotropic characteristics."( Imipramine blocks acute silicosis in a mouse model.
Biswas, R; Harkema, JR; Holian, A; Jessop, F; Trout, KL, 2017
)
2.62
"Imipramine is a tricyclic medication that has been used for the treatment of depression and other mood disorders. "( Imipramine-induced hyperpigmentation.
Bicknell, LM; Fernandez, M; McFaddin, CL; Parekh, P, 2017
)
3.34
"Imipramine is a tricyclic antidepressant inhibitor of norepinephrine and serotonin neuronal reuptake. "( Involvement of α1B-adrenoceptors in the anti-immobility effect of imipramine in the tail suspension test.
Pupo, AS; Ribeiro, CA, 2015
)
2.1
"Imipramine blue (IB) is a newly identified anti-invasive compound that effectively inhibits glioma invasion."( Imipramine blue halts head and neck cancer invasion through promoting F-box and leucine-rich repeat protein 14-mediated Twist1 degradation.
Arbiser, JL; Hsu, WH; Su, YH; Wang, CC; Yang, MH; Yang, WH, 2016
)
2.6
"Imipramine seems to be a better cost-utility antidepressant option for treating depressive disorders in primary care."( Fluoxetine and imipramine: are there differences in cost-utility for depression in primary care?
Haro, JM; Peñarrubia, MT; Pinto-Meza, A; Serrano-Blanco, A; Suárez, D, 2009
)
2.15
"Imipramine is a tertiary amine, which may act both in the periphery and/or pass through the blood-brain barrier (BBB) in unionized form and exhibit a central effect."( Synthesis of a quaternary bis derivative of imipramine as a novel compound with potential anti-enuretic effect.
Faizi, M; Jamali, B; Kobarfard, F; Roodsari, MS; Shafaghi, B; Soleymani, Z, 2009
)
1.34
"Imipramine is a tricyclic antidepressant drug that is one of those used widely for primary enuresis nocturna, attention deficit hyperactivity disorder, depression, and anxiety disorder in children and adolescents."( A case of imipramine-associated immune thrombocytopenia.
Aksoy, A; Erduran, E; Gedik, Y,
)
1.26
"Imipramine is a commonly used tricyclic antidepressant (TCA)."( Imipramine treatment improves cognitive outcome associated with enhanced hippocampal neurogenesis after traumatic brain injury in mice.
Farahvar, A; Han, X; Huang, JH; Samadani, U; Smith, DH; Tong, J; Wang, E; Yang, J; Zhang, J, 2011
)
2.53
"Imipramine is a useful treatment for enuresis when everything else has failed, especially among older children. "( Imipramine for therapy resistant enuresis: a retrospective evaluation.
Gepertz, S; Nevéus, T, 2004
)
3.21
"Imipramine (IP) is an amphiphilic amine that is clinically useful as a tricyclic antidepressant. "( Interaction of electrically neutral and cationic forms of imipramine with liposome and erythrocyte membranes.
Ahyayauch, H; Bennouna, M; Goñi, FM, 2004
)
2.01
"Imipramine is a well-established tricyclic antidepressant which was first approved for the treatment of depression in the late fifties. "( Exacerbation of harmaline-induced tremor by imipramine.
Al Deeb, S; Al Moutaery, K; Arshaduddin, M; Kadasah, S; Tariq, M, 2005
)
2.03
"Imipramine is a rare cause of gray-blue facial pigmentation. "( Imipramine-induced facial pigmentation: case report and literature review.
Lin, AN; Metelitsa, AI; Nguyen, GK, 2005
)
3.21
"Imipramine is an effective antiarrhythmic agent against ventricular arrhythmias and complex features of ventricular premature depolarizations at plasma concentrations ranging from 100 to 400 ng per ml. "( Cardiac and antiarrhythmic effects of imipramine in patients with ventricular arrhythmias.
Giardina, EG, 1984
)
1.98
"Imipramine is an effective antiarrhythmic drug with sustained duration of action, although its elimination t1/2 is relatively short."( Antiarrhythmic plasma-concentration range of imipramine against ventricular premature depolarizations.
Alchevsky, D; Bigger, JT; Brem, R; Giardina, EG; Louie, M, 1983
)
1.25
"Imipramine is a tricyclic antidepressant drug that also exhibits antiarrhythmic effects and whose clinical spectrum of activity is similar to that of quinidine. "( Imipramine blocks rapidly activating and delays slowly activating K+ current activation in guinea pig ventricular myocytes.
Delpón, E; Elizalde, A; Pérez, O; Sánchez-Chapula, J; Tamargo, J; Valenzuela, C, 1994
)
3.17
"Imipramine is an effective antidepressant agent that blocks the reuptake of monoamines. "( Chronic imipramine treatment induces downregulation of alpha-2 receptors in rat's locus coeruleus and A2 region of the tractus solitarius.
Hoffman, T; Jiménez-Rivera, CA; Santacana, G; Savage, DD; Segarra, O; Weiss, GK, 1996
)
2.17
"Imipramine is an antidepressant drug that is rarely associated with mild liver function abnormalities. "( Hepatic failure associated with imipramine therapy.
Ilan, Y; Reynes, M; Samuel, D; Tur-Kaspa, R, 1996
)
2.02
"Imipramine is a tricyclic antidepressant known to be bound in the serum primarily by alpha-1-acid glycoprotein. "( Altered disposition and antidepressant activity of imipramine in transgenic mice with elevated alpha-1-acid glycoprotein.
Baumann, H; Dewey, MJ; Fincher, TK; Holladay, JW; Yoo, SD, 1996
)
1.99
"Imipramine is a tricyclic antidepressant drug with a considerable hepatic first-pass metabolism resulting in highly variable pharmacokinetic characteristics and desipramine as active major metabolite. "( Relative bioavailability of imipramine (Tofranil) coated tablets in healthy volunteers.
Birkel, M; Bliesath, H; Gebbing, H; Gräve, M; Lehnfeld, R; Ullmann, U; Wolf, H, 2001
)
2.05
"Imipramine (IMP) is a biologically active amine which is removed from the circulation by the lungs. "( Effect of hyperoxia on imipramine uptake and metabolism by the isolated, perfused rat lung.
Block, ER; Cannon, JK, 1978
)
2.01
"Imipramine appears to be a potentially useful treatment for this subtype of hypochondriasis."( Imipramine an effective treatment for illness phobia.
Noyes, R; Wesner, RB,
)
2.3
"Imipramine is an established treatment for anxiety in adults. "( Use of imipramine in children with intractable asthma and psychiatric disorders: a warning.
Kanner, AM; Klein, RG; Mascia, A; Rubinstein, B, 1989
)
2.17
"Imipramine probably acts as a protonophore by increasing the rate of proton-gradient dissipation rather than by interfering with the hydrogen-pump system because, in gastric membranes, imipramine was 20-fold less potent than omeprazole in inhibiting the gastric H-K-adenosine triphosphatase activity."( Inhibition of acid secretion in guinea pigs by tricyclic antidepressants: comparison with ranitidine and omeprazole.
Batzri, S; Brugada, O; Harmon, JW; Rich, NM, 1988
)
1
"Imipramine is a tricyclic antidepressant that has been demonstrated to be useful in the treatment of certain voiding dysfunctions. "( Functional effects of imipramine on the rabbit urinary bladder: an in-vitro study.
Grover, R; Levin, RM; Ruggieri, MR; Wein, AJ, 1988
)
2.03
"Imipramine methiodide is a quaternary derivative of imipramine which does not cross the blood-brain barrier easily."( Comparison of imipramine-imipraminium in mice. To elucidate central or peripheral origin of effects of imipramine.
Frances, H; Simon, P, 1985
)
1.35

Effects

Imipramine has a variety of pharmacological effects including direct antimuscarinic activity, inhibition of catecholamine reuptake, direct muscle relaxant, and calcium antagonism. It has a proven efficiency in unselected enuretic patients, but is only indicated, if at all, in therapy-resistant cases.

Imipramine has been used for over four decades for the treatment of nocturnal enuresis, although the reason for its effect is not clear. It has been reported as significantly more effective against panic attacks than placebo or other psychoactive drugs in 12 of 16 studies.

ExcerptReferenceRelevance
"Imipramine has a diphenyl structural motif almost identical to that in carbamazepine (a dibenzazepine tricyclic compound), as well as a tertiary amine chain similar to that in many prototypical local anesthetics, and has also been reported to inhibit Na(+) channels in a use-dependent fashion."( Inhibition of Na(+) current by imipramine and related compounds: different binding kinetics as an inactivation stabilizer and as an open channel blocker.
Kuo, CC; Yang, YC, 2002
)
1.32
"Imipramine has a proven effect in enuresis but is now seldom used. "( Imipramine for therapy resistant enuresis: a retrospective evaluation.
Gepertz, S; Nevéus, T, 2004
)
3.21
"Imipramine has a proven efficiency in unselected enuretic patients, but due to its side-effect profile it is only indicated, if at all, in therapy-resistant cases."( Tolterodine and imipramine in refractory enuresis; a placebo-controlled crossover study.
Nevéus, T; Tullus, K, 2008
)
1.41
"Imipramine has a vasopressin independent antidiuretic effect if nocturnal polyuria is present. "( Single dose imipramine reduces nocturnal urine output in patients with nocturnal enuresis and nocturnal polyuria.
Djurhuus, JC; Hunsballe, JM; Olesen, OV; Pedersen, EB; Rittig, S, 1997
)
2.12
"Imipramine has a documented effect on such pain conditions on temporal summation."( The analgesic effect of codeine as compared to imipramine in different human experimental pain models.
Arendt-Nielsen, L; Bjørnsdottir, I; Enggaard, TP; Gram, LF; Hansen, SH; Poulsen, L; Sindrup, SH, 2001
)
1.29
"Imipramine has a role in patients who achieve partial continence after reconstruction, and who have a moderately small capacity bladder with poor compliance and uninhibited contractions."( The role of imipramine therapy in bladder exstrophy after bladder neck reconstruction.
Agarwala, S; Bhatnagar, V; Dave, S; Grover, VP; Mitra, DK, 2002
)
2.14
"Imipramine has a direct membrane action."( Effects of imipramine on cellular electrophysiological properties of cardiac Purkinje fibers.
Fozzard, HA; Rawling, DA, 1979
)
1.37
"Imipramine has a high clearance (0.8-1.5 l/min) and a corresponding high first pass elimination (30-70%)."( Imipramine: a model substance in pharmacokinetic research.
Gram, LF, 1988
)
2.44
"Imipramine has a variety of pharmacological effects including direct antimuscarinic activity, inhibition of catecholamine reuptake, direct muscle relaxant, and calcium antagonism."( Functional effects of imipramine on the rabbit urinary bladder: an in-vitro study.
Grover, R; Levin, RM; Ruggieri, MR; Wein, AJ, 1988
)
1.31
"Imipramine has been widely used as an antidepressant in the clinic over the years. "( NS398, a cyclooxygenase-2 inhibitor, reverses memory performance disrupted by imipramine in C57Bl/6J mice.
Bobula, B; Stachowicz, K; Tokarski, K, 2020
)
2.23
"Imipramine has been suggested as a treatment for antipsychotic-associated RE in one small study of patients prescribed thioridazine and a case series of patients prescribed iloperidone."( Retrograde ejaculation associated with quetiapine and treatment with low-dose imipramine.
Lyall, M; Roughley, M, 2019
)
1.46
"Imipramine has been surpassed by newer antidepressants for the treatment of depression in the past decade."( Neurologic and Cardiovascular Complications in Pediatric Life Threatening Imipramine Poisoning.
Cheung, KL; Fung, CK; Hon, KL; Lee, VW; Leung, AK; Wong, W, 2015
)
1.37
"Imipramine has been used for over four decades (early reports in 1960s) for the treatment of nocturnal enuresis, although the reason for its effect is not clear. "( Synthesis of a quaternary bis derivative of imipramine as a novel compound with potential anti-enuretic effect.
Faizi, M; Jamali, B; Kobarfard, F; Roodsari, MS; Shafaghi, B; Soleymani, Z, 2009
)
2.06
"Imipramine (IM) has been widely used in clinics for the treatment of some mental diseases. "( Suppression of adipogenesis in mouse mesenchymal stem cells by imipramine.
Li, H, 2012
)
2.06
"Imipramine (IM) has been widely used clinically for the treatment of mental disorders. "( Imipramine inhibits adipogenic differentiation in both 3T3-L1 preadipocytes and mouse marrow stromal cells.
Cai, G; Chen, Y; Fong, CC; Li, H; Yang, M, 2012
)
3.26
"Imipramine and doxepin have been reported to exhibit local anaesthetic properties."( Transdermal delivery of imipramine and doxepin from newly oil-in-water nanoemulsions for an analgesic and anti-allodynic activity: development, characterization and in vivo evaluation.
Campmany, AC; Campos, FF; Naveros, BC; Sandig, AG; Villena, MJ, 2013
)
1.42
"Imipramine has a diphenyl structural motif almost identical to that in carbamazepine (a dibenzazepine tricyclic compound), as well as a tertiary amine chain similar to that in many prototypical local anesthetics, and has also been reported to inhibit Na(+) channels in a use-dependent fashion."( Inhibition of Na(+) current by imipramine and related compounds: different binding kinetics as an inactivation stabilizer and as an open channel blocker.
Kuo, CC; Yang, YC, 2002
)
1.32
"Imipramine has a proven effect in enuresis but is now seldom used. "( Imipramine for therapy resistant enuresis: a retrospective evaluation.
Gepertz, S; Nevéus, T, 2004
)
3.21
"Imipramine has often been used as positive control in studies investigating the efficacy of new antidepressants. "( Imipramine dose in relation to therapeutic plasma level: are clinical trials using imipramine as a positive control flawed?
Birkenhäger, TK; Bruijn, JA; Moleman, P; van den Broek, WW; Vulto, AG, 2005
)
3.21
"Imipramine has a proven efficiency in unselected enuretic patients, but due to its side-effect profile it is only indicated, if at all, in therapy-resistant cases."( Tolterodine and imipramine in refractory enuresis; a placebo-controlled crossover study.
Nevéus, T; Tullus, K, 2008
)
1.41
"Imipramine has proven effective in reducing binging episodes, and further evaluation of antidepressants seems warranted."( Treatment of bulimia.
Conner, CS, 1983
)
0.99
"[3H]imipramine has been proposed as a specific label for serotonin uptake sites in brain."( [3H]imipramine labels sites on brain astroglial cells not related to serotonin uptake.
Morin, R; Vint, CK; Whitaker, PM, 1983
)
1.3
"Imipramine has a vasopressin independent antidiuretic effect if nocturnal polyuria is present. "( Single dose imipramine reduces nocturnal urine output in patients with nocturnal enuresis and nocturnal polyuria.
Djurhuus, JC; Hunsballe, JM; Olesen, OV; Pedersen, EB; Rittig, S, 1997
)
2.12
"Imipramine has proven efficacy for panic disorder. "( Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia.
Mavissakalian, MR; Perel, JM; Sloan, C; Talbott-Green, M, 1998
)
2.01
"Imipramine has been shown to reduce anxiety in patients with generalized anxiety disorder (GAD). "( Therapeutic effects of imipramine are counteracted by its metabolite, desipramine, in patients with generalized anxiety disorder.
Clark, CM; Hoehn-Saric, R; Kowalski, PA; McLeod, DR; Porges, SW, 2000
)
2.06
"Imipramine has a documented effect on such pain conditions on temporal summation."( The analgesic effect of codeine as compared to imipramine in different human experimental pain models.
Arendt-Nielsen, L; Bjørnsdottir, I; Enggaard, TP; Gram, LF; Hansen, SH; Poulsen, L; Sindrup, SH, 2001
)
1.29
"Imipramine has a role in patients who achieve partial continence after reconstruction, and who have a moderately small capacity bladder with poor compliance and uninhibited contractions."( The role of imipramine therapy in bladder exstrophy after bladder neck reconstruction.
Agarwala, S; Bhatnagar, V; Dave, S; Grover, VP; Mitra, DK, 2002
)
2.14
"Imipramine has a direct membrane action."( Effects of imipramine on cellular electrophysiological properties of cardiac Purkinje fibers.
Fozzard, HA; Rawling, DA, 1979
)
1.37
"Imipramine metabolism has been studied in both type I (streptozotocin-induced insulin-deficient) and type II (genetically insulin-resistant) diabetes in mice. "( Effects of genetic or chemically induced diabetes on imipramine metabolism. Respective involvement of flavin monooxygenase and cytochrome P-450-dependent monooxygenases.
Cresteil, T; Lemoine, A; Leroux, JP; Rouer, E; Rouet, P,
)
1.82
"Imipramine has a high clearance (0.8-1.5 l/min) and a corresponding high first pass elimination (30-70%)."( Imipramine: a model substance in pharmacokinetic research.
Gram, LF, 1988
)
2.44
"Imipramine has a variety of pharmacological effects including direct antimuscarinic activity, inhibition of catecholamine reuptake, direct muscle relaxant, and calcium antagonism."( Functional effects of imipramine on the rabbit urinary bladder: an in-vitro study.
Grover, R; Levin, RM; Ruggieri, MR; Wein, AJ, 1988
)
1.31
"Imipramine has been reported as significantly more effective against panic attacks than placebo or other psychoactive drugs in 12 of 16 studies."( Antidepressant drugs in anxiety disorders.
Modigh, K, 1987
)
0.99

Actions

Imipramine did not inhibit the acute phosphorylation of TH at Ser40 or TH activation induced by nicotine, but did inhibit the sustained responses to nicotine seen at 24 h. The imipramin-induced BDNF increase was suppressed with inhibitors for protein kinase A (PKA) or MEK/ERK. Imipramne is a rare cause of gray-blue facial pigmentation.

ExcerptReferenceRelevance
"The imipramine-induced BDNF increase was suppressed with inhibitors for protein kinase A (PKA) or MEK/ERK."( Imipramine induces brain-derived neurotrophic factor mRNA expression in cultured astrocytes.
Kawabe, K; Moriyama, M; Nakamura, Y; Takano, K; Yamasaki, H, 2012
)
2.3
"Imipramine promotes the non-amyloidogenic route of APP processing via stimulatory effects on PKC."( Imipramine and citalopram facilitate amyloid precursor protein secretion in vitro.
Bjelik, A; Hugyecz, M; Janka, Z; Kálmán, J; Kása, P; Pákáski, M, 2005
)
2.49
"Imipramine is a rare cause of gray-blue facial pigmentation. "( Imipramine-induced facial pigmentation: case report and literature review.
Lin, AN; Metelitsa, AI; Nguyen, GK, 2005
)
3.21
"Imipramine did not inhibit the acute phosphorylation of TH at Ser40 or TH activation induced by nicotine, but did inhibit the sustained responses to nicotine seen at 24 h."( Sustained phosphorylation of tyrosine hydroxylase at serine 40: a novel mechanism for maintenance of catecholamine synthesis.
Bobrovskaya, L; Bolster, EK; Dickson, PW; Dunkley, PR; Flaherty, JJ; Gilligan, C, 2007
)
1.06
"Imipramine was used to inhibit the serotonin uptake mechanism."( Influence of embolism and imipramine on kinetics of serotonin uptake by dog lung.
Dawson, CA; Linehan, JH; Rickaby, DA, 1984
)
1.29
"Imipramine caused an increase in 3H-DA efflux and this imipramine-induced efflux is Ca2+-independent."( Effect of imipramine on high potassium evoked 3H-dopamine release in the rat striatum.
Kamiya, H; Kohjimoto, Y; Saito, R; Sakurai, Y; Takano, Y, 1981
)
1.39
"Imipramine did increase sitting and standing heart rate without revealing a clear dosage correlation."( Blood pressure and heart rate response of panic disorder patients receiving imipramine in a dose-response treatment paradigm.
de Groot, CM; Mavissakalian, MR, 1994
)
1.24
"Imipramine caused an increase in the GH ratio in all subgroups."( Growth hormone secretion timing in depression: clinical outcome comparisons.
Franz, B; Grochocinski, VJ; Jarrett, DB; Kupfer, DJ; Miewald, JM, 1995
)
1.01
"Imipramine did not cause significant changes in pain perception during the cold pressor test."( The analgesic effect of codeine as compared to imipramine in different human experimental pain models.
Arendt-Nielsen, L; Bjørnsdottir, I; Enggaard, TP; Gram, LF; Hansen, SH; Poulsen, L; Sindrup, SH, 2001
)
1.29

Treatment

Imipramine treatment produced increase in general arousal, motility and reactivity as tested by various tests, changes in social behavior and only slight improvement of instrumental conditioned performance. Imiprams were significantly more likely than those taking placebo to report one or more adverse effects, which were predominantly anticholinergic in nature.

ExcerptReferenceRelevance
"Imipramine treatment caused diminished ovarian reserve and atretic follicle; however, agmatine treatment provided the maintenance of ovarian follicular reserve after MS."( The effect of maternal separation stress-induced depression on ovarian reserve in Sprague Dawley Rats: The possible role of imipramine and agmatine through a mTOR signal pathway.
Arıcıoğlu, F; Önel, T; Yaba, A; Yıldırım, E; Zortul, H, 2023
)
1.84
"Imipramine treatment compared with placebo significantly improved overall health in patients with multiple functional somatic syndromes when both treatments were supported by regular contacts with clinicians. "( Imipramine versus placebo for multiple functional somatic syndromes (STreSS-3): a double-blind, randomised study.
Agger, JL; Fink, PK; Gormsen, LK; Jensen, JS; Jensen, TS; Schröder, A, 2017
)
3.34
"Imipramine treatment was able to reverse depressive- and anxiety-like behaviors."( Imipramine treatment reverses depressive- and anxiety-like behaviors, normalize adrenocorticotropic hormone, and reduces interleukin-1β in the brain of rats subjected to experimental periapical lesion.
Barichello, T; Ceretta, RA; Dal-Pizzol, F; Dominguini, D; Generoso, JS; Michels, M; Netto, S; Réus, GZ; Simões, LR; Valim, RF; Valvassori, SS, 2019
)
2.68
"Imipramine treatment reversed the UCMS-induced alterations of the coat state (BALB/c, DBA), in the NSF test (A/J, BALB/c, C57BL/6) and in fecal corticosterone metabolites (BALB/c, C57BL/6)."( Multifaceted strain-specific effects in a mouse model of depression and of antidepressant reversal.
Belzung, C; Ibarguen-Vargas, Y; Palme, R; Surget, A; Touma, C, 2008
)
1.07
"Imipramine treatment caused increased plasma concentration of all amino acid, except for L-aspartate and taurine."( Forced swimming and imipramine modify plasma and brain amino acid concentrations in mice.
Furuse, M; Murakami, T; Tomonaga, S; Yamane, H, 2009
)
1.4
"Imipramine treatment significantly increased the number of neurons in the granule cell layer (GCL) and spine synapses in the CA1 in the FSL imipramine group (treated "depressed" rats) compared with the FSL saline group."( Imipramine treatment increases the number of hippocampal synapses and neurons in a genetic animal model of depression.
Chen, F; Madsen, TM; Nyengaard, JR; Wegener, G, 2010
)
2.52
"Imipramine treatment at 5 and 20 mg/kg/d enhanced BNIP3 mRNA expression only in the LH group but not in non-LH group or non-stressed group."( Enhanced expression of BCL2/adenovirus EIB 19-kDa-interacting protein 3 mRNA, a candidate for intrinsic depression-related factor, and effects of imipramine in the frontal cortex of stressed mice.
Matsumoto, K; Mingmalairak, S; Murakami, Y; Tohda, M, 2010
)
1.28
"Imipramine treatment did not affect this factor."( Chronic unpredictable stress-induced reduction in the hippocampal brain-derived neurotrophic factor (BDNF) gene expression is antagonized by zinc treatment.
Cieślik, K; Legutko, B; Nowak, G; Opoka, W; Ossowska, G; Sowa-Kućma, M; Wolak, M, 2011
)
1.09
"Imipramine treatment hit 13 disease clusters: tachycardia, palpitation, myocardial infarction, arrhythmias, heart block, precipitation of congestive heart failure; urinary retention, altered liver functions."( Prediction of adverse events by in vivo gene expression profiling exemplified for phytopharmaceuticals containing salicylates and the antidepressant imipramine.
Freischmidt, A; Heilmann, J; Kelber, O; Koptina, A; Müller, J; Sadeghlar, F; Ulrich-Merzenich, G; Wagner, H; Zeitler, H, 2012
)
1.3
"Imipramine treatment decreased anxiety levels in females, but not in males, in the normal weaning condition. "( Effects of sex and rearing environment on imipramine response in mice.
Kikusui, T; Mogi, K; Nagasawa, M; Shimokawa, Y, 2012
)
2.09
"Imipramine treatment in depression might exert antidepressant action through BDNF production from astrocytes, and glial BDNF expression might be a target of developing novel antidepressants."( Imipramine induces brain-derived neurotrophic factor mRNA expression in cultured astrocytes.
Kawabe, K; Moriyama, M; Nakamura, Y; Takano, K; Yamasaki, H, 2012
)
2.54
"Imipramine treatment amplified the PI response to the non subtype-selective mGlu receptor agonist, 1S,3R-aminocyclopentane-1,3-dicarboxylated (1S,3R-ACPD) in both hippocampal and cortical slices, but failed to affect the response to the selective mGlu1/5 receptor agonist, S-3,5-dihydroxyphenylglycine (DHPG)."( Imipramine treatment up-regulates the expression and function of mGlu2/3 metabotropic glutamate receptors in the rat hippocampus.
Cappuccio, I; Caricasole, A; Matrisciano, F; Melchiorri, D; Ngomba, RT; Nicoletti, F; Riozzi, B; Scaccianoce, S; Storto, M, 2002
)
2.48
"Imipramine is a useful treatment for enuresis when everything else has failed, especially among older children. "( Imipramine for therapy resistant enuresis: a retrospective evaluation.
Gepertz, S; Nevéus, T, 2004
)
3.21
"Imipramine treatment (50 mg three times daily) in 7 subjects served as a positive control."( Influence of St John's wort on catecholamine turnover and cardiovascular regulation in humans.
Goldstein, DS; Haertter, S; Jordan, J; Luft, FC; Schroeder, C; Stoeter, M; Tank, J, 2004
)
1.04
"Imipramine treatment minimized these CMS-induced reductions."( Effect of imipramine treatment on plasma dopamine beta-hydroxylase activity in chronic mild stress in rats.
Grabowska, M; Nowak, G; Papp, M; Schlegel-Zawadzka, M,
)
1.26
"Imipramine treatment further decreased harmaline-induced 5HT turnover in the brain stem."( Exacerbation of harmaline-induced tremor by imipramine.
Al Deeb, S; Al Moutaery, K; Arshaduddin, M; Kadasah, S; Tariq, M, 2005
)
1.31
"Imipramine treatment offset all the behavioral and neurochemical stress-induced modifications."( Hypothalamus-pituitary-adrenal modifications consequent to chronic stress exposure in an experimental model of depression in rats.
Cassanelli, A; Danielli, B; De Montis, MG; Raone, A; Rauggi, R; Scheggi, S, 2007
)
1.06
"Imipramine treatment also resulted in a decrease of extracellular field potentials evoked in layer II/III by stimulation of underlying sites in layer V."( Repeated administration of imipramine attenuates glutamatergic transmission in rat frontal cortex.
Bobula, B; Hess, G; Tokarski, K; Wabno, J, 2008
)
1.36
"Imipramine treatment was associated with significant improvement in both observer-rated and patient-rated depression scales."( Cardiovascular and antidepressant effects of imipramine in the treatment of secondary depression in patients with ischemic heart disease.
Barnes, R; Gumbrecht, G; Raskind, M; Veith, R, 1982
)
1.25
"The imipramine treated group were significantly older."( Plasma levels and clinical response with imipramine in a study comparing efficacy with mianserin and nomifensine.
Montgomery, DB; Montgomery, SA; Robinson, C; Roy, D; Wynne-Willson, S, 1983
)
1.01
"3 Imipramine (Imip) pretreatment before the second trial (10 mg/kg i.p on the 3 preceding days, and 2.5 mg/kg 1 h before) abolished these correlations."( Imipramine normalizes naturally-occurring and drug-induced differences in the exploratory activity of rats.
Harrison-Read, PE; Steinberg, H, 1980
)
2.26
"The imipramine-treatment group failed to have either earlier response or better final outcome."( Dexamethasone suppression test and selection of antidepressant medications.
Albala, AA; Carroll, BJ; Feinberg, M; Gardner, R; Greden, JF; Kronfol, Z; Mukhopadhyay, S, 1981
)
0.74
"The imipramine pretreatment reversed the tetrabenazine-induced sedation."( Effects of imipramine on behavior and brain norepinephrine metabolism in tetrabenazine treated rats: comparative study of a single administration with repeated administrations of imipramine.
Hori, A; Kariya, T; Nakagawara, M; Watanabe, A, 1983
)
1.14
"Imipramine treatment was maintained on a daily basis during the 7 days taken to complete the series of tests."( Attenuation of antipredator defensive behavior in rats following chronic treatment with imipramine.
Blanchard, DC; Blanchard, RJ; Magee, L; Rodgers, RJ; Shepherd, JK, 1993
)
1.23
"Imipramine treatment elicited a marked decrease in beta 1 binding in the outer laminae of the cingulate cortex, as well as in the motor and somatosensory areas of the frontal cortex."( Up-regulation of beta 1-adrenergic receptors in rat brain after chronic citalopram and fluoxetine treatments.
Hietala, J; Kuoppamäki, M; Laakso, A; Pälvimäki, EP; Syvälahti, E, 1994
)
1.01
"The imipramine-treated patients showed a higher frequency of adverse events, especially the anticholinergic type, than citalopram-treated patients."( Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study.
Damsbo, N; Fuglum, E; Horsgård, S; Jacobsen, LV; Rosenberg, C, 1994
)
1.12
"Imipramine treatment produced a reduction in urinary MHPG, an increase in the ratio of NMN to MHPG plus VMA, and a trend towards an increase in plasma NE which was significantly different than the effects seen in the fluvoxamine and placebo groups."( Effect of fluvoxamine, imipramine and placebo on catecholamine function in depressed outpatients.
Ballenger, JC; Johnson, MR; Kellner, CH; Laird, LK; Lydiard, RB; Morton, WA; Steele, TE,
)
1.16
"Imipramine-treated patients reported more anticholinergic side effects, whereas tiredness and headache were observed more frequently in the moclobemide-treated patients."( Moclobemide versus imipramine in depressed out-patients: a double-blind multi-centre study.
Jääskeläinen, J; Kaartinen, P; Kalli, A; Kilponen, E; Koskinen, T; Nikkilä, H; Pirttiperä, V; Rimón, R; Seppälä, J, 1993
)
1.34
"Imipramine treatment did not affect the rate of reentrainment after a 6-h advance in the light-dark cycle, did not alter the advanced-phase angle of entrainment of tau-mutant hamsters, did not affect the free-running period of wild type hamsters, and did not alter the phase-response curve to light pulses."( Effects of imipramine on circadian rhythms in the golden hamster.
Menaker, M; Refinetti, R, 1993
)
1.4
"Imipramine pretreatment did not change the immunochemically determined content of the CYP2D protein, suggesting that CYP2D is inactivated."( Inhibition and induction of cytochrome P450 isozymes after repetitive administration of imipramine in rats.
Fujio, N; Funae, Y; Horie, T; Imaoka, S; Masubuchi, Y; Narimatsu, S; Suzuki, T; Takahashii, C, 1995
)
1.23
"Imipramine treatment was safe and associated with improvement in depression in both adequately treated and intention-to-treat samples. "( Imipramine treatment of alcoholics with primary depression: A placebo-controlled clinical trial.
Agosti, V; Goldman, D; McGrath, PJ; Nunes, EV; Ocepek-Welikson, K; Quitkin, FM; Stewart, JW, 1996
)
3.18
"Imipramine treatment is effective for primary depression among actively drinking alcoholic outpatients, and may improve alcoholic outcome for those whose depression responds to treatment."( Imipramine treatment of alcoholics with primary depression: A placebo-controlled clinical trial.
Agosti, V; Goldman, D; McGrath, PJ; Nunes, EV; Ocepek-Welikson, K; Quitkin, FM; Stewart, JW, 1996
)
3.18
"Imipramine treatment was not significantly better than placebo for improvement in depression and anxiety ratings in this patient group."( The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings.
Zajecka, JM, 1996
)
1.02
"Imipramine treatment resulted in a significant 15% increase in heart rate on both day 14 and day 28, whereas heart rate tended to decrease under venlafaxine."( Subchronic antidepressant treatment with venlafaxine or imipramine and effects on blood pressure and heart rate: assessment by automatic 24-hour monitoring.
Benkert, O; Gründer, G; Schlösser, R; Wetzel, H, 1996
)
1.26
"Imipramine treatment resulted in reductions in the duration of immobility in both transgenic (130 +/- 21 sec) and control (54 +/- 33 sec) mice."( Altered disposition and antidepressant activity of imipramine in transgenic mice with elevated alpha-1-acid glycoprotein.
Baumann, H; Dewey, MJ; Fincher, TK; Holladay, JW; Yoo, SD, 1996
)
1.27
"Imipramine (IMI) treatment yielded complete remission of her symptoms for three years."( Panic attacks, complex partial seizures, and multiple meningiomas.
Nickell, PV, 1994
)
1.01
"4. Imipramine treatment, either by daily injections or by subcutaneous implantation of slow release imipramine-containing polymers reduced the elevated tryptophan hydroxylase apoenzyme levels in the frontal cortex of bulbectomized, but not of sham-operated control rats and restored the deficient learning performance of bulbectomized rats."( Influence of olfactory bulbectomy and subsequent imipramine treatment on 5-hydroxytryptaminergic presynapses in the rat frontal cortex: behavioural correlates.
Becker, A; Franke, C; Grecksch, G; Huether, G; Sabel, B; Schröder, U; Zhou, D, 1997
)
1.07
"Imipramine treatment, short- or long-term, did not alter the steady-state levels of GAT-1 mRNA."( Effects of phenelzine and imipramine on the steady-state levels of mRNAs that encode glutamic acid decarboxylase (GAD67 and GAD65), the GABA transporter GAT-1 and GABA transaminase in rat cortex.
Baker, GB; Bateson, AN; Charrois, GJ; Lai, CT; Tanay, VA, 1998
)
1.32
"Imipramine treatment (29 weeks) had no effect on alpha 2AR density or coupling, despite improvement in anxiety ratings."( Adrenergic receptor function in panic disorder. I. Platelet alpha 2 receptors: Gi protein coupling, effects of imipramine, and relationship to treatment outcome.
Antai-Otong, D; Blakeley, JE; Gurguis, GN; Orsulak, PJ; Petty, F; Rush, AJ; Vo, SP, 1999
)
1.24
"Imipramine treatment diminished this response enhancement in CMS exposed animals, but did not alter the proliferative responses of control subjects."( Effects of chronic mild stress (CMS) and imipramine administration, on spleen mononuclear cell proliferative response, serum corticosterone level and brain norepinephrine content in male mice.
Arregi, A; Azpiroz, A; Beitia, G; Brain, PF; Cacho, R; Fano, E; Garmendia, L, 1999
)
1.29
"Imipramine (IMI) treatment normalized tT4 values."( Effects of chronic mild stress (CMS) on thyroid hormone function in two rat strains.
Antoniou, K; Bekris, S; Christofidis, I; Kioukia, N; Papadopoulou-Daifoti, Z, 2000
)
1.03
"Imipramine treatment produced increase in general arousal, motility and reactivity as tested by various tests, changes in social behavior and only slight improvement of instrumental conditioned performance."( Changes in conditioned performance and general behavior produced by imipramine treatment in dogs.
Fonberg, E,
)
1.09
"Imipramine treatment produced only a slight decrease of food intake."( The effects of imipramine treatment on the unconditioned alimentary behavior and classical conditioned salivary reactions in dogs.
Fonberg, E; Korczyński, R, 1979
)
1.33
"Imipramine-treated platelets that were adherent to collagen showed significant depletion of metabolic ATP, but markedly diminished conversion of ATP to IMP as compared to control adherent platelets."( Relationships of adenine nucleotide metabolism to platelet-collagen adhesion.
Chen, AF; Morin, RJ, 1978
)
0.98
"In imipramine-treated patients this finding was associated with a decreased rate of drug elimination from plasma."( Relationship between age and tricyclic antidepressant plasma levels.
Cooper, TB; Friedman, MJ; Green, R; Ives, JO; Nies, A; Ravaris, CL; Robinson, DS, 1977
)
0.77
"Imipramine pretreatment not only blocked the positive inotropic effect of propranolol but resulted in an exaggerated negative inotropic effect in both areas of the left ventricle along with a significant fall in systemic arterial blood pressure."( A positive inotropic effect of propranolol on the canine myocardium: a presynaptic effect.
Daniell, HB; Pierre, AJ; Webb, JG, 1976
)
0.98
"Imipramine-treated patients were significantly more likely than those taking placebo to report one or more adverse effects, which were predominantly anticholinergic in nature."( A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients.
Fabre, LF, 1992
)
1.27
"The imipramine-treated patients had superior global outcome."( Adjunctive imipramine for dysphoric schizophrenic patients with past histories of cannabis abuse.
Alvir, JM; Bermanzohn, PC; Mason, SE; Rifkin, A; Siris, SG, 1992
)
1.15
"In imipramine-treated rats the beta-down-regulation was still evident in the presence of TPA; after electroconvulsive treatment the phorbol ester-induced potentiation was so high that no significant beta-down-regulation could be observed."( Different mechanisms of beta-adrenoceptor down-regulation by chronic imipramine and electroconvulsive treatment: possible role for protein kinase C.
Nalepa, I; Vetulani, J, 1991
)
1.03
"For imipramine-treated patients, high social support predicted a better response at 6 weeks, while development of hypomania during follow-up was associated with a better response at 6 weeks; absence of life events during the 6-month follow-up and initial non-suppression of dexamethasone predicted a better outcome at 6 months."( Predictors of antidepressant treatment outcome in melancholia: psychosocial, clinical and biological indicators.
Bulbena, A; Catalan, R; Gasto, C; Menchon, JM; Vallejo, J, 1991
)
0.76
"In imipramine-treated animals LFES elicited much stronger contractions than in the controls."( Effects of histaminergic drugs on the contractile activity of smooth muscles from imipramine-treated rats.
Todorov, S, 1990
)
1.02
"Imipramine treatment resulted in similar although less pronounced changes.(ABSTRACT TRUNCATED AT 250 WORDS)"( Acute and chronic studies on functional aspects of coexistence.
Bartfai, T; Bertorelli, R; Consolo, S; Diaz-Arnesto, L; Fisone, G; Hökfelt, T; Iverfeldt, K; Ogren, SO; Palazzi, E,
)
0.85
"Imipramine treatment assists the adaptive process and accelerates the clinical recovery."( Platelet serotonin uptake dynamic changes in depression: effects of long-term imipramine treatment and clinical recovery.
Quintana, J,
)
1.08
"Imipramine treatment decreased the peak value of 5-HT concentration at 1000 to about 65% and appears to abolish the rhythm of 5-HT concentration."( Circadian rhythm of serotonin binding in rat brain--II. Influence of sleep deprivation and imipramine.
Rotsch, M; Schulz, E; Wesemann, W; Zöfel, P, 1986
)
1.21
"Imipramine treatment produced a down-regulation of the Bmax for 3H-dihydroalprenolol binding to cortical beta-adrenoceptors that was not dependent upon the time of day the animals were killed."( Cortical beta- and alpha 2- adrenoceptor binding, hypothalamic noradrenaline and pineal melatonin concentrations measured at different times of the day after repeated treatment of rats with imipramine, zimeldine, alaproclate and amiflamine.
Ask, AL; Fowler, CJ; Hall, H; Kelder, D; Ross, SB; Sääf, J, 1986
)
1.18
"Imipramine treatment elicited a significantly greater decrease in these adrenergic sites in the aged (39.2%) than in the adult (27.6%) animals."( The effect of imipramine treatment on brain serotonin receptors and beta-adrenoceptors and on pineal beta-adrenergic function in adult and aged rats.
Cooper, T; Friedman, E; Yocca, F, 1986
)
1.35
"2. Imipramine treatment resulted in an increase in state 3 respiration rates with all the substrates tested as early as one week after treatment; this was sustained through the second week of treatment."( Enhanced oxidative phosphorylation in rat liver mitochondria following prolonged in vivo treatment with imipramine.
Katyare, SS; Rajan, RR, 1988
)
1
"Imipramine-treated patients reported the most and placebo patients the least number of adverse effects."( Alprazolam, diazepam, imipramine, and placebo in outpatients with major depression.
Amsterdam, JD; Chung, HR; Csanalosi, IB; Hurowitz, AM; Kaplan, M; London, J; Rickels, K; Wiseman, K, 1987
)
1.31
"Oral imipramine treatment (100 to 600 mg, twice daily) led to frequent erection and masturbation while at rest in the stall in a nonsexual context."( Imipramine-induced erection, masturbation, and ejaculation in male horses.
Garcia, MC; Kenney, RM; McDonnell, SM; Van Arsdalen, KN, 1987
)
2.17
"Imipramine treatment was attempted for nonoverweight patients with negative ear, nose and throat (ENT) findings and for patients who had not responded to weight reduction or ENT surgery (in all patients the apneas were not considered life threatening)."( Preliminary clinical experience with imipramine HCl in the treatment of sleep apnea syndrome.
Alroy, GG; Lavie, P; Peled, R; Rubin, AH, 1986
)
1.27
"Treatment with imipramine provided significant improvement of QoL by PP analysis (72±17 and 61±19, respectively; P=0.048), but ITT analysis did not reveal any differences between imipramine and placebo (68±19 and 61±19, respectively; P=0.26)."( Imipramine for Treatment of Esophageal Hypersensitivity and Functional Heartburn: A Randomized Placebo-Controlled Trial.
Charatcharoenwitthaya, P; Leelakusolvong, S; Limsrivilai, J; Pausawasdi, N, 2016
)
2.22
"Treatment with imipramine, an ASMase inhibitor, inhibited the MF-induced EGFR clustering."( Acid sphingomyelinase mediates 50-Hz magnetic field-induced EGF receptor clustering on lipid raft.
Feng, B; Li, X; Sun, L; Sun, W; Wang, Y, 2016
)
0.77
"On treatment with imipramine, wild-type mice became sedated and produced imipramine N-oxide in the brain and other tissues. "( Deletion of the mouse Fmo1 gene results in enhanced pharmacological behavioural responses to imipramine.
Chandan, P; Hernandez, D; Janmohamed, A; Omar, BA; Phillips, IR; Shephard, EA, 2009
)
0.91
"The treatment with imipramine reversed all the parameters described above."( Depressive-like parameters in sepsis survivor rats.
Barichello, T; Cassol, OJ; Comim, CM; Constantino, LC; Constantino, LS; Dal-Pizzol, F; Kapczinski, F; Petronilho, F; Quevedo, J; Stertz, L, 2010
)
0.68
"Pretreatment with imipramine (10 and 20mg/kg) and venlafaxine (5 and 10mg/kg) significantly reversed immobilized stress-induced behavioral and biochemical alterations."( Nitric oxide mechanism in protective effect of imipramine and venlafaxine against acute immobilization stress-induced behavioral and biochemical alteration in mice.
Garg, R; Gaur, V; Kumar, A; Kumar, P, 2009
)
0.93
"Treatment with imipramine decreased the immobility time in nondiabetic and diabetic rats, compared with both nondiabetic and diabetic rats treated with saline."( Imipramine treatment reverses depressive-like behavior in alloxan-diabetic rats.
Aguiar, BW; Ceretta, LB; Kapczinski, F; Lersh, C; Pfaffenseller, B; Quevedo, J; Réus, GZ; Ribeiro, KF; Stringari, RB; Zappellini, G, 2012
)
2.16
"Treatment with imipramine in the SD rats did not induce significant differences in the number of mitochondria."( Mitochondrial plasticity of the hippocampus in a genetic rat model of depression after antidepressant treatment.
Chen, F; Madsen, TM; Nyengaard, JR; Wegener, G, 2013
)
0.73
"Pretreatment with imipramine, buspirone, or placebo was compared in 40 patients meeting the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition criteria for panic disorder and in patients who were discontinuing long-term benzodiazepine use. "( Imipramine and buspirone in patients with panic disorder who are discontinuing long-term benzodiazepine therapy.
García-España, F; Greenblatt, DJ; Mandos, LA; Rickels, K; Rynn, M; Schweizer, E, 2003
)
2.1
"Treatment with imipramine (3 x 30 mg/kg i.p.) induced a significantly shorter duration of immobility during the FST 5 min, but with no difference between ischemia and control rats."( Does rat global transient cerebral ischemia serve as an appropriate model to study emotional disturbances?
Allain, H; Amiot, N; Bantsiele, GB; Bentué-Ferrer, D; Bourin, M; Reymann, JM, 2004
)
0.66
"Treatment with imipramine (10mg/kg i.p., once daily) commenced after experimental week 3."( Behavioural and neurochemical effects induced by chronic mild stress applied to two different rat strains.
Antoniou, K; Bekris, S; Daskas, S; Papadopoulou-Daifoti, Z, 2005
)
0.67
"Pretreatment with imipramine or CD14 blockade was associated with attenuation of all of these LPS-induced events."( Acid sphingomyelinase is required for lipid Raft TLR4 complex formation.
Billgrin, J; Bulger, E; Cuschieri, J; Garcia, I; Maier, RV, 2007
)
0.66
"Treatment with imipramine decreased Stress-Sensitivity and increased Reward Experience (positive affect reactivity to positively appraised activities)."( Reduced stress-sensitivity or increased reward experience: the psychological mechanism of response to antidepressant medication.
Barge-Schaapveld, DQ; de Vries, M; Mengelers, R; Nicolson, NA; Peeters, F; van Os, J; Wichers, MC, 2009
)
0.69
"Treatment with imipramine hydrochloride decreased the number of sites, as measured with either ligand, in both patient groups and increased catecholamine levels in patients with panic attacks."( Platelet alpha 2-adrenergic receptor binding and plasma catecholamines. Before and during imipramine treatment in patients with panic anxiety.
Cameron, OG; Curtis, GC; Hollingsworth, PJ; Nesse, RM; Smith, CB, 1984
)
0.83
"Treatment with imipramine showed 62.1% improvement (+/- s.d."( A double-blind controlled clinical trial comparing fluvoxamine with imipramine.
Dreyfus, JF; Guelfi, JD; Pichot, P, 1983
)
0.84
"Treatment with imipramine or chlorpromazine alone for 14 days decreased the density of 5-HT2 receptor binding sites in rat cortex; the combination of the two drugs produced a greater reduction in 5-HT2 binding sites than imipramine or chlorpromazine alone."( Reduction of serotonin-2 receptors in rat cerebral cortex after subchronic administration of imipramine, chlorpromazine, and the combination thereof.
Meltzer, HY; Mikuni, M, 1984
)
0.83
"Treatment with imipramine and doxepin, but not placebo, was associated with significant improvement (P less than 0.001) in standard ratings of depression."( Cardiovascular effects of tricyclic antidepressants in depressed patients with chronic heart disease.
Barnes, RF; Caldwell, JH; Gumbrecht, G; Raskind, MA; Ritchie, JL; Veith, RC, 1982
)
0.6
"Rats treated with imipramine did not differ from those treated with saline on these parameters."( Effects of serotonergic agents on food-restriction-induced hyperactivity.
Altemus, M; Galliven, E; Glowa, JR; Leong, YM; Murphy, DL, 1996
)
0.62
"Treatment with imipramine decreased auditory P300 latencies and increased auditory P300 amplitudes."( Prolonged P300 latency in attention deficit hyperactivity disorder predicts poor response to imipramine.
Persky, B; Sangal, JM; Sangal, RB, 1996
)
0.85
"Treatment with imipramine was associated with decreased beta AR coupling and density in the high-conformational state."( Adrenergic receptor function in panic disorder. II. Neutrophil beta 2 receptors: Gs protein coupling, effects of imipramine treatment and relationship to treatment outcome.
Antai-Otong, D; Blakeley, JE; Gurguis, GN; Orsulak, PJ; Petty, F; Rush, AJ; Vo, SP,
)
0.68
"Pretreatment with imipramine (30 mg/kg s.c.) significantly reduced the YM643- or sumiferon-induced increases in immobility time."( Corticotropin-releasing hormone receptors mediate consensus interferon-alpha YM643-induced depression-like behavior in mice.
Miyata, K; Yamano, M; Yasuda, S; Yuki, H, 2000
)
0.63
"Treatment with imipramine is increasingly in disfavour because the relapse rate is unacceptably high and fatal overdose is a real possibility."( Nocturnal enuresis: what is happening?
Harari, MD; Moulden, A, 2000
)
0.65
"Pretreatment with imipramine, MK 801 and ketamine significantly prevented the effect of shock."( Interaction between N-methyl-D-aspartate receptor antagonists and imipramine in shock-induced depression.
Bapna, JS; Chandra, D; Chaturvedi, HK, 1999
)
0.86
"Treatment with imipramine resulted in a clinical improvement or cure in 16/22 patients (72.7%), with an average reduction in incontinent episodes of 78.7% (P<0.001)."( The use of short-form quality of life questionnaires to measure the impact of imipramine on women with urge incontinence.
Fischer, JR; Misko, CA; Woodman, PJ, 2001
)
0.88
"Treatment with imipramine did not change the basal threshold of aversive electrical stimulation measured before intra-DPAG injection of the 5-HT agonists."( Chronic imipramine enhances 5-HT(1A) and 5-HT(2) receptors-mediated inhibition of panic-like behavior in the rat dorsal periaqueductal gray.
Almeida, LP; Cabral, AH; Jacob, CA; Landeira-Fernandez, J; Magierek, V; Nogueira, RL; Ramos, PL; Zangrossi, H; Zanoveli, JM, 2002
)
1.09
"Treatment with imipramine can reduce these behavioural changes but is only effective when given repeatedly prior to onset of CMS."( Reduction in preference for saccharin by repeated unpredictable stress in mice and its prevention by imipramine.
Harkin, A; Houlihan, DD; Kelly, JP, 2002
)
0.87
"Treatment with imipramine (1 mg/kg) after the whiplash is able to remove these behavioral and biochemical disturbances."( [Memorization and central catecholamines after a craniocervical injury carried out in rats: influence of imipramine administration (author's transl)].
Boismare, F; Le Poncin, M; Lefrançois, J, 1977
)
0.81
"Pretreatment with imipramine resulted in 76% inhibition of the release reaction, but only 5% inhibition of adhesion."( Relationships of adenine nucleotide metabolism to platelet-collagen adhesion.
Chen, AF; Morin, RJ, 1978
)
0.58
"When treatment with imipramine was terminated, vaginal cyclicity resumed within the next 2 to 8 days."( Disruption of female rat vaginal cyclicity by daily treatment with imipramine.
Maswood, S; Uphouse, L, 1992
)
0.83
"2. Treatment with imipramine (10 subjects) was associated with a significant decrease of T4 and FTI and treatment with diazepam (8 subject) was associated with a significant decrease of T4."( The changes of thyroid hormone during pharmacological treatment of panic disorder patients.
Balon, R; Glitz, DA; Pohl, R; Ramesh, C; Yeragani, VK, 1991
)
0.6
"Pretreatment with imipramine, desipiramine or fluvoxamine significantly potentiated the suppressant effect of d-amphetamine on responding; pretreatment with trazodone had no significant effect."( Interaction between antidepressants and d-amphetamine on variable-interval performance.
Bradshaw, CM; Shah, K; Szabadi, E, 1990
)
0.6
"(a) Treatment with imipramine resulted in an increase of nerve fibres demonstrating immunoreactivity to antisera against dynorphin A and alpha-neoendorphin."( Immunohistochemical evidence for different opioid systems in the rat superior cervical ganglion as revealed by imipramine treatment and receptor blockade.
Folan, JC; Heym, C,
)
0.66
"Treatment by imipramine, desipramine, chlorpromazine, perphenazine and propericiazine 8 h before the administration with methamphetamine completely inhibited the urinary excretion of p-OH-MP whereas the excretion of amphetamine was enhanced by about 700 to 800%."( The effect of phenothiazine and dibenzazepine pretreatment on the metabolism of methamphetamine in rats.
Fujita, M; Kozuka, H; Mori, M, 1985
)
0.62
"Treatment with imipramine inhibited metabolism of both sparteine and debrisoquine (MR values about doubled), but did not affect the interpatient correlations."( Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
Bech, P; Bertilsson, L; Brøsen, K; Gram, LF; Klysner, R; Otton, SV, 1986
)
0.9
"Pretreatment with imipramine, desipramine, trimipramine, amitriptyline, nortriptyline and doxepin reduced clonidine-induced EEG synchrony without showing any effects per se."( Modification by tricyclic antidepressants of cortical EEG changes induced by clonidine in conscious rats.
Kulkarni, SK; Nayar, U; Parale, MP,
)
0.45

Toxicity

Doxepin was more neurotoxic than amitriptyline, and both imipramine and trimipramines were more toxic than desipramne or amitripyline. During the study, the adverse events were generally mild to moderate and most subsided with continued treatment. The proportions of patients experiencing at least one side effect or dropping out due to side effects were almost twice as high in the imipRamine group.

ExcerptReferenceRelevance
" It is concluded that all four drugs show the toxic effects classically associated with tricyclic antidepressants but the relative toxicity amongst these agents varies considerably and is in the order amitriptyline greater than imipramine greater than maprotiline greater than mianserin."( The relative toxicity of amitriptyline, imipramine, maprotiline and mianserin in rabbits in vivo.
Hughes, IE; Radwan, S, 1979
)
0.71
" Our report describes the serious dose-related cardiac and central nervous system toxic effects of imipramine."( Imipramine toxicity.
Rohner, TJ; Sanford, EJ, 1975
)
1.91
" Adverse events were reported or observed in 56% of moclobemide patients and in 69% of imipramine patients."( Efficacy and safety of moclobemide compared with imipramine in the treatment of major depressive disorder. Double-blind multicenter study, Austria.
Baumhackl, U; Gallhofer, B; Geretsegger, C; Hebenstreit, GF; Loidl, M; Radmayr, E; Saletu, M; Schöny, W; Stabl, M, 1990
)
0.76
"At the present time, there is some concern over the haematological adverse effects of antidepressants."( Reliability of data on haematotoxicity of antidepressants. A retrospective assessment of haematological monitoring in clinical studies on tricyclics.
Biscos-Garreau, M; Girard, M,
)
0.13
" No adverse reactions were reported, including hypertensive and hyperpyrexic crises."( The safety of switching rapidly from tricyclic antidepressants to monoamine oxidase inhibitors.
Kahn, D; Opler, LA; Silver, JM, 1989
)
0.28
" These toxic effects of endogenously produced neuroamines may be antagonized by nimodipine or flunarizine."( Ca2+ modulators as antidotes to imipramine and neurotransmitter toxicity.
Nahas, G; Trouve, R, 1987
)
0.56
"Clinical outcome and adverse effects associated with concurrent alprazolam and imipramine administration were studied in 29 patients with major depressive disorder who completed a 6-week trial in which they served as their own controls."( Clinical outcome and adverse effect profile associated with concurrent administration of alprazolam and imipramine.
Antal, EJ; Ereshefsky, L; Evans, RL; Grimmig, J; Hamann, G; Lobeck, F; Rawls, WN; Smith, RB; Wells, BG, 1988
)
0.72
"Drug-induced hematological disorders appear as a rare but serious side effect of the drugs use."( [Hematologic toxicity of antidepressive agents].
Galbaud du Fort, G,
)
0.13
"Acute anticholinergic delirium has been reported to occur following ingestion of antidepressants, neuroleptics and antiparkinsonian drugs in toxic and therapeutic doses."( Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.
Banno, V; Jones, BD; Moreau, A, 1986
)
0.27
" Reported incidences of adverse events can be viewed as being a combination of psychoactive drug effects, disease state effects and other concomitant effects."( Use of statistics in the analysis of side effect data from clinical trials of psychoactive agents.
Assenzo, JR; Shu, VS, 1982
)
0.26
" The proportions of patients experiencing at least one side effect or dropping out due to side effects were almost twice as high in the imipramine group."( Multicenter double-blind comparison of nomifensine and imipramine for efficacy and safety in depressed outpatients.
Abrahams, LM; Bremner, JD; Crupie, JE; McCawley, A; Proctor, RC; Sathananthan, GL, 1984
)
0.72
" The findings suggest a more favorable side effect profile for nomifensine, which was associated with a lower frequency of sedating and anticholinergic effects than was seen in the imipramine group."( A double-blind comparative evaluation of the efficacy and safety of nomifensine, imipramine, and placebo in depressed geriatric outpatients.
Feighner, JP; Hendrickson, G; Merideth, CH, 1984
)
0.69
" Side effect information was collected at each visit."( An overview of side effects and long-term experience with nomifensine from United States clinical trials.
Hardiman, S; Nash, RJ; Yakabow, AL, 1984
)
0.27
" However, the laboratory pharmacological characteristics of agents are a more reliable predictor of side effect profiles than they are of their therapeutic activities."( Comparative side effect profiles of trazodone and imipramine: special reference to the geriatric population.
Gershon, S, 1984
)
0.52
" We found no major difference between non-elderly and elderly depressed patients as concerns efficacy, total incidence of adverse findings or safety parameters such as laboratory values and heart rate."( Are there any differences in the safety and efficacy of brofaromine and imipramine between non-elderly and elderly patients with major depression?
Möller, HJ; Müller, H; Volz, HP, 1995
)
0.52
" During the study, the adverse events were generally mild to moderate and most subsided with continued treatment; the most frequent were nausea for venlafaxine and dry mouth for imipramine."( Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression.
Cohn, C; Crowder, J; Davidson, J; Dunner, D; Feighner, J; Kiev, A; Patrick, R; Shrivastava, RK, 1994
)
0.72
" If a side effect profile is known, it will be easier for a clinician to choose the right drug and the appropriate management by taking into account compliance, safety and efficacy in each patient under treatment."( Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo.
Benkert, O; Cassano, GB; Curtis, G; Deltito, J; Hippius, H; Klerman, G; Maier, W; Petracca, A; Shera, D; Toni, C, 1994
)
0.52
"Comprehensive review of safety data from approximately 3500 patients who received nefazodone in premarketing clinical trials demonstrates the drug to be very well tolerated, with a favorable side effect profile compared with other antidepressant drugs."( The safety profile of nefazodone.
Kaplita, SB; Marcus, RN; Roberts, DL; Robinson, DS; Seminara, JA; Smith, JM; Stringfellow, JC, 1996
)
0.29
" Discriminant analysis revealed that the combination of trimipramine with bright light results in a different side effect profile compared with drug monotherapy."( Side effects of adjunct light therapy in patients with major depression.
Hatzinger, M; Hemmeter, U; Holsboer-Trachsler, E; Müller, MJ; Seifritz, E, 1997
)
0.54
"Very little is known about the pharmacokinetics of neuroleptic drugs in breast-feeding mothers and their infants or about possible adverse effects in the infants."( Neuroleptic drugs in breast-milk: a study of pharmacokinetics and of possible adverse effects in breast-fed infants.
Craggs, M; Kumar, R; Smith, B; Yoshida, K, 1998
)
0.3
" Concentrations of haloperidol in the adult range were found in plasma from 2 of 5 infants assayed by EIA but there was no evidence of any acute or delayed adverse effects."( Neuroleptic drugs in breast-milk: a study of pharmacokinetics and of possible adverse effects in breast-fed infants.
Craggs, M; Kumar, R; Smith, B; Yoshida, K, 1998
)
0.3
"The respective adverse effects of imipramine and desipramine on serum thyroid hormone levels and their accumulation in thyroid were investigated in male Wistar rats."( Thyroid accumulation and adverse effects of imipramine and desipramine in rats after long-term administration.
Buxeraud, J; Lachâtre, G; Lagorce, JF; Marquet, P; Raby, C; Rousseau, A; Sauvage, MF, 1998
)
0.84
" The rate of discontinuation due to adverse effects with reboxetine was not significantly different from that observed with placebo in short-term studies."( Reboxetine: tolerability and safety profile in patients with major depression.
Tanum, L, 2000
)
0.31
" These results indicate that imipramine and sertraline are equally effective for the treatment of major depression in later life, although adverse reactions are more frequent among subjects treated with imipramine than with sertraline."( Antidepressant efficacy and safety of low-dose sertraline and standard-dose imipramine for the treatment of depression in older adults: results from a double-blind, randomized, controlled clinical trial.
Almeida, OP; Forlenza, OV; Hirata, ES; Stoppe, A, 2001
)
0.83
" The data also revealed that weight gain is a significant and specific side effect of 1-year imipramine maintenance treatment; however, the likelihood of reporting sexual dysfunction decreased over time, with no difference between the placebo and imipramine maintenance conditions."( Specific side effects of long-term imipramine management of panic disorder.
Guo, S; Mavissakalian, M; Perel, J, 2002
)
0.81
" Adverse events were significantly less in patients treated with SAMe compared to those treated with IMI."( A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder.
Chiaie, RD; Pancheri, P; Scapicchio, P, 2002
)
0.51
"Acrocyanosis is probably the most unusual side effect of tricyclic antidepressant drugs."( Acrocyanosis as a side effect of tricyclic antidepressants: a case report.
Aydoğan, M; Coşkun, A; Gökalp, AS; Karakaya, I,
)
0.13
" No toxic effects in RCSN-3 cells were observed when the cells were incubated with 100 microm FeCl3 alone or complexed with dopamine."( Monoamine transporter inhibitors and norepinephrine reduce dopamine-dependent iron toxicity in cells derived from the substantia nigra.
Cardenas, S; Caviedes, P; Graumann, R; Martinez-Alvarado, P; Olea-Azar, C; Paris, I; Perez-Pastene, C; Raisman-Vozari, R; Segura-Aguilar, J; Vieira, MN, 2005
)
0.33
" This review focuses on the tolerability, occurrence of adverse events, precautions required to prevent severe adverse events, and essential pharmacological interaction in the treatment of ADHD symptoms by non-stimulants."( The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder.
Banaschewski, T; Heise, CA; Himpel, S; Rothenberger, A, 2005
)
0.33
" Mixed-effects models were used to assess longitudinal differences among the treatment groups with respect to side effect burden and dropout rates during the acute, maintenance, and follow-up phases of treatment."( A comparison of medication side effect reports by panic disorder patients with and without concomitant cognitive behavior therapy.
Barlow, D; Goetz, R; Gorman, J; Gorman, L; Lewin, D; Marcus, SM; Martinez, J; Mosovich, S; Ray, S; Shear, MK; Woods, S, 2007
)
0.34
" Specifically, doxepin was more neurotoxic than amitriptyline, and both imipramine and trimipramine were more toxic than desipramine or amitriptyline."( Differential neurotoxicity of tricyclic antidepressants and novel derivatives in vitro in a dorsal root ganglion cell culture model.
Gerner, P; Haller, I; Keller, C; Klimaschewski, L; Lirk, P; Wang, GK, 2007
)
0.57
" Antidepressant monotherapy was found to be a safe and effective treatment for bipolar-II depression."( Efficacy and safety of antidepressant monotherapy in the treatment of bipolar-II depression.
Agosti, V; Stewart, JW, 2007
)
0.34
" Clinicians should select antidepressants considering their pharmacologic profiles and avoiding adverse effects."( [Review of pharmacological efficacies and side effects of antidepressants].
Ikenouchi-Sugita, A; Nakamura, J; Yoshimura, R, 2007
)
0.34
" The tested drugs were very toxic to the protozoan Spirostomum ambiguum and the crustacean Thamnocephalus platyurus with the LC50 values around 1 mg l(-1)."( In vitro biotransformation of amitriptyline and imipramine with rat hepatic S9 fraction: evaluation of the toxicity with Spirotox and Thamnotoxkit F Tests.
Nałecz-Jawecki, G, 2008
)
0.6
"Studies show that tricyclic antidepressants prescribed for migraines, anxiety, and child enuresis have numerous adverse effects in living cells."( In vitro studies of DNA damage caused by tricyclic antidepressants: a role of peroxidase in the side effects of the drugs.
Azar, N; Korobkova, EA; Ng, W; Nizamova, M; Venkatratnam, A; Williams, AK, 2010
)
0.36
"Gene expression profiles of Sprague-Dawley (SD) rats treated with a standardized willow bark extract (WB), its salicin rich ethanol fraction (EtOH-FR) or the tricyclic antidepressant imipramine were evaluated for their potential to induce adverse events."( Prediction of adverse events by in vivo gene expression profiling exemplified for phytopharmaceuticals containing salicylates and the antidepressant imipramine.
Freischmidt, A; Heilmann, J; Kelber, O; Koptina, A; Müller, J; Sadeghlar, F; Ulrich-Merzenich, G; Wagner, H; Zeitler, H, 2012
)
0.77
"Gene expression profiles (Agilent Whole Genome Array, n=4/group) obtained from the peripheral blood of male SD rats treated with WB (STW 33-I), EtOH-FR (30 mg/kg bw) or imipramine (20 mg/kg bw) were analysed comparatively by the Ingenuity Systems Programme, which allows to conduct model calculations of thresholds for theoretical potential adverse events (AE)."( Prediction of adverse events by in vivo gene expression profiling exemplified for phytopharmaceuticals containing salicylates and the antidepressant imipramine.
Freischmidt, A; Heilmann, J; Kelber, O; Koptina, A; Müller, J; Sadeghlar, F; Ulrich-Merzenich, G; Wagner, H; Zeitler, H, 2012
)
0.77
" Those correspond to known potential adverse events."( Prediction of adverse events by in vivo gene expression profiling exemplified for phytopharmaceuticals containing salicylates and the antidepressant imipramine.
Freischmidt, A; Heilmann, J; Kelber, O; Koptina, A; Müller, J; Sadeghlar, F; Ulrich-Merzenich, G; Wagner, H; Zeitler, H, 2012
)
0.58
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43
" In the continuation and taper phases combined there were 211 adverse events in the paroxetine group, 147 on imipramine and 100 on placebo."( Study 329 continuation phase: Safety and efficacy of paroxetine and imipramine in extended treatment of adolescent major depression.
Abi-Jaoude, E; Healy, D; Jureidini, J; Le Noury, J; Nardo, JM; Raven, M; Tufanaru, C, 2016
)
0.88
" Relapse and adverse events on both active drugs open up the risks of a prescribing cascade."( Study 329 continuation phase: Safety and efficacy of paroxetine and imipramine in extended treatment of adolescent major depression.
Abi-Jaoude, E; Healy, D; Jureidini, J; Le Noury, J; Nardo, JM; Raven, M; Tufanaru, C, 2016
)
0.67

Pharmacokinetics

The feasibility of the brain microdialysis method for direct measurement and pharmacokinetic study of imipramine (Imip) and its metabolite desipramin (DMI) was investigated in the rat brain. Pharmacokinetic studies on quinupramine and imiphamine in plasma and brain were also performed in rats after a single oral administration. The mean elimination half-life for imipamine was significantly decreased in alcoholics (8.02)

ExcerptReferenceRelevance
"Our preliminary pharmacodynamic studies on the lower urinary tract of adult female dogs indicate that cholinergic and adrenergic (alpha and beta) neuroreceptors in the urethra appear to coordinate the detrusor and urethral function during micturition."( Cholinergic and adrenergic neuroreceptors in urinary tract of female dogs. Evaluation of function with pharmacodynamics.
Gonick, P; Heber, D; Khanna, OP, 1975
)
0.25
"The hemodynamic, cardiographic, and initial pharmacokinetic characteristics of the de novo administration of the 2-hydroxymetabolite (2-OH-IMI) of imipramine (IMI), compared with its parent was studied in a swine preparation."( Imipramine and 2-hydroxyimipramine: comparative cardiotoxicity and pharmacokinetics in swine.
Perel, JM; Pollock, BG, 1992
)
1.93
" Significantly higher variability was found in the pharmacokinetic parameters of the metabolite."( Population pharmacokinetics of imipramine in children.
Domínguez-Gil, A; Fernández de Gatta, MM; García, MJ; Tamayo, M, 1992
)
0.57
"Researchers used population pharmacokinetic parameters and data on the concentration effect relationship from 49 6-13 year old children suffering from enuresis who attended an outpatient psychiatric clinic at University Clinical Hospital in Salamanca, Spain to design rational dosing guidelines of the antidepressant imipramine (IMI) for individual patients."( Population pharmacokinetics of imipramine in children.
Domínguez-Gil, A; Fernández de Gatta, MM; García, MJ; Tamayo, M, 1992
)
0.74
" We prospectively tested a new pharmacokinetic model that allows flexible dosing and sampling to determine maintenance requirements in patients receiving TCAs."( Early individualization of tricyclic antidepressant dosing using a Bayesian pharmacokinetic model.
Harralson, AF; Hetnal, MJ; Jacisin, JJ; Kehoe, WA; Kwentus, JA; Sheffel, WB, 1991
)
0.28
" Recent pharmacokinetic studies in diverse patient populations such as the depressed elderly, children and alcoholics have revealed decreased clearance of imipramine in the elderly and increased clearance of both imipramine and desipramine in chronic alcoholics."( Clinical pharmacokinetics of imipramine and desipramine.
Pollock, BG; Sallee, FR, 1990
)
0.77
" A relationship between age and kinetic parameters such as area under the curve, elimination phase constant, half-life and total body clearance was observed."( Imipramine pharmacokinetics in depressed geriatric patients.
Baraldo, M; Benetello, P; Furlanut, M; Zara, G, 1990
)
1.72
" There were no indications to assume a changed absorption of imipramine due to vinpocetine as would be reflected in Cmax and tmax values."( Vinpocetine therapy does not change imipramine pharmacokinetics in man.
Braun, W; Grandt, R; Hitzenberger, G; Schmid, R, 1990
)
0.8
" Pharmacokinetic parameters were determined from multiple blood samples drawn over 60 hours."( Intravenous pharmacokinetics of 2-hydroxyimipramine in alcoholics and normal controls.
Barnhill, JG; Ciraulo, AM; Ciraulo, DA; Jaffe, JH; Tarmey, MF, 1990
)
0.54
" The present studies show that pharmacokinetic variations of imipramine in the brain might correlate with the altered levels of 5-HIAA, NE and MHPG."( Correlative changes of serotonin and catecholamines with pharmacokinetic alterations of imipramine in rat brain.
Kobayashi, A; Nakazawa, K; Sugita, S; Suzuki, S; Yoshida, T, 1989
)
0.74
"The pharmacokinetic profiles of imipramine (IMI) and its major active metabolites were determined in pregnant rats following an acute 30 mg/kg ip IMI dose."( Pharmacokinetics of imipramine and its major metabolites in pregnant rats and their fetuses following a single dose.
DeVane, CL; Simpkins, JW,
)
0.74
"The selection of a starting dose for an antidepressant, and subsequent clinical titration to an appropriate therapeutic dosage, should be based on pharmacokinetic and pharmacodynamic principles."( Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: evaluation of doxepin and imipramine--new data and review.
Davis, CM; Ereshefsky, L; LeRoy, A; Tran-Johnson, T, 1988
)
0.49
"Information on steady-state concentrations of parent tricyclic antidepressants (TCAs) and their major metabolites in plasma is useful in ascertaining compliance, for possible pharmacokinetic changes during longer treatment, and for prospective individualized dosing procedures."( Compliance during tricyclic antidepressant therapy: pharmacokinetic and analytical issues.
Perel, JM, 1988
)
0.27
" The mean elimination half-life for imipramine was significantly decreased in alcoholics (8."( Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers.
Barnhill, JG; Ciraulo, DA; Jaffe, JH, 1988
)
0.84
" The pharmacodynamic effects of oxazepam were increased by the concomitant use of imipramine, and these effects were in reasonably good agreement with the change in brain concentration of oxazepam."( [Drug interaction of imipramine hydrochloride to the pharmacodynamics and pharmacokinetics of oxazepam].
Igarashi, T; Kitagawa, H; Ohmori, S; Okiyama, M; Ueno, K, 1987
)
0.82
" Pharmacokinetic studies on quinupramine and imipramine in plasma and brain were also performed in rats after a single oral administration."( Effects of quinupramine on the central monoamine uptake systems and involvement of pharmacokinetics in its pharmacological activities.
Kohno, S; Murai, K; Nishimoto, T; Ohata, K; Sakamoto, H; Tatsumi, H; Yokoyama, N, 1987
)
0.53
"A study of the relationship between pharmacokinetic profiles and temporal changes in quantitative EEG following imipramine administrations showed that a single dose of imipramine administered by different routes decreased the alpha-power spectra of healthy subjects."( Pharmacokinetic profiles and temporal changes in quantitative EEG after imipramine administrations.
Iwaya, N; Miyoshi, K; Morita, Y; Shinkuma, D, 1987
)
0.72
"The use of observational data, collected during the routine clinical care of patients, has been advocated as a means to obtain clinically relevant information regarding the pharmacokinetic parameters of drugs."( An evaluation of population pharmacokinetics in therapeutic trials. Part II. Detection of a drug-drug interaction.
Antal, EJ; Ereshefsky, L; Evans, RL; Grasela, TH; Smith, RB; Wells, BG, 1987
)
0.27
" Tricyclic pharmacokinetic parameters, determined from plasma samples over 48 hours, indicated decreased total body clearance, increased elimination half-life, and higher peak plasma levels during disulfiram treatment."( Pharmacokinetic interaction of disulfiram and antidepressants.
Barnhill, J; Boxenbaum, H; Ciraulo, DA, 1985
)
0.27
" Pharmacokinetic data on benzodiazepines thus in particular are important for design of dose, dose intervals and prediction (warning) about possible accumulation after repeated doses."( The contribution of pharmacokinetics to the best use of benzodiazepines and antidepressants.
Gram, LF, 1982
)
0.26
" The assessment of TCA actions that may be additive, synergistic, or antagonistic requires precise knowledge of pharmacodynamic potency and control of pharmacokinetic behavior."( Active metabolites of antidepressants: pharmacodynamics and relevant pharmacokinetics.
Lane, EA; Potter, WZ; Rudorfer, MV, 1984
)
0.27
" Time-efficacy calculations showed the maximal pharmacodynamic effect of pirlindol in the 4th to 6th hour, of 75 mg imipramine in the 2nd hour, of 20 mg tranylcypromine in the 4th hour and of 150 mg nomifensine in the 6th hour."( [Classification and determination of the pharmacodynamics of a new tetracyclic antidepressive agent, pirlindol, using pharmaco-EEG and psychometry].
Grünberger, L; Linzmayer, L; Saletu, B; Stöhr, H; Wittek, R, 1983
)
0.48
"A review of pharmacodynamic studies of nomifensine in healthy subjects indicates that nomifensine caused neither negative nor positive (euphoric) mood alterations and led to no impairments in various tests of performance and to some improvement in vigilance, attention, and psychomotor performance."( Pharmacodynamics of nomifensine: a review of studies in healthy subjects.
Siegfried, K; Taeuber, K, 1984
)
0.27
" doses, elimination half-life of imipramine was increased during cimetidine treatment (22."( Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability.
Abernethy, DR; Greenblatt, DJ; Shader, RI, 1984
)
1.99
" The apparent elimination half-life of imipramine was 20."( Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly.
Forette, F; Gomeni, R; Henry, JF; Hervy, MP; Hrdina, PD; Morselli, PL; Rovei, V, 1980
)
0.79
"Imipramine was specifically deuterated in either both aromatic rings or in the N-methyl group, or in both positions, and the pharmacokinetic properties of the products were determined in the rat and compared with those of the non-deuterated analogue."( Effect of deuteration of imipramine on its pharmacokinetic properties in the rat.
Ioannides, C; Parke, DV; Sacra, P; Taylor, IW; Turner, JC, 1983
)
2.01
" Nonlinear least-squares fitting of cortical concentration-effect data to the pharmacodynamic Emax model equation after the separate administration of desipramine and desmethyldesipramine generated Emax estimates for desipramine and desmethyldesipramine of approximately 36 and 29%, respectively, and EC50 estimates of 365 and 467 ng/g, respectively."( The pharmacodynamics of desipramine and desmethyldesipramine in rats.
Argenti, D; D'Mello, AP, 1994
)
0.29
" Suriclone AUC, Cmax and Tmax were not affected by imipramine, and reciprocally."( Pharmacokinetic and pharmacodynamic study of suriclone imipramine interaction in man.
Bouquet, S; Chakroun, H; Chapelle, G; Chevalier, P; Gaillot, J; Guillet, P; Montay, G; Perault, MC; Vandel, B, 1994
)
0.79
" The feasibility of the brain microdialysis method for direct measurement and pharmacokinetic study of imipramine (Imip) and its metabolite desipramine (DMI) was investigated in the rat brain."( Measurement and pharmacokinetic analysis of imipramine and its metabolite by brain microdialysis.
Ishikawa, K; Sato, Y; Shibanoki, S; Sugahara, M, 1994
)
0.76
" Compared with a control session, treatment with fluvoxamine caused a significant prolongation of imipramine half-life (from 22."( Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects.
Avenoso, A; Campo, GM; Caputi, AP; Perucca, E; Pollicino, AM; Spina, E, 1993
)
0.76
"The pharmacokinetic interaction between chloroquine (CQ) and imipramine was investigated in six healthy volunteers who received 300 mg of CQ, 50 mg of imipramine, and combined doses of both drugs in a randomized, crossover design."( Lack of pharmacokinetic interaction between chloroquine and imipramine.
Ogunbona, FA; Onyeji, CO; Toriola, TA, 1993
)
0.77
" Chronic treatment with promazine or imipramine increased concentrations of the parent compounds and their demethylated metabolites, and prolonged their half-life in the plasma and brain."( The pharmacokinetics of promazine and its metabolites after acute and chronic administration to rats--a comparison with the pharmacokinetics of imipramine.
Boksa, J; Daniel, W; Janczar, L; Syrek, M,
)
0.6
"02), a prolongation in imipramine half-life (from 16."( Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects.
Avenoso, A; Campo, GM; Caputi, AP; Perucca, E; Scordo, MG; Spina, E, 1997
)
0.86
" The changes in cardiac output with time could be linked to the pharmacokinetic model by a linear relationship."( Modelling of non-linear pharmacokinetics in sheep after short-term infusion of cardiotoxic doses of imipramine.
Gundert-Remy, U; Hellige, G; Meineke, I; Nottrott, M; Schmidt, W; Schröder, T, 1997
)
0.51
"To examine the pharmacokinetic interaction between the selective serotonin reuptake inhibitor sertraline and the tricyclic antidepressants desipramine or imipramine in 12 healthy male subjects."( The effect of sertraline on the pharmacokinetics of desipramine and imipramine.
Bergstrom, RF; Cerimele, BJ; Goldberg, MJ; Kurtz, DL, 1997
)
0.73
"Multiple-dose, but not single-dose, treatment with sertraline significantly reduced apparent plasma clearance (CL/F) and prolonged the half-life of desipramine relative to baseline."( The effect of sertraline on the pharmacokinetics of desipramine and imipramine.
Bergstrom, RF; Cerimele, BJ; Goldberg, MJ; Kurtz, DL, 1997
)
0.53
"This pharmacokinetic interaction is likely the result of an inhibition of CYP2D6 tricyclic metabolism by sertraline."( The effect of sertraline on the pharmacokinetics of desipramine and imipramine.
Bergstrom, RF; Cerimele, BJ; Goldberg, MJ; Kurtz, DL, 1997
)
0.53
" We have investigated the role of the lungs in pharmacokinetic drug interactions between tricyclic antidepressants and SSRIs."( Lung as reservoir for antidepressants in pharmacokinetic drug interactions.
Fukuda, H; Obata, T; Okubo, Y; Sasaki, Y; Sudo, Y; Suhara, T; Suzuki, K; Yoshida, K; Yoshikawa, K, 1998
)
0.3
" The administration of the enteric-coated tablets showed a flip-flop mechanism with a terminal elimination half-life 10-fold higher than the 3-hour half-life reported after intravenous infusion."( Clinical pharmacokinetics of acamprosate.
Chabac, S; Durbin, P; Houin, G; Hulot, T; Potgieter, A; Saivin, S, 1998
)
0.3
" The varying concentration ratios of antidepressant/thioridazine in vivo appear to be more important to the final result of the pharmacokinetic interactions than are relative direct inhibitory effects of the antidepressants on thioridazine metabolism observed in vitro."( Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants.
Daniel, WA; Haduch, A; Syrek, M; Wójcikowski, J, 2000
)
0.31
" The serum concentration-versus-time curve for each horse was analyzed separately to estimate pharmacokinetic values."( Pharmacokinetics of imipramine in narcoleptic horses.
Hines, MT; Mealey, KL; Mealey, RH; Peck, KE, 2001
)
0.63
" Key assessments included pharmacokinetic analysis of quetiapine, the Udvalg for kliniske undersøgelser (UKU) Side Effect Rating Scale, and safety evaluations (e."( Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine.
Alva, G; Arvanitis, LA; Carreon, D; Kalali, A; Potkin, SG; Thyrum, PT; Yeh, C, 2002
)
0.62
" We also measured pharmacokinetic parameters: the level of IMI and its metabolite, desipramine (DMI), in the rat plasma and brain (1 h after the forced swimming test)."( Effects of combined treatment with imipramine and metyrapone in the forced swimming test in rats. Behavioral and pharmacokinetic studies.
Daniel, WA; Rogóz, Z; Skuza, G; Wójcikowski, J,
)
0.41
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004
)
0.32
" The pharmacokinetic interaction can be excluded, since AMA did not change significantly the antidepressant level in the rat plasma and brain, measured 1 h after exposure to the forced swimming test."( Synergistic effect of imipramine and amantadine in the forced swimming test in rats. Behavioral and pharmacokinetic studies.
Daniel, WA; Kot, M; Kuśmider, M; Rogóz, Z; Skuza, G; Wójcikowski, J,
)
0.45
" Since there was no increase in brain imipramine/desipramine or zinc brain concentration after combined zinc and imipramine treatment, the data suggest that pharmacodynamic rather than pharmacokinetic interaction between zinc and imipramine is responsible for behavioral effect in the forced swim test."( Pharmacokinetic interaction after joint administration of zinc and imipramine in forced swim test in mice.
Baś, B; Dybała, M; Niewiara, E; Nowak, G; Opoka, W; Pomierny, L; Szymura-Oleksiak, J; Wyska, E,
)
0.64
" For the prediction of in vivo plasma levels, various pharmacokinetic parameters such as alpha, beta, volume of distribution, and AUC0-infinity."( Single and multiple dose pharmacokinetic evaluation of a transdermal delivery system of imipramine hydrochloride.
Dravid, P; Jain, A; Khandavilli, S; Panchagnula, R, 2005
)
0.55
" Since there was no increase in IMI, DMI or magnesium concentration after joint administration of magnesium and IMI, the data suggest that pharmacodynamic rather than pharmacokinetic interaction between magnesium and IMI is accountable for behavioral effect in the FST."( Enhancement of antidepressant-like activity by joint administration of imipramine and magnesium in the forced swim test: Behavioral and pharmacokinetic studies in mice.
Fidecka, S; Kedzierska, E; Librowski, T; Nowak, G; Pilc, A; Poleszak, E; Szewczyk, B; Szymura-Oleksiak, J; Wlaź, P; Wyska, E, 2005
)
0.56
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" This study investigated the pharmacokinetic and pharmacological interactions between imipramine and sodium alginate in rats."( Pharmacokinetic and pharmacodynamic studies of drug interaction following oral administration of imipramine and sodium alginate in rats.
Aimoto, T; Araki, H; Imai, K; Inoue, N; Suemaru, K; Watanabe, S, 2008
)
0.79
" Following a single method qualification run, the method was applied to the quantitation of pharmacokinetic study samples after oral administration of imipramine to male rats."( Comparison of fused-core and conventional particle size columns by LC-MS/MS and UV: application to pharmacokinetic study.
Fast, DM; Groeber, EA; Pabbisetty, D; Song, W; Steenwyk, RC, 2009
)
0.55
"Physiologically based pharmacokinetic (PBPK) models were developed for design and optimization of liposome therapy for treatment of overdoses of tricyclic antidepressants and local anesthetics."( A physiologically based pharmacokinetic (PBPK) model for predicting the efficacy of drug overdose treatment with liposomes in man.
Chauhan, A; Howell, BA, 2010
)
0.36
" Information on the kinetics of these drug interactions with HSA would be valuable in understanding the pharmacokinetic behavior of these drugs and could provide data that might lead to the creation of improved assays for these analytes in biological samples."( Kinetic studies of drug-protein interactions by using peak profiling and high-performance affinity chromatography: examination of multi-site interactions of drugs with human serum albumin columns.
Hage, DS; Ohnmacht, CM; Papastavros, E; Schiel, JE; Smith, QR; Tong, Z, 2011
)
0.37
" In this study, fexofenadine, verapamil, risperidone, ondansetron, and imipramine were used as model compounds to investigate the effectiveness of MIM in pharmacokinetic studies."( Development of a novel high-throughput analytical methodology, multiple injection method, for quantitative analysis in drug metabolism and pharmacokinetic studies using liquid chromatography with tandem mass spectrometry.
Ohkawa, T; Tanaka, Y; Yasui, H, 2011
)
0.6
" The objective of the present study is to determine whether the human pharmacokinetics of desipramine following dosing of imipramine can be predicted using static and dynamic physiologically-based pharmacokinetic (PBPK) models from in vitro input data for CYP2D6 extensive metabolizer (EM) and poor metabolizer (PM) populations."( The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine.
Callegari, E; Nguyen, HQ; Obach, RS, 2016
)
0.83
"A physiologically based pharmacokinetic (PBPK) model is developed that focuses on the kinetic parameters of drug association and dissociation with albumin, alpha-1 acid glycoprotein (AGP), and brain tissue proteins, as well as drug permeability at the blood-brain barrier, drug metabolism, and brain blood flow."( Physiologically Based Pharmacokinetic Model of Brain Delivery of Plasma Protein Bound Drugs.
Pardridge, WM, 2023
)
0.91

Compound-Compound Interactions

The aim of this study was to see whether low-dose gabapentin is effective in treating cancer-related neuropathic pain when combined with imipramine. In the present study, the antidepressant like activity of curcumin and its combination with fluoxetine and imipsramine was studied.

ExcerptReferenceRelevance
" Serum triiodothyronine (T3) and T4 by radioimmunoassay showed that PTU alone and in combination with Li lowered serum T4, while a high level of T4 by its supplement was suppressed by co-administration of Li."( Effect of lithium carbonate administration singly or in combination with some psychotropic drugs on the radioiodide uptake by mouse thyroid.
Akamatsu, S; Kamata, N; Kawada, J; Kurata, M; Kuwae, T; Minakuchi, K; Nishida, M; Takasugi, M; Teraoka, K, 1989
)
0.28
" This treatment was combined with either placebo, diazepam (10 mg/day) or dixyrazine (50 mg/day)."( Comparison of the serum levels in primary non-agitated depressed out-patients treated with imipramine in combination with placebo, diazepam or dixyrazine.
Feet, PO; Holm, V; Larsen, S; Liden, A; Lillevold, PE; Robak, OH, 1987
)
0.49
" Although the simple screen suggests the presence of the drug-drug interaction, limited information regarding pharmacokinetic parameters is available and those parameters that can be estimated are biased."( An evaluation of population pharmacokinetics in therapeutic trials. Part II. Detection of a drug-drug interaction.
Antal, EJ; Ereshefsky, L; Evans, RL; Grasela, TH; Smith, RB; Wells, BG, 1987
)
0.27
" All patients were treated with imipramine (100-200 mg-day) combined with either placebo, diazepam (10 mg/day) or dixyrazine (50 mg/day) for 8 weeks."( A double blind study in out-patients with primary non-agitated depression treated with imipramine in combination with placebo, diazepam or dixyrazine.
Feet, PO; Larsen, S; Robak, OH, 1985
)
0.78
" The implications of this on the prediction of drug-drug interactions from in vitro data are discussed."( Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions.
Margolis, JM; Obach, RS, 2003
)
0.32
" These treatments were combined with imipramine or placebo for a total of eight experimental conditions."( Treatment of panic disorder with agoraphobia: randomized placebo-controlled trial of four psychosocial treatments combined with imipramine or placebo.
Borgeat, F; Coutu, MF; Dupuis, G; Fleet, R; Mainguy, N; Marchand, A; Todorov, C, 2008
)
0.82
"The present study describes a new analytical approach for the detection and characterization of chemically reactive metabolites using glutathione ethyl ester (GSH-EE) as the trapping agent in combination with hybrid triple quadrupole linear ion trap mass spectrometry."( Screening and characterization of reactive metabolites using glutathione ethyl ester in combination with Q-trap mass spectrometry.
Fitch, WL; Wen, B, 2009
)
0.35
"We aimed to investigate and compare the effects of erlotinib and gefitinib on UDP-glucuronosyltransferase (UGT) activities and to quantitatively evaluate their drug-drug interaction (DDI) potential due to UGT inhibition."( Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.
House, L; Liu, Y; Ramírez, J; Ratain, MJ, 2010
)
0.36
" The aim of this study was to see whether low-dose gabapentin is effective in treating cancer-related neuropathic pain when combined with low-dose imipramine."( Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine.
Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010
)
0.77
"Low-dose gabapentin-antidepressant combination with opioids was effective in managing neuropathic cancer pain without severe adverse effects."( Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine.
Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010
)
0.57
" In the present study, the antidepressant like activity of curcumin and its combination with fluoxetine and imipramine was studied in acute model (three doses 24, 5 and 1 h before test) of forced swimming test (FST) in glass jar and tail suspension test (TST) in mice and in chronic model (14 day study) of FST with water wheel in rats."( Evaluation of antidepressant like activity of curcumin and its combination with fluoxetine and imipramine: an acute and chronic study.
Anovadiya, A; Sanmukhani, J; Tripathi, CB,
)
0.56
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38

Bioavailability

Imipramine doses indicated no difference in absolute bioavailability between the elderly and young of either sex. Higher levels of gastrointestinal radioactivity (mainly in the stomach lumen) indicated a slower imipramsine absorption rate in the subacute group.

ExcerptReferenceRelevance
"A new methodology for comparative bioavailability testing is described in which each drug formulation is compared with a stable isotope-labeled variant of the drug that is consumed orally in solution at the same time the tested formulation is ingested."( Bioavailability of imipramine tablets relative to a stable isotope-labeled internal standard: increasing the power of bioavailability tests.
Anbar, M; Buttrill, SE; Cabana, BE; Cairns, T; Dighe, S; Dyer, RL; Flynn, NW; Heck, HA, 1979
)
0.59
" The list includes diagnosis and patient selection; pharmacodynamics, bioavailability and tissue sensitivity; natural history; placebo response, nonspecific factors; compliance and adverse effects; the effects of concurrent life events, illness and treatment, and the bias in evaluating the outcome of treatment."( Factors influencing clinical response to psychotropic drugs. Imipramine in depression.
Donlon, PT, 1979
)
0.5
" Higher levels of gastrointestinal radioactivity (mainly in the stomach lumen) indicated a slower imipramine absorption rate in the subacute group."( Subacute imipramine: changes in single dose pharmacokinetics in rats.
Beaubien, AR; Huddleston, JA; James, HF; Mathieu, LF, 1977
)
0.89
" The bioavailability of an orally administered dose of imipramine ranged between 29."( Plasma levels of imipramine and desipramine in man after different routes of administration.
Johansson, R; Nagy, A, 1975
)
0.84
" This method is suitable for in vivo bioavailability studies of unchanged clomipramine, dehydroimipramine, and imipramine after a single oral dose of as little as 25 mg."( Measurement of clomipramine, N-desmethyl-clomipramine, imipramine, and dehydroimipramine in biological fluids by selective ion monitoring, and pharmacokinetics of clomipramine.
Dubois, JP; Küng, W; Theobald, W; Wirz, B, 1976
)
0.72
" When PGF2 alpha was infused at a rate of 5 mumols kg-1 h-1, the absorption rate of water decreased from 51."( The effect of dinoprost on transport of water and imipramine through rat small intestinal membranes.
Arimori, K; Deshimaru, M; Nakano, M, 1992
)
0.54
"Twelve healthy male subjects completed this randomized, placebo controlled, four-period crossover trial to determine the effect of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine."( Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine.
Danis, M; Dukes, GE; Hak, LJ; Han, YH; Hermann, DJ; Hussey, EK; Krol, TF; Powell, JR, 1992
)
0.69
" AUCs of day 10 without and of day 21 during concomitant vinpocetine treatment were compared, demonstrating the independence of imipramine's bioavailability from concomitant vinpocetine treatment."( Vinpocetine therapy does not change imipramine pharmacokinetics in man.
Braun, W; Grandt, R; Hitzenberger, G; Schmid, R, 1990
)
0.76
" (2) Since in the low frequency range the drugs exhibited contrary effects upon spontaneous and evoked EEG activity, the pre-/post-stimulus relationship of the delta power was found to be the most sensitive measure for monitoring the cerebral bioavailability of the tested drugs."( Pre-stimulus/post-stimulus relations in EEG spectra and their modulations by an opioid and an antidepressant.
Bromm, B; Meier, W; Scharein, E, 1989
)
0.28
" imipramine doses indicated no difference in absolute bioavailability between the elderly and young of either sex."( Imipramine and desipramine disposition in the elderly.
Abernethy, DR; Greenblatt, DJ; Shader, RI, 1985
)
2.62
" IMI concentrations were measured by gas-liquid chromatography using nitrogen-phosphorous detection and pharmacokinetic and bioavailability parameters determined by iterative nonlinear least-squares regression analysis."( Absolute bioavailability of imipramine: influence of food.
Abernethyl, DR; Divoll, M; Greenblatt, DJ; Harmatz, JS; Shader, RI, 1984
)
0.56
" It was assumed that pretreatment with cimetidine, because of its inhibition of metabolic pathways of both demethylation and hydroxylation as well as its ability to reduce hepatic extraction of these drugs, would increase bioavailability and decrease clearance of both drugs."( Cimetidine interaction with imipramine and nortriptyline.
Henauer, SA; Hollister, LE, 1984
)
0.56
" imipramine doses indicated absolute bioavailability was 40."( Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability.
Abernethy, DR; Greenblatt, DJ; Shader, RI, 1984
)
2.62
" Absolute bioavailability increased in OCS users (from 27."( Imipramine disposition in users of oral contraceptive steroids.
Abernethy, DR; Greenblatt, DJ; Shader, RI, 1984
)
1.71
" Absolute bioavailability increased in OC users (from 27."( Imipramine disposition in users of oral contraceptive steroids.
Abernethy, DR; Greenblatt, DJ; Shader, RI, 1984
)
1.71
"Assessment of seizure risk in individuals involves consideration of predisposing factors, the antidepressant selected, and the bioavailability of the drug."( Seizures associated with antidepressants: a review.
Jacobs, SC; Nelson, JC; Rosenstein, DL, 1993
)
0.29
"The aim of this work was to improve the oral bioavailability of a recently discovered, novel structural class of 5-HT1A receptor agonists: aryl-{[4-(6-R-pyridin-2-ylmethyl)-amino]-methyl}-piperidin-1 -yl-metha none."( Novel derivatives of 2-pyridinemethylamine as selective, potent, and orally active agonists at 5-HT1A receptors.
Assié, MB; Bonnaud, B; Cosi, C; Funes, P; Jubault, N; Kleven, M; Koek, W; Vacher, B, 1999
)
0.3
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" This study describes the bioavailability of 3 formulations of imipramine."( Relative bioavailability of imipramine (Tofranil) coated tablets in healthy volunteers.
Birkel, M; Bliesath, H; Gebbing, H; Gräve, M; Lehnfeld, R; Ullmann, U; Wolf, H, 2001
)
0.84
" The pharmacokinetic characteristics, Cmax, AUC, t1/2 and tmax were determined and the relative bioavailability of the two coated tablet formulations was calculated with the aqueous solution as reference."( Relative bioavailability of imipramine (Tofranil) coated tablets in healthy volunteers.
Birkel, M; Bliesath, H; Gebbing, H; Gräve, M; Lehnfeld, R; Ullmann, U; Wolf, H, 2001
)
0.6
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
" SCY-635 was shown to be orally bioavailable in multiple animal species and produced blood and liver concentrations of parent drug that exceeded the 50% effective dose determined in the bicistronic con1b-derived replicon assay."( SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
Erdmann, F; Fischer, G; Harris, R; Hopkins, S; Huang, Z; Murray, MG; Ribeill, Y; Scorneaux, B; Smitley, C; Wring, S, 2010
)
0.36
" Co-effectors in the extract improve the bioavailability of active constituents such as hypericin (1) (pharmacokinetic synergy)."( Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
Butterweck, V; Nahrstedt, A, 2010
)
0.36
" To show the importance of physicochemical properties, the classic QSAR and CoMFA of neonicotinoids and prediction of bioavailability of pesticides in terms of membrane permeability in comparison with drugs are described."( Importance of physicochemical properties for the design of new pesticides.
Akamatsu, M, 2011
)
0.37
"In this letter, we reported the design and synthesis of three potent, selective, and orally bioavailable 11β-HSD1 inhibitors labeled with (14)C: AMG 456 (1), AM-6949 (2), and AM-7715 (3)."( Synthesis, in Vitro Covalent Binding Evaluation, and Metabolism of (14)C-Labeled Inhibitors of 11β-HSD1.
Fan, P; He, X; Jiang, M; McMinn, DL; Monshouwer, M; Powers, JP; Rew, Y; Sun, D; Tu, H; Yan, X; Ye, Q, 2014
)
0.4
", ip) indicate that the liver is the primary site of biotransformation of the compound, suggesting that both 22a and its metabolite(s) are active, compensating probably low bioavailability of the parent molecule."( Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Bednarski, M; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pękala, E; Powroźnik, B; Słoczyńska, K; Walczak, M; Waszkielewicz, AM; Żesławska, E, 2016
)
0.43
" Compound 12g with MIC values of 5 μg/ml as a representative may possess better oral bioavailability and indicated high permeability by the parallel artificial membrane permeation assay of the blood-brain barrier (PAMPA-BBB)."( Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.
An, Q; Deng, Y; Liu, P; Luo, Y; Sang, Z; Tang, Y; Wang, T; Yang, T; Yang, Y; Zhang, T, 2018
)
0.48
" These compounds were found to be orally bioavailable and highly effective."( Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety.
Eswaran, S; Narayanan, S; Shivarudraiah, P; Shruthi, TG; Subramanian, S, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"The knowledge on human serum albumin (HSA) binding is of utmost importance as it affects pharmacokinetic behavior and bioavailability of drugs."( Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
Bajusz, D; Balogh, GT; Dargó, G; Müller, J; Simon, K, 2020
)
0.56

Dosage Studied

Fluvoxamine markedly inhibits the demethylation of imipramine. Dosage was flexible and administered on a three-times-a-day schedule. Mean maximum daily dose of 182 mg for venlafaxine and 176 mg for imipramsine.

ExcerptRelevanceReference
" In determination of the optimal individual dosage must continue to be an empirical process based on clinical observations and experience."( [Correlation between plasma concentration and clinical effect of neuroleptics and antidepressants].
Modestin, J; Petrin, A, 1976
)
0.26
" A dosing strategy for the combbination of clomipramine and haloperidol is described."( [The treatment of chronic pain symptoms with psychotropic drugs (author's transl)].
Kocher, R, 1976
)
0.26
" A clearcut dosage schedule for in- and out-patients using imipramine (Tofranil) or chlorimipramine (Anafranil) and haloperidol (Haldol) is established."( [The treatment of chronic pain with psychotropic drugs].
Kocher, R, 1978
)
0.5
" Important factors which influence this situation are the diagnostic criteria used to select patients for drug treatment, the dosage prescribed and individual compliance."( The role of plasma level monitoring of tricyclic antidepressant drugs as an aid to treatment.
Braithwaite, R, 1979
)
0.26
" Dosage ranged from 50-225 mg daily, and treatment lasted from 2-26 weeks."( A review of controlled studies with nomifensine, performed outside the UK.
Habermann, W, 1977
)
0.26
" Commonly used drugs are discussed and the effects of disease, drug dosage and hypoalbuminaemia on drug-protein binding are reviewed."( Protein binding of drugs--the clinical significance.
Buchanan, N, 1978
)
0.26
" Ten of them received amitriptyline in a daily dosage of 20-75 mg for 53 weeks (average); in 2, electrocardiographic side effects developed, viz, inversion of the T waves or evidence of acute coronary insufficiency."( Cardiovascular side effects of long-term therapy with tricyclic antidepressants in the aged.
Oei, LS; Rodstein, M, 1979
)
0.26
"Tricyclic antidepressant plasma levels were measured in patients and healthy subjects after a single dise of desmethylimipramine (DMI) or imipramine (IMI) and after chronic dosing to steady states."( Prediction of steady-state imipramine and desmethylimipramine plasma concentrations from single-dose data.
Amsterdam, JD; Brunswick, DJ; Mendels, J; Stern, SL, 1979
)
0.77
" This temporary effect on growth is present during the first few years of treatment and seems related to drug dosage and to the presence or absence of drug holidays."( The effects of stimulant medication on the growth of hyperkinetic children.
Hung, W; Lipman, RS; Overall, JE; Roche, AF, 1979
)
0.26
" Both drugs were given in a dosage of 25 mg 3-times daily over a period of 4 weeks, and patients' progress was assessed using psychiatric and psychological rating scales for depression."( Amoxapine in depressive illness.
Holden, JM; Kerry, RJ; Orme, JE, 1979
)
0.26
" Plasma levels of the tricyclics were relatively stable on both dosage schedules due to the long plasma half-lives of these drugs."( Imipramine and desipramine plasma levels: relationship to dosage schedule and sampling time.
Biggs, JT; Meyer, DA; Preskorn, SH; Rosen, SH; Ziegler, VE, 1978
)
1.7
" With increase of antidepressants dosage received by a subordinate rat its competing ability becomes enhanced too; this may cause a change in domination."( [Effect of pharmacologic substances on the dominance-submission relationship in a pair of rats].
Kampov-Polevoi, AB, 1978
)
0.26
" Imipramine in the usual dosage range and schedule was used when an antidepressant was indicated."( Dialysis, depression and antidepressants.
Egan, JD; Haffke, EA; Rajendran, S, 1978
)
1.17
"Because of persistent evidence that tricyclic antidepressants are generally underprescribed in respect to dosage and duration of treatment, a large group of family physicians attending a postgraduate course were asked specifically about their prescribing habits for these drugs."( Tricyclic antidepressant prescribing habits: a comparison of family physicians and psychiatrists.
Hull, AL; Ketai, RM, 1978
)
0.26
"Fifty-one newly hospitalized depressed patients participated in a double-blind comparison of two dosage levels of imipramine hydrochloride (150 mg vs 300 mg daily)."( Two dosages of imipramine in hospitalized endogenous and neurotic depressives.
Cuculic, Z; Kellner, R; Lee, JH; Simpson, GM, 1976
)
0.82
" Nevertheless the effectiveness of repeated activated charcoal dosage in lowering antidepressant concentrations of visceral organs is unpredictable."( Treatment of experimental imipramine and desipramine poisoning in the rat.
Olling, M; Rauws, AG, 1976
)
0.56
" No systemic changes of heart frequency and blood pressure were found during the infusions in spite of the high dosage of tricyclic antidepressants given such a short period as 1 hour."( Investigation of the orthostatic reaction after intravenous administration of imipramine, chlorimipramine, and inimpramine-N-oxide.
Bake, B; Dencker, SJ, 1976
)
0.48
" No correlations were found between dosage level and changes in weight and height percentiles."( Growth of hyperkinetic children taking methylphenidate, dextroamphetamine, or imipramine/desipramine.
Gross, MD, 1976
)
0.48
" Dosage was 1-3 mg daily."( Effect of flupenthixol on depression with special reference to combination use with tricyclic antidepressants. An uncontrolled pilot study with 45 patients.
Baba, O; Fujiwara, J; Hanaoka, M; Ishino, H; Sasaki, K, 1976
)
0.26
" The most effective dosage schedule was imipramine, 10 mg per kilogram, for 7 days followed by 5-HT, 100 mg per kilogram, 6 hours after the final imipramine dose."( Imipramine-serotonin induced myopathy.
Mendell, JR; Olson, WH; Parker, JM; Silverman, LM; Verrill, HL, 1976
)
1.97
" A dosage schedule for in- and outpatients has been established, using imipramine (Tofranil) or chlorimipramine (Anafranil), and haloperidol (Haldol)."( The use of psychotropic drugs in the treatment of chronic, severe pains.
Kocher, R, 1976
)
0.49
" The urinary excretion kinetics of bethanidine during and after repetive oral dosing was also studied."( Pharmacokinetics of bethanidine in hypertensive patients.
Bellward, G; Cunningham, R; Dayton, P; Gibaldi, M; Israili, A; McNay, J; Shen, D; Throne, M, 1975
)
0.25
" Simultaneous administration of imipramine and pentobarbital at the same dosage as in male rats is lethal for female rats without bile fistula within 30 min."( Biotransformation and biliary excretion of imipramine in rats under various experimental conditions.
Gigon, PL, 1975
)
0.8
" At all dosage levels its effect on blood pressure was biphasic."( Influence of some antidepressant drugs on the circulatory system. I. Imipramine.
Banaszkiewicz, W; Grzymislawska, I; Mrozikiewicz, A, 1975
)
0.49
" Intraventricular injection of phenylephrine produced a dose-dependent hypothermia, whereas no dose-response relationship was obtained by isoproterenol."( [Role of brain biogenic amines in the central thermoregulatory mechanism of the rat (author's transl)].
Fukushima, N, 1975
)
0.25
" Dose-response effects of fluoxetine and desipramine on displacement of [3H]imipramine binding in forebrain regions indicate that the ligand labels predominantly high capacity, low affinity binding sites."( Autoradiographic characterization of [3H]imipramine and [3H]citalopram binding in rat and human brain: species differences and relationships to serotonin innervation patterns.
Breese, GR; Duncan, GE; Kaldas, RS; Kirkman, JA; Little, KY; Stumpf, WE, 1992
)
0.78
" The question was whether maintaining antidepressant medication at the dosage used to treat the acute episode beyond 3 years would continue to provide a significant prophylactic effect compared with medication discontinuation after the 3 years of effective maintenance treatment."( Five-year outcome for maintenance therapies in recurrent depression.
Cornes, C; Frank, E; Grochocinski, VJ; Kupfer, DJ; Mallinger, AG; McEachran, AB; Perel, JM; Thase, ME, 1992
)
0.28
" Mianserin was given in the fixed dosage of 60 mg per day, whereas the dose of imipramine was adjusted to yield the optimal plasma concentration of imipramine plus desipramine of 400-600 nmol."( Lack of effect of mianserin on the symptoms of diabetic neuropathy.
Beck-Nielsen, H; Brøsen, K; Gram, LF; Grodum, E; Sindrup, SH; Skjold, T; Tuxen, C, 1992
)
0.51
" Administration of imipramine did not affect skeletal muscle force development at the dosage used to create heart failure."( Imipramine induced heart failure in the dog: a model to study the effect of cardiac assist devices.
Cheriex, EC; Habets, J; Lucas, CM; Penn, OC; van der Nagel, T; van der Veen, FH; Wellens, HJ, 1992
)
2.05
" The population pharmacokinetic parameters obtained in the study permit dosage individualisation using a bayesian algorithm."( Population pharmacokinetics of imipramine in children.
Domínguez-Gil, A; Fernández de Gatta, MM; García, MJ; Tamayo, M, 1992
)
0.57
"Researchers used population pharmacokinetic parameters and data on the concentration effect relationship from 49 6-13 year old children suffering from enuresis who attended an outpatient psychiatric clinic at University Clinical Hospital in Salamanca, Spain to design rational dosing guidelines of the antidepressant imipramine (IMI) for individual patients."( Population pharmacokinetics of imipramine in children.
Domínguez-Gil, A; Fernández de Gatta, MM; García, MJ; Tamayo, M, 1992
)
0.74
" The imipramine dosage was flexible to give a plasma concentration around 200 nmol/l and mianserin was given at a fixed dosage of 30 mg daily."( Combined treatment with imipramine and mianserin. A controlled pilot study.
Bech, P; Clemmesen, L; Klysner, R; Lauritzen, L; Loldrup, D; Lunde, M; Schaumburg, E; Waarst, S, 1992
)
1.1
" When imipramine or desipramine are to be coadministered with fluoxetine, a lower dosage may be needed to maintain steady-state concentrations and to avoid undesirable side effects caused by excessive tricyclic concentrations."( Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction.
Bergstrom, RF; Lemberger, L; Peyton, AL, 1992
)
0.76
"Three methods for estimating maintenance dosage requirements of imipramine were compared retrospectively in 146 enuretic patients."( Dosage optimization methods applied to imipramine and desipramine in enuresis treatment.
Domínguez-Gil, A; Fernández de Gatta, MM; García, MJ; Tamayo, M, 1992
)
0.79
" The results suggest that studies employing other benzodiazepines or other ALP dosage or taper schedules would be required to demonstrate any benefit for the IMI plus early benzodiazepine cotreatment strategy over IMI alone in the routine pharmacologic management of panic disorder."( Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder.
Charney, DS; Heninger, GR; Koleszar, AS; Krystal, JH; Nagy, LM; Woods, SW, 1992
)
0.53
" Flexible dosage at therapeutic levels resulted in increased heart rate and blood pressure and in decreased cardiac vagal control in patients receiving imipramine but not alprazolam or placebo."( Effects of alprazolam and imipramine on parasympathetic cardiac control in patients with generalized anxiety disorder.
Hoehn-Saric, R; McLeod, DR; Porges, SW; Zimmerli, WD, 1992
)
0.78
"A monoclonal antibody was used to study the dose-response relationship for antibody-mediated redistribution of tricyclic antidepressants (TCA) in rats."( Redistribution of tricyclic antidepressants in rats using a drug-specific monoclonal antibody: dose-response relationship.
Brunn, GJ; Gilbertson, DG; Keyler, DE; Matta, SG; Milavetz, JM; Pentel, PR; Pond, SM,
)
0.13
" Since the behavioural effects of B-HT 920 vary according to the dosage employed, discussion centres on what receptors might conceivably underly these effects and on their preclinical relevance."( Effects of B-HT 920 in the tail-suspension test.
Cassinadri, M; Ferrari, F; Tampieri, A; Tartoni, PL, 1991
)
0.28
"Patients who failed to respond to sustained, adequate treatment with the tricyclic imipramine (mean maximum dosage = 260 mg/day) and interpersonal psychotherapy were withdrawn from imipramine and treated in a standardized, but open-label 6-week trial with either phenelzine (N = 4; 60 mg/day) or tranylcypromine (N = 36; mean = 38."( Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors.
Frank, E; Hamer, T; Kupfer, DJ; Mallinger, AG; Thase, ME, 1992
)
0.88
"The phenomenon occurred in all patients during the first 3 weeks of treatment and disappeared within several days when the tricyclic dosage was reduced or the medication was withdrawn."( Painful ejaculation associated with antidepressants in four patients.
Aizenberg, D; Hermesh, H; Karp, L; Weizman, A; Zemishlany, Z, 1991
)
0.28
"One hundred and twelve patients suffering from moderate to severe major depression (DSM III) were enrolled into a study to compare the antidepressant activity and side effect profiles of two dosage groups of minaprine (200 mg and 300 mg per day) and one of imipramine (150 mg per day) in psychiatric practice."( Minaprine and dose response in depression. An investigation of two fixed doses of minaprine compared with imipramine.
Baldwin, DS; Herrington, RN; Livingston, HM; Montgomery, SA; Patel, A; Priest, RG; Steinert, J, 1991
)
0.67
" We prospectively tested a new pharmacokinetic model that allows flexible dosing and sampling to determine maintenance requirements in patients receiving TCAs."( Early individualization of tricyclic antidepressant dosing using a Bayesian pharmacokinetic model.
Harralson, AF; Hetnal, MJ; Jacisin, JJ; Kehoe, WA; Kwentus, JA; Sheffel, WB, 1991
)
0.28
" Similarly, in pigeons trained to discriminate imipramine from saline, noneffective doses of CRF shifted the imipramine dose-response curve more than twofold to the left."( Interactions of corticotropin-releasing factor with antidepressant and anxiolytic drugs: behavioral studies with pigeons.
Barrett, JE; Zhang, L, 1990
)
0.54
" Patients were allocated at random to receive one or other drug for a period of 4 weeks, dosage starting at 50 mg for the first 3 days and increasing to 100 mg daily for a further 3 days."( Fluvoxamine and imipramine in the treatment of depressive patients: a double-blind controlled study.
Baignoli, G; Ecari, U; Gonella, G, 1990
)
0.63
" Patients were treated for 6 weeks up to a target dosage of 5 mg/kg/day and assessed weekly by the Hamilton Rating Scale for Depression (HAM-D) and Clinical Global Impressions Improvement scale (CGI)."( The pharmacotherapy of depressive illness in adolescence: I. An open label trial of imipramine.
Freeman, R; Rigali, J; Strober, M, 1990
)
0.5
" A second question was whether maintaining antidepressant medication at the dosage used to treat the acute episode rather than decreasing to a "maintenance" dosage would provide prophylaxis superior to that observed in earlier trials in which a maintenance dosage strategy was employed."( Three-year outcomes for maintenance therapies in recurrent depression.
Cornes, C; Frank, E; Grochocinski, VJ; Jarrett, DB; Kupfer, DJ; Mallinger, AG; McEachran, AB; Perel, JM; Thase, ME, 1990
)
0.28
" The dosage of moclobemide (25 patients) was 300 mg daily for the first 5 days, after which it could be increased to 600 mg."( Moclobemide, imipramine and placebo in the treatment of major depression.
Alves, A; Mundim, FD; Nardi, AE; Schmid-Burgk, W; Versiani, M, 1990
)
0.65
" The imipramine dosage was significantly higher in the combined treatment group than in the imipramine-only group."( Possible influence of carbamazepine on plasma imipramine concentrations in children with attention deficit hyperactivity disorder.
Brown, CS; Cold, JA; Froemming, JH; Jabbour, JT; Self, TH; Wells, BG, 1990
)
1.05
" The results obtained show that the variables which are most associated with the reduction of enuresis are, in decreasing order: the dosage of imipramine administered, the duration of treatment, compliance and the level/dose ratio for the sum of the drug and metabolite levels."( The influence of clinical and pharmacological factors on enuresis treatment with imipramine.
Domínguez-Gil, A; Fernández de Gatta, MM; Galindo, P; García, MJ; Gutierrez, J; Rey, F; Tamayo, M, 1990
)
0.71
" The authors report on the efficacy of lithium augmentation in an open-label study of 20 outpatients with recurrent major depression who had not responded to greater than or equal to 12 weeks of treatment with imipramine (mean dosage = 256 mg/day) and psychotherapy."( Treatment of imipramine-resistant recurrent depression: II. An open clinical trial of lithium augmentation.
Frank, E; Jarrett, DB; Kupfer, DJ; Thase, ME, 1989
)
0.83
" Dose-response curves obtained with a holding potential of -140 mV were best fitted by 2:1 stoichiometry in all three drugs and were shifted in the direction of lower concentrations when a holding potential of -90 mV was used."( Block of sodium channels by psychotropic drugs in single guinea-pig cardiac myocytes.
Narahashi, T; Ogata, N, 1989
)
0.28
" Imipramine and nortriptyline also caused a rightward shift in the dose-response curve of histamine-induced cAMP generation."( Tricyclic antidepressants and acid secretory response of rabbit gastric cells.
Batzri, S, 1985
)
1.18
"Thirty-seven children (6-13 years old), receiving a flexible dosage of imipramine (IMI) for nocturnal enuresis, were evaluated."( Steady-state serum concentrations of imipramine, its main metabolites and clinical response in primary enuresis.
Benetello, P; Bonin, P; Furlanut, M; Montanari, G; Pellegrino, PA; Schiaulini, P,
)
0.64
"The aim of the present study was to characterize the kinetic behavior of imipramine (IMI) and desipramine in enuretic children and to evaluate the performance of different methods for dosage prediction based on individual and/or population data."( Prediction of imipramine serum levels in enuretic children by a Bayesian method: comparison with two other conventional dosing methods.
Amador, D; Domínguez-Gil Hurlé, A; Fernández de Gatta, MM; García, MJ; Gutiérrez, JR; Rey, F; Tamayo, M, 1989
)
0.87
" S1 served as a control and at S2-4 oxotremorine dose-response curves were taken expressing the dose-related inhibition of the evoked release of [3H]norepinephrine as percentage of the control."( Antagonism by tricyclic antidepressants of the muscarinic receptors located on the adrenergic nerve endings in rabbit heart atrium.
Perel, JM; Somogyi, GT, 1989
)
0.28
" Significant decreases were still present in many brain areas on the same dosage schedule 30 days after drug administration."( Effects of high-dose methamphetamine administration on serotonin uptake sites in rat brain measured using [3H]cyanoimipramine autoradiography.
Aronson, CE; Brunswick, DJ; Kovachich, GB, 1989
)
0.49
"25-250 microM) as well as after multiple dosing of IMI was studied."( [Physiological principles of imipramine pharmacokinetics].
Szymura-Oleksiak, J, 1989
)
0.57
" In an ongoing 3-year maintenance trial, the authors are using imipramine in dosages greater than 150 mg/day for both acute and continuation treatment (4 to 6 months) of recurrent depression in order to test the efficacy of this dosage level."( Adequate treatment with imipramine in continuation treatment.
Frank, E; Kupfer, DJ; Perel, JM, 1989
)
0.82
" Dosage ranged from 600 to 2,400 mg/day for fengabine and 50 to 200 mg/day for TCAs."( Fengabine, a new GABAmimetic agent in the treatment of depressive disorders: an overview of six double-blind studies versus tricyclics.
Garreau, M; Magni, G; Orofiamma, B; Palminteri, R, 1989
)
0.28
" The authors report on the lack of efficacy of adjunctive L-triiodothyronine (T3; 25 micrograms/day) in a sample of 20 outpatient unipolar depressives who had not responded to greater than or equal to 12 weeks of treatment with imipramine (mean dosage = 240 mg/day) and interpersonal psychotherapy."( Treatment of imipramine-resistant recurrent depression: I. An open clinical trial of adjunctive L-triiodothyronine.
Jarrett, DB; Kupfer, DJ; Thase, ME, 1989
)
0.83
" Ovariectomy (OVX) had no effect on imipramine binding, consonant with the biphasic dose-response relationship for estradiol."( Direct effects of ovarian hormones on antidepressant binding sites.
Dwyer, KD; Roy, EJ; Wilson, MA, 1989
)
0.55
" The study shows that it is possible to obtain a good estimation of individual dosage needs from one or more serum concentrations obtained at steady state."( Predictive techniques applied to imipramine therapeutic drug monitoring.
Domínguez-Gil, A; Fernandez de Gatta, MM; Garcia, MJ; Montojo, C; Ramón Gutierrez, J; Rey, F; Tamayo, M, 1989
)
0.56
" All patients were markedly improved when the daily dosage of the antidepressant was reduced with a simultaneous decrease of the blood concentrations."( High blood concentrations of imipramine or clomipramine and therapeutic failure: a case report study using drug monitoring data.
Balant, LP; Balant-Gorgia, AE; Garrone, G, 1989
)
0.57
" Imipramine and fluoxetine have already been compared in other studies, but never at such a low dosage (20 mg) for fluoxetine."( A double-blind study of fluoxetine and imipramine in major depression.
Bressa, GM; Brugnoli, R; Pancheri, P, 1989
)
1.46
", once daily for 14 days) the dose-response curve of the isolated rat anococcygeal muscle to phenylephrine shifted to the left, and furthermore, the -log KA value (affinity) for phenylephrine was significantly increased without affecting the affinity for guanfacine."( Enhancement of central and peripheral alpha 1-adrenoceptor sensitivity and reduction of alpha 2-adrenoceptor sensitivity following chronic imipramine treatment in rats.
Hong, KW; Lee, WS; Rhim, BY, 1986
)
0.47
" Maternal weight gain was significantly reduced in a dose-response manner, but litter size and pup weight on postnatal day (PND) 1 were unaffected."( Effect of prenatal imipramine exposure on development of the postnatal rat heart and brain.
Delongchamp, RR; Harmon, JR; Kimmel, GL; Webb, PJ, 1986
)
0.6
" No significant correlation was found between the dosage and the serum concentration of imipramine or desipramine."( Comparison of the serum levels in primary non-agitated depressed out-patients treated with imipramine in combination with placebo, diazepam or dixyrazine.
Feet, PO; Holm, V; Larsen, S; Liden, A; Lillevold, PE; Robak, OH, 1987
)
0.72
" During a double-blind drug and dose selection phase, investigators were permitted to change drug or dosage to achieve greater than or equal to 70% suppression in VPC frequency and greater than 90% suppression of runs of VPC with the exception of patients assigned to placebo, who continued receiving it."( Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS.
, 1988
)
0.55
", twice daily for 14 days) the pressor dose-response curves to phenylephrine, methoxamine and cirazoline (alpha 1-adrenoceptor agonists) significantly shifted to the left with decreased PD50 values in pithed rats; however, the dose-response curve to Sgd 101/75, a selective alpha 1-adrenoceptor agonist was not affected."( Increased alpha 1- and decreased alpha 2-adrenoceptor sensitivities upon chronic treatment with imipramine in mediating cardiovascular responses in pithed rats.
Hong, KW; Jung, HO; Rhim, BY; Yu, DH, 1987
)
0.49
" 5-HT agonists stimulated [3H]inositol phosphate accumulation in a dose-related but biphasic manner and only the high-affinity component of the dose-response curve was sensitive to antagonists."( 5-Hydroxytryptamine-stimulated inositol phospholipid hydrolysis in rat cerebral cortex slices: pharmacological characterization and effects of antidepressants.
Kendall, DA; Nahorski, SR, 1985
)
0.27
" Maternal weight gained during the dosing period was decreased in a dose-related manner, but there were no dose-related differences in offspring body weights."( Early neurobehavioral and neurochemical alterations in rats prenatally exposed to imipramine.
Ali, SF; Buelke-Sam, J; Newport, GD; Slikker, W, 1986
)
0.5
" Imipramine exerted negative dose-response effects on motor performance (motor speed, motor pursuit), while it improved hyperactive behavior and attention and raised the heart rate slightly."( Motor performance in hyperactive children treated with imipramine.
Evans, RW; Gualtieri, CT, 1988
)
1.43
" In a 6-week, double-blind, parallel-design study with flexible dosage scheduling, the authors compared the effects of alprazolam with those of imipramine in 60 patients who had generalized anxiety disorder."( Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms.
Hoehn-Saric, R; McLeod, DR; Zimmerli, WD, 1988
)
0.74
" Our study indicates that the discontinuation of diazepam, even when given in moderate dosage over a relatively short period of time, may cause withdrawal reactions in combined antidepressant/diazepam treatment."( Withdrawal reactions to diazepam in combined imipramine/diazepam treatment of primary nonagitated depressed outpatients.
Feet, PO; Larsen, S; Lillevold, PE; Robak, OH, 1988
)
0.53
" Analysis of the total tricyclic concentration and the parent: desmethylated ratio revealed that those subjects in a depressive recurrence previously had had a lower imipramine: desipramine ratio (despite matched dosing and nonsignificant total plasma concentrations) than nonrecurrents."( Imipramine metabolism in recurrent depressive episodes.
Garvey, M; Tollefson, G; Tuason, VB; Valentine, R,
)
1.77
"The incidence of potentially toxic serum levels (greater than or equal to 400 ng/ml) was analyzed in a group of 196 monitored patients on a standard dosage regimen (75-225 mg/day) of several antidepressants: imipramine, amitriptyline, nortriptyline, maprotiline and clomipramine."( High levels of tricyclic antidepressants in conventional therapy: determinant factors.
Domínguez-Gil, A; Fernández de Gatta, MM; García, MJ; Gutierrez, JR; Tamayo, M, 1988
)
0.46
" In the past decade, therapeutic monitoring of antidepressant drugs and use of pharmacokinetic principles have been shown to be an improvement over the dose-response approach."( Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: evaluation of doxepin and imipramine--new data and review.
Davis, CM; Ereshefsky, L; LeRoy, A; Tran-Johnson, T, 1988
)
0.49
"Information on steady-state concentrations of parent tricyclic antidepressants (TCAs) and their major metabolites in plasma is useful in ascertaining compliance, for possible pharmacokinetic changes during longer treatment, and for prospective individualized dosing procedures."( Compliance during tricyclic antidepressant therapy: pharmacokinetic and analytical issues.
Perel, JM, 1988
)
0.27
"Plasma drug concentrations and clinical response were measured in two groups of hospitalised depressed patients, who received amitriptyline or imipramine double-blind, in a dosage of 250 mg for four weeks."( Imipramine and amitriptyline plasma concentrations and clinical response in major depression.
Bowden, C; Brunswick, D; Hanin, I; Kocsis, JH, 1986
)
1.91
" Weight-corrected imipramine dosage did not predict either clinical response or plasma level in the individual subject."( Imipramine in prepubertal major depressive disorders.
Chambers, WJ; Davies, M; Goetz, R; King, J; Lupatkin, W; Perel, JM; Puig-Antich, J; Stiller, RL; Tabrizi, MA, 1987
)
2.05
" These unexpected adverse behavioral effects were discussed with respect to dosage and diagnostic considerations."( Preliminary study of imipramine in profoundly retarded residents.
Aman, MG; Teehan, CJ; Vaithianathan, C; White, AJ, 1986
)
0.59
" The authors report on practices related to dosage buildup, side effects, concurrent medical conditions, blood level information, and maintenance on tricyclics."( A survey of psychiatrists' practices related to the use of tricyclic antidepressants.
Ban, TA; Friedel, RO; Goldberg, SC; Hamer, RM; Tilley, DH, 1986
)
0.27
" Regardless of the reason for use, nonpsychiatric physicians were found to use relatively low dosages, rarely plan or effect dosage increases, and rarely discontinue medication."( Antidepressant treatment of medical-surgical inpatients by nonpsychiatric physicians.
Callies, AL; Popkin, MK, 1987
)
0.27
" In each patient, tinnitus subsided spontaneously within 2-4 weeks of onset without any specific treatment, even though the daily dosage of imipramine and the plasma tricyclic levels were constant or increased."( Imipramine and tinnitus.
Greden, JF; Grunhaus, L; Tandon, R, 1987
)
1.92
"The authors examined dose-response relationships in 62 agoraphobic patients receiving either imipramine or placebo under double-blind conditions in conjunction with behavioral interventions."( Imipramine in the treatment of agoraphobia: dose-response relationships.
Mavissakalian, M; Perel, J, 1985
)
1.93
" The dosage schedule provided an initial dose of 2 capsules/day which was to be gradually increased up to a maximum dose of 9 capsules/day."( Diclofensine and imipramine. A double-blind comparative trial in depressive out-patients.
Capponi, R; Hormazabal, L; Schmid-Burgk, W, 1985
)
0.61
" Therapy was initiated at 50 mg/day; thereafter, dosage ranged between 100 and 300 mg/day for both drugs."( A double-blind placebo-controlled study of fluvoxamine and imipramine in depression.
Dominguez, RA; Goldstein, BJ; Jacobson, AF; Steinbook, RM, 1985
)
0.51
" Dose-response curves indicated that the effectiveness with which chloride enhanced binding was similar with age, even though the absolute increase in binding was less."( 3H-imipramine binding in aged mouse brain: regulation by ions and serotonin.
Severson, JA,
)
0.75
" The effects on the overall response and the induction and elicitation phases were evaluated, using two alternative dosage schedules for each agent."( Different effects of psychotropic drugs on delayed hypersensitivity responses in mice.
Descotes, J; Evreux, JC; Tedone, R, 1985
)
0.27
" Based on amino acid patterns and serum drug levels only half of the patients received an optimal therapy on the applied schematic dosage schedule."( Biochemical and diagnostic classification and serum drug levels: relation to antidepressive effect of imipramine.
Elley, J; Krautwald, O; Larsen, OB; Møller, SE; Ortmann, J; Reisby, N, 1985
)
0.48
" It seems that administration of IMI with drinking water may be recommended as a reliable and convenient dosage schedule in experiments which need prolonged treatment with IMI."( Chronic dosage of imipramine in animal experiment: concentrations of imipramine and desipramine in the rat brain after various modes of dosage.
Danek, L; Daniel, W; Melzacka, M; Rurak, A; Vetulani, J,
)
0.47
" The dose-response relationship for hyperactivity in grouped mice following the injection of morphine sulphate has been established."( Monoamine mediation of the morphine-induced activation of mice.
Carroll, BJ; Sharp, PT, 1972
)
0.25
"A case is reported of fatal aplastic anemia developing in a 50-year-old woman who received lithium carbonate in the generally accepted dosage for a manic-depressive disorder."( Aplastic anemia associated with lithium therapy.
Chaudhry, ZA; Hussain, MZ; Khan, AG, 1973
)
0.25
" The starting dosage was 10 mg."( A double-blind comparison of a new antidepressant, protryptiline, with imipramine and amitryptiline.
Davanloo, H; Moll, A; Straker, M, 1966
)
0.48
" Antenatal patients taking a once-daily dosage of prophylactic iron were more co-operative than those taking divided dosages."( Drug defaulting in a general practice.
Porter, AM, 1969
)
0.25
" Increasing doses of nortriptyline produced a parallel shift of the hypothermic log dose-response curve for intraventricular injections of noradnamine to the right."( The interactions of noradnamine and imipramine-like antidepressant drugs.
Cowell, P, 1969
)
0.52
" The ED50s of the effective neuroleptics for this inhibition were similar to those reported for antagonism of amphetamine-induced stereotypic behavior in the rat and the slopes of the dose-response curves were parallel indicating a common site and mechanism of action, presumably blockade of postsynaptic dopaminergic receptors."( Effect of neuroleptics and tricyclic antidepressants upon d-amphetamine discrimination.
Schechter, MD, 1980
)
0.26
" Administration of nitrazepam with other drugs, except aminopyrine, or of estazolam together with haloperidol exhibited an anticonvulsive pattern different from the case of dosing with either drug alone."( [Pharmacology of a 1H-1, 2, 4-triazolyl benzophenone derivative (450191-S), a new sleep-inducer (III). Behavioral study on interactions of 450191-S and other drugs in mice].
Horiuchi, M; Ibii, N; Yamamoto, K, 1984
)
0.27
" A drug-free and a placebo day were followed by dosing with imipramine, 1 mg/kg per day, given in two divided doses."( Antiarrhythmic effect of imipramine hydrochloride in patients with ventricular premature complexes without psychological depression.
Bigger, JT; Giardina, EG, 1982
)
0.81
" The mean maintenance dosage of trazodone was 300 mg (range 200-350 mg) and of imipramine 160 mg (range 150-175 mg)."( A double blind comparison of the efficacy and safety of trazodone and imipramine in endogenous depression.
Al-Yassiri, MM; Ankier, SI; Bridges, PK, 1983
)
0.73
" Finally, the strategy of a drug treatment is considered with regard to the choice of the best drug and the best dosage for a given depressed patient."( [Biological treatments of depression (author's transl)].
Cuche, H; Zarifian, E,
)
0.13
" The cholesterol removal and all the agents used induced dose-response decreases in membrane lipid order as measured by fluorescence polarization or ESR."( The effects of membrane lipid order and cholesterol on the internal and external cationic sites of the Na+-K+ pump in erythrocytes.
Bruckdorfer, KR; Chailley, B; Claret, M; Giraud, F, 1981
)
0.26
" Its pharmaco-EEG profile, especially after higher dosage (150 and 225 mg), was characterized by a decrease in delta and theta activity, an increase in alpha activity and a delta and theta activity, an increase in alpha activity and a decrease in beta activity, as well as by an attenuation of the average frequency and frequency deviation and a trend towards an augmentation of the amplitude and amplitude variability."( [Classification and determination of the pharmacodynamics of a new tetracyclic antidepressive agent, pirlindol, using pharmaco-EEG and psychometry].
Grünberger, L; Linzmayer, L; Saletu, B; Stöhr, H; Wittek, R, 1983
)
0.27
"A 5-week double-blind study compared amoxapine to imipramine (2:1 dosage ratio) in the treatment of depressed outpatients."( Double-blind comparison of amoxapine and imipramine in the treatment of depressed patients.
Cohen, BM; Curren, FC; Falk, WE; Gelenberg, AJ; Hicks, RH; Lydiard, RB; McCormick, MG; Wojcik, JD, 1984
)
0.79
" The metabolite/parent ratios and the disposition of the individual metabolites confirm findings that chronic dosing results in only limited accumulation of hydroxy metabolites."( The analysis and disposition of imipramine and its active metabolites in man.
DeVane, CL; Jusko, WJ; Sutfin, TA, 1984
)
0.55
"It is important to understand both the kinetic and the dynamic implications of dosing TCAs and BZs in the elderly, for whom these drugs are frequently prescribed."( Implications of dosing tricyclic antidepressants and benzodiazepines in geriatrics.
Cutler, NR; Narang, PK, 1984
)
0.27
"The administration of (+)-Cyanidanol-3 [+)-catechin) to the rat using a subchronic dosing regime based on that currently used in the therapy of acute viral hepatitis in man, largely prevented the changes in the disposition of a single dose of [14C]imipramine hydrochloride induced by the hepatotoxin, D-(+)-galactosamine hydrochloride in rats."( The prevention by (+)-Cyanidanol-3 of hepatitis-induced changes in the disposition of imipramine in the rat.
Griffiths, LA; Hackett, AM; Shaw, IC, 1984
)
0.67
" Dosage regimens were adjusted individually to obtain a favorable response with regard to the frequency of enuresis and to the possible occurrence of side effects."( Monitoring of serum levels of imipramine and desipramine and individualization of dose in enuretic children.
Acosta, A; de Gatta, MF; Dominguez-Gil, A; García, MJ; Gutierrez, JR; Rey, F, 1984
)
0.56
" This finding may be related to the relatively low drug concentrations in this group of patients, a high placebo response rate, or noncompliance with the prescribed dosage regimen."( Concentrations of imipramine and its metabolites during enuresis therapy.
DeVane, CL; Sawyer, WP; Walker, RD; Wilson, JA, 1984
)
0.6
" Neither binodaline nor the desmethyl derivative was found to influence cerebral levels of NA, 5-HT and DA following acute dosing in rats."( Influence of the antidepressant binodaline on biogenic amine uptake and brain levels in the rat.
Benfield, DP; Luscombe, DK, 1983
)
0.27
" Active compounds exhibited an inverted U-shaped dose-response curve."( Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
Butler, DE; L'Italien, YJ; Marriott, JG; Nordin, IC; Poschel, PH; Zweisler, L, 1984
)
0.27
" After oral dosing absolute systemic bioavailability increased, resulting in decreased apparent oral clearance in the absence of any change in oral elimination t1/2."( Imipramine disposition in users of oral contraceptive steroids.
Abernethy, DR; Greenblatt, DJ; Shader, RI, 1984
)
1.71
"The pharmacology, pharmacokinetics, clinical trials, side effects, and dosage of amoxapine are reviewed."( Evaluation of amoxapine.
Evans, RL; Kinney, JL,
)
0.13
" The antidepressant effects of the substance were independently recognized in seven uncontrolled clinical trials and verified in 11 published standard controlled clinical studies in which viloxazine in the dosage range from 150- to 300-mg dosage was equal in overall therapeutic efficacy to imipramine and amitriptyline, but produced a lower incidence of side effects."( Viloxazine: a review of the literature.
Ban, TA; McEvoy, JP; Wilson, WH, 1980
)
0.44
" Therapeutic effects were the same but once daily dosage produced drowsiness whilst thrice daily dosage did not."( Trazodone in depression.
Wheatley, D, 1980
)
0.26
" A fixed dose of 150 mg was used for both drugs for four weeks, employing randomized methodology with placebo capsules and tablets to balance dosage schedules."( A controlled double blind comparative study of single dose administration of imipramine pamoate and divided dose of imipramine hydrochloride in depressive illness.
Khorana, AB,
)
0.36
" This case suggests that single daily dosing of tricyclic antidepressants may be more hazardous to the liver than divided doses."( Toxic hepatitis and single daily dosage imipramine therapy.
DeVane, CL; Harris, R; Moskovitz, R; Stewart, RB, 1982
)
0.53
" The achievement of such results with moderate doses might indicate a possible relationship between the optimal dosage of the antidepressive drug and the intensity of the mood disorder."( [Imipramine and neuro-psychiatry. Retrospective study of 557 out-patients treated in a neuro-psychiatric unit (author's transl)].
Boulenger, JP; Brion, S, 1982
)
1.17
"01), but at 150 and 180 min after dosing QS2I was significantly lower."( Hemodynamic responses of trazodone and imipramine.
Burgess, CD; George, CF; Hames, TK, 1982
)
0.53
"Two schedules of imipramine (IM) administration were compared, a single intraperitoneal dose (10 mg/kg) (I) and chronic oral dosage (10 mg/kg twice a day for 14 days) (II)."( Different pharmacokinetic and pharmacological effects following acute and chronic treatment with imipramine.
Daniel, W; Maj, J; Melzacka, M; Mogilnicka, E, 1982
)
0.82
" All active compounds gave inverted U-shaped dose-response curves."( Cognition-activating properties of 3-(Aryloxy)pyridines.
Butler, DE; Marriott, JG; Poschel, BP, 1981
)
0.26
" The loss of inward current in the region of negative slope conductance is dose-dependent, highly reproducible and relatively resistant to desensitization, and for these reasons a valid dose-response relationship can be described."( Dopamine inhibits burst-firing of neurosecretory cell R 15 in Aplysia californica: establishment of a dose-response relationship.
Gospe, SM; Wilson, WA, 1980
)
0.26
" However, assessment of the results of previous studies is confounded by the relative lack of standards in diagnostic criteria, outcome measures, dosage and duration of treatment."( Studies of reversible and selective inhibitors of monoamine oxidase A in dysthymia.
Pétursson, H, 1995
)
0.29
"The aim of this study was to characterize the specific effects of imipramine in the treatment of panic disorder with agoraphobia and to delineate dose-response and possibly plasma level-response relationships."( Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships.
Mavissakalian, MR; Perel, JM, 1995
)
1.97
" There was a positive dose-response relationship, with significant group differences involving primarily the high- and medium-dose groups versus the placebo group."( Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships.
Mavissakalian, MR; Perel, JM, 1995
)
1.73
"This article presents panic diary results of a dose-response study with imipramine hydrochloride in panic disorder with agoraphobia patients."( Dose-response characterization of the antipanic effects of imipramine.
Mavissakalian, MR; Perel, JM, 1994
)
0.76
" The dosage was 3 x 300 mg hypericum extract LI 160 or 3 x 25 mg imipramine daily."( Effectiveness and tolerance of the hypericum extract LI 160 in comparison with imipramine: randomized double-blind study with 135 outpatients.
Arnoldt, KH; Hübner, WD; Vorbach, EU, 1994
)
0.75
" Side effects were assessed through the Dosage Record Emergent Symptoms at days 0, 7, 14, 30, 45, and 60."( Effects of moclobemide on depressive symptoms and cognitive performance in a geriatric population: a controlled comparative study versus imipramine.
Delle Chiaie, R; Donnini, M; Gambino, C; Pancheri, P; Seripa, S; Trillo, L; Vicario, E, 1994
)
0.49
"Doctors' prescription and dosing behaviour was investigated using data from 9 clinical trials in 550 patients treated with psychotropics."( Correct titration of non-drugs and some other methodological issues.
Beneke, M; Fritze, J; Rasmus, W; Rød, IS, 1994
)
0.29
" Dosage was flexible and administered on a three-times-a-day schedule, with a mean maximum daily dose of 182 mg for venlafaxine and 176 mg for imipramine."( Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients.
Feighner, J; Mandos, LA; Rickels, K; Schweizer, E, 1994
)
0.78
" By patient self-report, improvement of anxiety symptoms associated with depression was evident with nefazodone as early as the first week of treatment, and benefit was seen with both nefazodone dosage groups."( A double-blind comparison of nefazodone, imipramine, and placebo in major depression.
Ecker, JA; Elie, R; Faludi, G; Fontaine, R; Kaplita, S; Kensler, TT; Ontiveros, A; Roberts, DL, 1994
)
0.55
"5 mg/kg), each dosage being given for 2 weeks."( Plasma levels and efficacy of imipramine treatment for enuresis.
Fritz, GK; Rockney, RM; Yeung, AS, 1994
)
0.58
" In many instances, a knowledge of the drug metabolism status of a patient can be helpful in the selection of a drug and its dosage regimen, and in the prediction of possible drug/drug interactions when two or more drugs have to be administered concomitantly."( Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping.
Coutts, RT, 1994
)
0.29
" The time course and dose-response relationships for this effect were examined after treatment with two representative antidepressant drugs (imipramine and citalopram) and electriconvulsive shock (ECS)."( Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments.
Layer, RT; Nowak, G; Paul, IA; Popik, P; Skolnick, P, 1994
)
0.49
"This article reports the effects of imipramine on heart rate and blood pressure in panic disorder patients who participated in an 8-week double-blind dosage response treatment protocol."( Blood pressure and heart rate response of panic disorder patients receiving imipramine in a dose-response treatment paradigm.
de Groot, CM; Mavissakalian, MR, 1994
)
0.79
" Addition of fluvoxamine to patients on a stable desipramine dosage regimen resulted in a slight, but statistically not significant, increase in desipramine plasma concentrations."( Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients.
Avenoso, A; Campo, GM; Caputi, AP; Pollicino, AM; Spina, E, 1993
)
0.53
" These findings indicate that, at the dosage tested, fluvoxamine markedly inhibits the demethylation of imipramine without affecting significantly the CYP2D6-mediated hydroxylation of desipramine."( Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects.
Avenoso, A; Campo, GM; Caputi, AP; Perucca, E; Pollicino, AM; Spina, E, 1993
)
0.75
"Of 60 depressed alcoholics who completed an open trial of imipramine, 27 (45%) responded with improvement in both mood and drinking behavior, and eight (13%) responded after further dosage increases or treatment with disulfiram."( Imipramine treatment of alcoholism with comorbid depression.
Harrison, W; McGrath, PJ; Nunes, EV; Ocepek-Welikson, K; Quitkin, FM; Stewart, JP; Tricamo, E, 1993
)
1.97
" The dosage was designed as a fixed-adjustable regimen for an active treatment period of six weeks."( Paroxetine in the treatment of Chinese patients with depressive episode: a double-blind randomized comparison with imipramine.
Chan, CH; Chiu, HJ; Hong, CJ, 1996
)
0.5
" Repeated (14 days, twice daily), but not single, administration of imipramine (10 mg/kg) shifted the dose-response curves for serotonin and 8-OH-DPAT to the left."( Imipramine increases the 5-HT1A receptor-mediated inhibition of hippocampal neurons without changing the 5-HT1A receptor binding.
Bijak, M; Czyrak, A; Maćkowiak, M; Tokarski, K; Wedzony, K, 1996
)
1.97
" In this study, we conducted dose-response curves for each of the cholesterol transport pathways."( Quantitative analysis of hydrophobic amine inhibition of intracellular cholesterol transport.
Andemariam, B; Liscum, L; McWilliams, GL; Underwood, KW, 1996
)
0.29
" Determining the best dosing strategy has been the goal of recent treatment studies with alcohol-dependent patients."( Dosing issues in the pharmacotherapy of alcoholism.
Mason, BJ, 1996
)
0.29
" The dose was adjusted to a predefined fixed blood level to avoid suboptimal dosing of imipramine."( A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients.
Bruijn, JA; Moleman, P; Mulder, PG; van de Wetering, BJ; van den Broek, WW; van der Mast, RC; van Hulst, AM, 1996
)
0.75
" The method was applied for the determination of these substances in the pharmaceutical dosage forms."( Voltammetric determination of imipramine hydrochloride and amitriptyline hydrochloride using a polymer-modified carbon paste electrode.
Biryol, I; Küçükyavuz, Z; Uslu, B, 1996
)
0.58
" Dosing instructions for buspirone and guidelines for switching patients from benzodiazepines to buspirone are offered."( Strategies for treatment of generalized anxiety in the primary care setting.
Rickels, K; Schweizer, E, 1997
)
0.3
" A muscarinic agonist, carbachol, produced a dose-related rightward shift of the dose-response curve to IMI."( Suppression of the rat micturition reflex by imipramine.
Kim, CY; Sohn, UD, 1997
)
0.56
" In these rats, the power values were less than three times those before the dosing of PTZ or beta-CCM."( [A study of the effects of antidepressants on the GABAA receptor and its complex based on the drug actions on the power-spectral changes of rat hippocampal EEG induced by GABA antagonists and inverse agonists].
Hatsuda, S; Matsubara, M; Miura, K; Murakami, H; Nakazawa, K; Ohara, M; Sugita, S; Suzuki, S; Terashima, M, 1997
)
0.3
" Input files require estimates of binding coefficients, first- and/or second-order metabolism constants, level of interaction between the two chemicals, and dosing information."( A computer model and program for xenobiotic disposition during pregnancy.
Luecke, RH; Pearce, BA; Wosilait, WD; Young, JF, 1997
)
0.3
" We recommend repeat measurement of imipramine concentrations 1 week after the start of any butalbital-containing product or barbiturate, and dosage adjustments based on the results and on the patient's response to the change."( Possible interaction between imipramine and butalbital.
Amsden, GW; Garey, KW; Johns, CA,
)
0.7
" However, multiple dosing with either ACPC or DCS (6 daily doses, 200 mg/kg) produced an apparent behavioral adaptation, as the immobility data were indistinguishable from chronic saline administration."( Chronic administration of NMDA glycine partial agonists induces tolerance in the Porsolt swim test.
Boje, KM; Lopes, T; Neubauer, P, 1997
)
0.3
" Dose-response curves for each drug, conducted at each drug's t1/2, indicated considerable differences in potency (EC50) at stimulating [3H]MPP+ release from C6-hSERT cells [3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) > imipramine > 1-[2-diphenylmethoxy]ethyl-4-(3-phenylpropyl)-piperazine (GBR-12935) threo-(+/-)-methylphenidate > cocaine > mazindol > 2-beta-carbomethoxy-3beta-(4-fluorophenyl)tropane (CFT) > (+)methamphetamine > amphetamine > DA > fenfluramine > norepinephrine (NE) > 5-HT]."( [3H]substrate- and cell-specific effects of uptake inhibitors on human dopamine and serotonin transporter-mediated efflux.
Eshleman, AJ; Janowsky, A; Johnson, RA; Meyers, T; Neve, KA, 1998
)
0.48
" Imipramine increased the maximum response to 5-HT without altering the EC50 of the dose-response curve."( Chronic imipramine administration amplifies the serotonin2A receptor-induced intracellular Ca2+ mobilization in C6 glioma cells through a calmodulin-dependent pathway.
Kamei, K; Muneoka, K; Muraoka, S; Takigawa, M, 1998
)
1.64
" In the case of the hypericum extracts the dose-response relationship was inverted U-shaped with a MED value of 20 mg/kg and a maximal effect of 41% and 32% immobility reduction, for Ze 117 and LI 160, respectively."( Comparison of hypericum extracts with imipramine and fluoxetine in animal models of depression and alcoholism.
de Beun, R; De Vry, J; Jentzsch, KR; Maurel, S; Schreiber, R, 1999
)
0.57
" Thirty-two reports (29 studies) evaluated adverse effects of drug therapy; many of the side effects associated with stimulant use appear to be relatively mild and of short duration and to respond to dosing or timing adjustments."( Treatment of attention-deficit/hyperactivity disorder.
Boyle, M; Cunningham, C; Jadad, AR; Kim, M; Schachar, R, 1999
)
0.3
" Therefore, despite considerable reductions in total serum levels of IMI and DMI, but when the unchanged free fraction concentration of these compounds is maintained, a dosage elevation of IMI does not seem to be necessary after CBZ addition to TCA therapy."( Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression.
Szymura-Oleksiak, J; Wasieczko, A; Wyska, E, 2001
)
0.59
"Potentially serious adverse effects may be seen in horses administered doses of imipramine that exceed a dosage of 2 mg/kg."( Pharmacokinetics of imipramine in narcoleptic horses.
Hines, MT; Mealey, KL; Mealey, RH; Peck, KE, 2001
)
0.86
" The dose-response curve followed an inverse U-shape."( Acute and chronic actions of a dry methanolic extract of Hypericum perforatum and a hyperforin-rich extract on dopaminergic and serotonergic neurones in rat nucleus accumbens.
Mannel, M; Rommelspacher, H; Siemanowitz, B, 2001
)
0.31
" Further, in C57Bl/6 mice, imipramine produced a "U-shaped" dose-response curve in the FST, whilst no evidence of a biphasic response was present in the TST at doses up to 45 mg/kg."( Intra- and interstrain differences in models of "behavioral despair".
Bai, F; Clay, M; Li, X; Lindstrom, T; Skolnick, P,
)
0.43
" Fluoxetine increased the quetiapine area under the plasma concentration time curve during a 12-hour interval (+12%), maximum plasma concentration during the dosing interval (C(ss)(max); +26%), and minimum plasma concentration at the end of the dosing interval (+8%), although it decreased oral clearance (-11%)."( Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine.
Alva, G; Arvanitis, LA; Carreon, D; Kalali, A; Potkin, SG; Thyrum, PT; Yeh, C, 2002
)
0.62
" The total daily dosage of trazodone was 100 mg (50 mg in one subject), and of imipramine 40 mg (20 mg in one subject)."( Effects of trazodone and imipramine on the biological rhythm: an analysis of sleep EEG and body core temperature.
Endo, S; Nakamura, S; Suzuki, H; Yamadera, H, 2002
)
0.85
" For the first woman an increase in the lithium dosage combined with a substitution of the antidepressant resulted in a complete recovery and for the second woman, an increase in the lithium dosage combined with the continued use of the same antidepressant resulted in a recovery to a large extent."( [Manic state during the addition of lithium in the case of depression resistant to imipramine].
Beck-Lie A Fat, JR; Birkenhäger, TK; Renes, JW, 2002
)
0.54
" The heterocyclic agent trazodone significantly inhibited paw oedema by 46 and 41% at 1 and 2h after dosing at the highest dose (40 mg kg(-1)) examined."( Evaluation of the anti-inflammatory and anti-nociceptive effects of different antidepressants in the rat.
Abdel-Salam, OM; El-Shenawy, SM; Nofal, SM, 2003
)
0.32
" Furthermore, the two methods were applied to pharmaceutical dosage form."( Determination of imipramine in presence of iminodibenzyl and in pharmaceutical dosage form.
el-Zeany, BA; Farid, NF; Moustafa, AA, 2003
)
0.66
" The clinical parameters and outcomes for the model were derived from a series of systematic clinical trials with imipramine utilising uniform dosage procedures and validated response criteria."( Cost effectiveness of acute imipramine therapy versus two imipramine maintenance treatment regimens for panic disorder.
Flynn, JA; Mavissakalian, MR; Revicki, DA; Schmier, JK, 2000
)
0.81
" Mechanisms of desipramine toxicity and its dosage recommendations are discussed."( Excess fatality from desipramine and dosage recommendations.
Amitai, Y; Frischer, H, 2004
)
0.32
"01), and the high dosage significantly inhibited the activity of MAO-A in hypothalamus (P<0."( [Effect of madecassoside on depression behavior of mice and activities of MAO in different brain regions of rats].
Chen, Y; Han, T; Liu, MR; Qin, LP; Rui, YC; Zheng, HC, 2004
)
0.32
"The absence of significant differences in efficacy between selective serotonin re-uptake inhibitors (SSRIs) and imipramine in these trials is at least in part due to improper dosing of the latter; imipramine with therapeutic drug monitoring may be more effective than SSRIs."( Imipramine dose in relation to therapeutic plasma level: are clinical trials using imipramine as a positive control flawed?
Birkenhäger, TK; Bruijn, JA; Moleman, P; van den Broek, WW; Vulto, AG, 2005
)
1.98
" The mean imipramine dosage was 209 mg/day (standard deviation: 91."( Imipramine is effective in preventing relapse in electroconvulsive therapy-responsive depressed inpatients with prior pharmacotherapy treatment failure: a randomized, placebo-controlled trial.
Birkenhäger, TK; Bruijn, JA; Moleman, P; Mulder, PG; van den Broek, WW, 2006
)
2.18
"After a drug-free period and four days of placebo use, patients were randomised either to imipramine or to fluvoxamine (phase 1); the antidepressant dosage was fixed according to a predetermined plasma level."( [Comparison of the effectiveness of two treatment strategies in inpatients with a depressive disorder. A double-blind study of imipramine followed by lithium addition versus fluvoxamine followed by lithium addition].
Birkenhäger, TK; Bruijn, JA; Moleman, P; Mulder, PG; van den Broek, WW, 2006
)
0.76
"The present study has addressed the question of what is more important for the occurrence of adaptive changes observed in the organism treated with antidepressant drugs: a daily dosing of the drug or the period of time necessary for the plastic events to develop."( Delayed effects of antidepressant drugs in rats.
Dziedzicka-Wasylewska, M; Faron-Górecka, A; Kuśmider, M, 2006
)
0.33
" A metaregression did not reveal a statistically significant relation between the mean moclobemide dosage for each study and the risk ratio for response rates."( A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.
Fava, M; Papakostas, GI, 2006
)
0.33
" dosing of a novel MCHR1 antagonist, N-[3-(1-{[4-(3,4-difluorophenoxy)-phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847), in three mouse models predictive of antidepressant/anxiolytic-like activity: novelty suppressed feeding (NSF) in 129S6/SvEvTac mice and light/dark paradigm (L/D) and forced swim test (FST) in BALB/cJ mice."( Efficacy of the MCHR1 antagonist N-[3-(1-{[4-(3,4-difluorophenoxy)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocam
Craig, DA; David, DJ; Dong, D; Gerald, CP; Hegde, LG; Hen, R; Holick, KA; Klemenhagen, KC; Marzabadi, MR; Mendez, I; Ping, XI; Santarelli, L; Saxe, MD; Swanson, CJ; Zhong, H, 2007
)
0.34
" This symptom gradually abated within a week and when the dosage of milnacipran was increased to 100 mg day(-1) at 2 months, no further piloerection occurred."( Piloerection induced by replacing fluvoxamine with milnacipran.
Hazui, T; Hori, S; Matsuo, N; Miki, A; Nakano, M; Ohtani, H; Sawada, Y; Suzuki, Y; Yagi, H; Yamamoto, A, 2007
)
0.34
" Thus, different dosing regiments are needed to achieve similar brain drug levels in juvenile and adult rats."( Appropriate dosing regimens for treating juvenile rats with desipramine for neuropharmacological and behavioral studies.
Burke, WJ; Bylund, DB; Deupree, JD; Kozisek, ME, 2007
)
0.34
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
" CD1 mice were dosed either acutely or chronically with either antidepressants or 5-HT receptor subtype selective antagonists."( Hippocampal Bcl-2 expression is selectively increased following chronic but not acute treatment with antidepressants, 5-HT(1A) or 5-HT(2C/2B) receptor antagonists.
Hutson, PH; Murray, F, 2007
)
0.34
" At maintenance phase immediately before relapse, average dosage was 42."( Adequacy of continuation and maintenance treatments for major depression in Japan.
Akechi, T; Azuma, H; Fujita, A; Furukawa, TA; Kitamura, T; Takahashi, K, 2008
)
0.35
" The contradiction between our results and those of several previous studies may be due to the fixed plasma level dosing of imipramine refraining from concurrent psychotropic medication or limiting our patient sample to patients with mood-congruent psychotic features."( Efficacy of imipramine in psychotic versus nonpsychotic depression.
Birkenhager, TK; Bruijn, JA; Moleman, P; Mulder, PG; van den Broek, WW, 2008
)
0.93
" dosing with either fluoxetine or imipramine."( Differential sensitivity to SSRI and tricyclic antidepressants in juvenile and adult mice of three strains.
Baker, KB; Davis, KW; Gerhardt, B; Lanthorn, TH; Malbari, MM; Mason, SS; Pogorelov, VM; Ritter, R; Savelieva, KV; Wray, SP, 2009
)
0.63
" Side effects were common and almost half these patients became tolerant, needing higher dosage to control symptoms."( Natural history, symptoms and treatment of the narcoleptic syndrome.
Asselman, P; Baraitser, M; Marsden, CD; Parkes, JD, 1975
)
0.25
" When managing a patient with nonpsychotic depression and inadequate response to the maximum dose of a single antidepressant, the physician should first identify factors that may contribute to the poor response, such as suboptimal dosage resulting from nonadherence, inadequate duration of therapy, and comorbid medical and psychiatric conditions."( Clinical inquiries. What's best when a patient doesn't respond to the maximum dose of an antidepressant?
Lo, V; Maggio, L, 2010
)
0.36
" The method was also successfully applied for the determination of Imi in pharmaceutical dosage form."( Determination of imipramine and trimipramine by capillary electrophoresis with electrochemiluminescence detection.
Du, H; You, T; Yu, C, 2011
)
0.71
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
"Vanillin at the dosage of 100 mg/kg has demonstrated antidepressant activity in mice, which is comparable with fluoxetine."( Evaluation of antidepressant activity of vanillin in mice.
Chowta, M; Pallempati, G; Rai, A; Shoeb, A; Singh, A,
)
0.13
" With 14-day stress, a comparison of the activities of catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPX) and accumulation of malondialdehyde (MDA) revealed a decrease of the first two measures in susceptible, but not in resilient animals or in stressed mice chronically dosed with imipramine (7mg/kg/day)."( Lasting downregulation of the lipid peroxidation enzymes in the prefrontal cortex of mice susceptible to stress-induced anhedonia.
Anokhin, K; Anthony, DC; Cline, BH; Dolgov, O; Kubatiev, A; Lesch, KP; Lysko, A; Malin, D; Schroeter, C; Steinbusch, HW; Strekalova, T, 2015
)
0.59
" As the dosage of imipramine (a cationic amphiphilic drug) increased, both the PP and cellular phospholipid content increased."( Putative biomarker for phospholipid accumulation in cultured cells treated with phospholipidosis-inducing drugs: alteration of the phosphatidylinositol composition detected using high-performance liquid chromatography-tandem mass spectrometry.
Hamaguchi, R; Kuroda, Y; Tanimoto, T, 2014
)
0.74
" The enzyme activity varied according to the dose, brain region, and acute or chronic dosing protocols."( Acute and Chronic Treatments with Quetiapine Increase Mitochondrial Respiratory Chain Complex Activity in the Rat Brain.
Abelaira, HM; Bruchchen, L; Carlessi, AS; Carvalho-Silva, M; da Luz, JR; Gomes, LM; Ignácio, ZM; Matias, BI; Quevedo, J; Rebelo, J; Réus, GZ; Streck, EL; Titus, SE, 2015
)
0.42
" Sixty seven percent of the dosed imipramine was recovered within 24 h, with 95 and 5% of drug-related material detected in feces and urine, respectively."( Absolute quantification of imipramine and its metabolites in vivo utilizing calibrators from radiolabeled in vitro incubations.
Bhutani, P; Chacko, S; Mandlekar, S; Shah, D; Subramanian, M; Varkhede, N, 2016
)
1.01
" The objective of the present study is to determine whether the human pharmacokinetics of desipramine following dosing of imipramine can be predicted using static and dynamic physiologically-based pharmacokinetic (PBPK) models from in vitro input data for CYP2D6 extensive metabolizer (EM) and poor metabolizer (PM) populations."( The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine.
Callegari, E; Nguyen, HQ; Obach, RS, 2016
)
0.83
" The role of the α2C-AR in modulating two key depression-related behaviours in the Flinders Sensitive Line (FSL) rat was studied using a dose-response analysis following subcutaneous administration with the selective α2C-AR antagonist ORM-10921 (0."( The α2C-adrenoceptor antagonist, ORM-10921, exerts antidepressant-like effects in the Flinders Sensitive Line rat.
Harvey, BH; Sallinen, J; Shahid, M; Uys, MM, 2017
)
0.46
"2 mg/kg/rat dosage of haloperidol provided orally to rats for 2 weeks enhanced vacuous chewing movements that escalated when the process proceeded for 5 weeks."( Co-treatment with imipramine averted haloperidol-instigated tardive dyskinesia: Association with serotonin in brain regions.
Haleem, DJ; Samad, N; Yasmin, F, 2016
)
0.77
"The present work aims to investigate the anxiolytic activity of 6-styryl-2-pyrone (STY), obtained from Aniba panurensis, in behavioral tests and amino acids dosage on male Swiss mice."( The anxiolytic-like effect of 6-styryl-2-pyrone in mice involves GABAergic mechanism of action.
Barbosa-Filho, JM; Chaves, EMC; Dantas, LP; Honório-Júnior, JER; Lúcio, ASSC; Monteiro, VS; Nonato, DTT; Patrocínio, MCA; Sousa, CNS; Vasconcelos, SMM; Viana, GSB, 2018
)
0.48
" Patient demographics and baseline testing were assessed, as well as medication dosing and side effects of all patients."( Imipramine for refractory daytime incontinence in the pediatric population.
Arlen, AM; Collett-Gardere, T; Franco, I; Zelkovic, PF, 2018
)
1.92
" We also investigated the effects of dosing time on the pharmacological activity of several antidepressants acting on serotonergic, noradrenergic, and/or dopaminergic neurons."( Antidepressants with different mechanisms of action show different chronopharmacological profiles in the tail suspension test in mice.
Ishibashi, T; Iwadate, R; Kawai, H; Kawashima, Y; Kudo, N; Mitsumoto, A, 2019
)
0.51
"Tricyclic antidepressants (TCA) continue to be an important group of drugs, but it is unclear whether a dose-response relationship is supported by high-level evidence."( Dose effects of tricyclic antidepressants in the treatment of acute depression - A systematic review and meta-analysis of randomized trials.
Baethge, C; Braun, C; Bschor, T; Henssler, J; Rink, L; Schwarzer, G, 2022
)
0.72
"So far, data on a dose-response relationship in TCAs from direct dose comparisons are inconclusive."( Dose effects of tricyclic antidepressants in the treatment of acute depression - A systematic review and meta-analysis of randomized trials.
Baethge, C; Braun, C; Bschor, T; Henssler, J; Rink, L; Schwarzer, G, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
adrenergic uptake inhibitorAdrenergic uptake inhibitors are drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.
EC 3.4.21.26 (prolyl oligopeptidase) inhibitorAny EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of prolyl oligopeptidase (EC 3.4.21.26).
antidepressantAntidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
dibenzoazepine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
Imipramine Action Pathway3521
Imipramine Metabolism Pathway612
thyroid hormone metabolism II (via conjugation and/or degradation)632

Protein Targets (131)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
USP1 protein, partialHomo sapiens (human)Potency35.48130.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency21.59570.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency6.11430.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency0.56230.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency32.86700.000221.22318,912.5098AID1259243; AID743042; AID743054
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency5.62340.011212.4002100.0000AID1030
regulator of G-protein signaling 4Homo sapiens (human)Potency0.94660.531815.435837.6858AID504845
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency21.45520.000214.376460.0339AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency29.84930.003041.611522,387.1992AID1159553
estrogen nuclear receptor alphaHomo sapiens (human)Potency98.12000.000229.305416,493.5996AID743079; AID743080; AID743091
cytochrome P450 2D6Homo sapiens (human)Potency6.91780.00108.379861.1304AID1645840
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency14.95890.001019.414170.9645AID743191
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency25.11890.035520.977089.1251AID504332
activating transcription factor 6Homo sapiens (human)Potency0.30110.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency23.914519.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency8.59720.057821.109761.2679AID1159526; AID1159528
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency15.71430.00207.533739.8107AID891
D(1A) dopamine receptorHomo sapiens (human)Potency8.89390.02245.944922.3872AID488982; AID488983
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency15.84890.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency24.41260.000323.4451159.6830AID743065; AID743067
atrial natriuretic peptide receptor 2 precursorHomo sapiens (human)Potency16.48160.00669.809418.4927AID1347050
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency9.95060.00378.618923.2809AID2667; AID2668
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency29.40760.000627.21521,122.0200AID651741; AID743219
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency10.69100.425612.059128.1838AID504536
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency40.53340.005612.367736.1254AID624032
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.67740.00106.000935.4813AID943; AID944
lamin isoform A-delta10Homo sapiens (human)Potency0.79430.891312.067628.1838AID1487
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency7.94330.316212.765731.6228AID881
Cellular tumor antigen p53Homo sapiens (human)Potency13.33320.002319.595674.0614AID651631
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency7.94330.00638.235039.8107AID881
D(1A) dopamine receptorSus scrofa (pig)Potency5.21190.00378.108123.2809AID2667
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency31.62280.009610.525035.4813AID1479145
Ataxin-2Homo sapiens (human)Potency28.18380.011912.222168.7989AID588378
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency37.93300.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 2Homo sapiens (human)IC50 (µMol)0.60000.40003.10009.7000AID692192
Solute carrier family 22 member 1 Homo sapiens (human)IC50 (µMol)20.68330.21005.553710.0000AID1442001; AID386625; AID692194
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Voltage-dependent L-type calcium channel subunit alpha-1CCavia porcellus (domestic guinea pig)IC50 (µMol)8.30000.02201.64228.9000AID1207188
Sodium-dependent noradrenaline transporterMus musculus (house mouse)Ki0.01400.01200.09050.2900AID134216; AID145696
Voltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)IC50 (µMol)8.30000.00032.63119.0000AID1207188
Solute carrier family 22 member 3Homo sapiens (human)Ki42.00000.12000.12000.1200AID681584
Bile salt export pumpHomo sapiens (human)IC50 (µMol)134.00000.11007.190310.0000AID1443980; AID1473738
Prostaglandin G/H synthase 1Ovis aries (sheep)Ki0.16000.00162.12129.0000AID5444
5-hydroxytryptamine receptor 1AHomo sapiens (human)Ki3.73000.00010.532610.0000AID1801081
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)IC50 (µMol)0.04400.00040.629810.0000AID6418
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Ki0.02300.00020.667710.0000AID5241
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)IC50 (µMol)0.30000.00052.780225.1700AID142503
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)0.00510.00002.015110.0000AID1332024
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)50.00000.00002.800510.0000AID1210069
D(2) dopamine receptorHomo sapiens (human)IC50 (µMol)0.41000.00000.74728.0000AID1054120
D(2) dopamine receptorHomo sapiens (human)Ki0.72600.00000.651810.0000AID63979
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)0.04400.00040.908610.0000AID6418
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Ki0.02300.00010.601710.0000AID5241
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.16000.00021.874210.0000AID36851
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Ki0.22000.00010.949010.0000AID218673
Sphingomyelin phosphodiesteraseHomo sapiens (human)IC50 (µMol)5.00005.00005.30005.6000AID1357284
DRattus norvegicus (Norway rat)IC50 (µMol)2.09920.00030.50267.7625AID179927; AID243189
D(3) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.81000.00030.39075.4000AID179927
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)0.04400.00031.38338.4000AID6418
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)3.38840.00031.09147.7625AID243189
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)Ki4.90000.00000.929610.0000AID218807
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)3.38840.00031.09147.7625AID243189
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)Ki4.90000.00000.970810.0000AID218807
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)3.38840.00031.06917.7625AID243189
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)Ki4.90000.00000.937510.0000AID218807
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.16000.00021.270410.0000AID36851
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)Ki0.22000.00000.575110.0000AID218673
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)0.07400.00081.541620.0000AID351894
Sodium-dependent noradrenaline transporter Homo sapiens (human)Ki0.01600.00031.465610.0000AID145895
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)IC50 (µMol)3.38840.00070.97749.7000AID243189
D(1B) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.81000.00030.35635.4000AID179927
5-hydroxytryptamine receptor 2AHomo sapiens (human)IC50 (µMol)0.22000.00010.88018.8500AID1054119
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki0.12700.00000.385510.0000AID5355; AID5444
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki0.16000.00010.954910.0000AID5945
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)IC50 (µMol)0.04400.00051.48357.8000AID6418
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)IC50 (µMol)0.04400.00311.73607.8000AID6418
D(4) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.81000.00030.38715.4000AID179927
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)IC50 (µMol)0.04400.00501.79627.8000AID6418
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)IC50 (µMol)0.04400.00040.615610.0000AID6418
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Ki0.02300.00020.590910.0000AID5241
5-hydroxytryptamine receptor 6Rattus norvegicus (Norway rat)IC50 (µMol)0.04400.00501.50894.6000AID6418
Histamine H1 receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00010.00000.32271.2589AID87513
Sodium-dependent serotonin transporterHomo sapiens (human)IC50 (µMol)0.00740.00010.86458.7096AID1054118; AID1285675; AID1299180; AID1332024; AID1336374; AID1597295; AID1718178; AID255317; AID346472; AID351887; AID566273; AID729797; AID751835; AID752199; AID773434
Sodium-dependent serotonin transporterHomo sapiens (human)Ki0.08790.00000.70488.1930AID1152645; AID1196338; AID1299179; AID1299181; AID1299182; AID1332036; AID1458656; AID1517958; AID1597295; AID1675411; AID204880; AID338160; AID346472; AID431484; AID612016; AID751835
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)IC50 (µMol)0.81000.00030.81978.4900AID179927
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)Ki0.02900.00000.705610.0000AID1570058; AID1601979
5-hydroxytryptamine receptor 7 Rattus norvegicus (Norway rat)IC50 (µMol)0.04400.00501.42824.6000AID6418
Pleiotropic ABC efflux transporter of multiple drugsSaccharomyces cerevisiae S288CIC50 (µMol)22.00001.30003.37279.6000AID581672
5-hydroxytryptamine receptor 2C Mus musculus (house mouse)Ki0.16000.00080.50322.8420AID5679
5-hydroxytryptamine receptor 7Homo sapiens (human)Ki3.73000.00030.380610.0000AID1801081
5-hydroxytryptamine receptor 5ARattus norvegicus (Norway rat)IC50 (µMol)0.04400.00501.35984.6000AID6418
5-hydroxytryptamine receptor 5BRattus norvegicus (Norway rat)IC50 (µMol)0.04400.00501.35984.6000AID6418
Histamine H1 receptorHomo sapiens (human)IC50 (µMol)0.02700.00000.44365.1768AID1054121
Histamine H1 receptorHomo sapiens (human)Ki0.01000.00000.511010.0000AID1675412
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)IC50 (µMol)14.00000.00071.600310.0000AID144767
Sodium channel protein type 1 subunit alphaHomo sapiens (human)IC50 (µMol)3.60000.00232.82969.0000AID1207159
Sodium channel protein type 4 subunit alphaHomo sapiens (human)IC50 (µMol)3.60000.00013.507510.0000AID1207159
5-hydroxytryptamine receptor 3ARattus norvegicus (Norway rat)IC50 (µMol)0.04400.00021.13514.6000AID6418
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.16000.00001.819410.0000AID36851
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Ki0.22000.00000.965010.0000AID218673
Histamine H2 receptorCavia porcellus (domestic guinea pig)IC50 (µMol)1.90000.00402.15557.2000AID87880
5-hydroxytryptamine receptor 6Homo sapiens (human)Ki3.73000.00020.522910.0000AID1801081
5-hydroxytryptamine receptor 7Cavia porcellus (domestic guinea pig)IC50 (µMol)17.10002.03005.53139.9000AID386625
Cytochrome P450 2J2Homo sapiens (human)IC50 (µMol)50.00000.01202.53129.4700AID1210069
D(2) dopamine receptorMus musculus (house mouse)Ki0.72600.11201.60643.9811AID61054
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.81000.00010.54948.4000AID179927
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)IC50 (µMol)14.00000.00071.630610.0000AID144767
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)IC50 (µMol)14.00000.00061.525710.0000AID144767
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)IC50 (µMol)14.00000.00071.747210.0000AID144767
Voltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)IC50 (µMol)22.00000.04004.113710.0000AID1850268
Sodium channel protein type 7 subunit alphaHomo sapiens (human)IC50 (µMol)3.60000.03603.73359.0000AID1207159
Voltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)IC50 (µMol)8.30000.00032.59559.0000AID1207188
Sodium-dependent dopamine transporter Homo sapiens (human)IC50 (µMol)25.60000.00071.841946.0000AID351888
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)3.39130.00091.901410.0000AID1207218; AID161281; AID243151; AID243189; AID408340; AID420668; AID51930; AID576612
Voltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)IC50 (µMol)8.30000.00032.63119.0000AID1207188
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)IC50 (µMol)8.30000.00032.25459.6000AID1207188
Sodium channel protein type 5 subunit alphaHomo sapiens (human)IC50 (µMol)3.60000.00033.64849.2000AID1207159
Sodium channel protein type 9 subunit alphaHomo sapiens (human)IC50 (µMol)3.60000.00602.77499.0000AID1207159
Sigma intracellular receptor 2Rattus norvegicus (Norway rat)Ki2.10700.00241.10509.3000AID1718151
Sodium-dependent serotonin transporterMus musculus (house mouse)Ki0.02350.00040.59574.1000AID134217; AID204217
Sodium-dependent dopamine transporterMus musculus (house mouse)Ki10.00000.40400.68731.0350AID134215
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)IC50 (µMol)14.00000.00071.741110.0000AID144767
5-hydroxytryptamine receptor 4 Rattus norvegicus (Norway rat)IC50 (µMol)0.04400.00501.35524.6000AID6418
Solute carrier family 22 member 1Rattus norvegicus (Norway rat)IC50 (µMol)16.00000.18003.68578.8000AID681348
Multidrug and toxin extrusion protein 2Homo sapiens (human)IC50 (µMol)100.00000.16003.95718.6000AID692196
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)IC50 (µMol)14.00000.00071.741110.0000AID144767
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Multidrug and toxin extrusion protein 1Homo sapiens (human)IC50 (µMol)10.00000.01002.765610.0000AID692195
Sodium channel protein type 2 subunit alphaHomo sapiens (human)IC50 (µMol)3.60000.00003.740110.0000AID1207159
5-hydroxytryptamine receptor 3BRattus norvegicus (Norway rat)IC50 (µMol)0.04400.00041.17424.6000AID6418
Sodium channel protein type 3 subunit alphaHomo sapiens (human)IC50 (µMol)3.60000.00532.80859.0000AID1207159
Sigma non-opioid intracellular receptor 1Rattus norvegicus (Norway rat)Ki0.34300.00030.26715.0700AID1718165
Solute carrier family 22 member 2Rattus norvegicus (Norway rat)IC50 (µMol)9.90001.00004.446710.0000AID681345
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)IC50 (µMol)14.00000.00071.741110.0000AID144767
Sodium channel protein type 11 subunit alphaHomo sapiens (human)IC50 (µMol)3.60000.03004.36959.0000AID1207159
Sodium channel protein type 8 subunit alphaHomo sapiens (human)IC50 (µMol)3.60000.00113.47059.0000AID1207159
TransporterRattus norvegicus (Norway rat)IC50 (µMol)0.81000.00081.95628.8000AID179927
TransporterRattus norvegicus (Norway rat)Ki0.01600.00010.866710.0000AID145696
Sodium channel protein type 10 subunit alphaHomo sapiens (human)IC50 (µMol)3.60000.00803.17529.0000AID1207159
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Major prion proteinHomo sapiens (human)EC50 (µMol)10.00000.30004.900010.0000AID161627
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Snq2pSaccharomyces cerevisiae EC1118INH198.00003.20006.26008.8000AID581808
Cytochrome P450 1A2Homo sapiens (human)Km5.00005.00007.00009.0000AID1209253
Cytochrome P450 3A4Homo sapiens (human)Km5.00001.93005.90608.7000AID1209243
UDP-glucuronosyltransferase 1A4Homo sapiens (human)Km310.00007.00007.00007.0000AID214939; AID624633
Cytochrome P450 2C19Homo sapiens (human)Km5.00001.70005.38338.7500AID1209252
Pleiotropic ABC efflux transporter of multiple drugsSaccharomyces cerevisiae S288CINH166.00004.20006.18338.3000AID581806
UDP-glucuronosyltransferase 1A3Homo sapiens (human)Km472.00007.34007.34007.3400AID624632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (627)

Processvia Protein(s)Taxonomy
activation of cysteine-type endopeptidase activity involved in apoptotic processSolute carrier family 22 member 2Homo sapiens (human)
positive regulation of gene expressionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
monoatomic cation transportSolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin transportSolute carrier family 22 member 2Homo sapiens (human)
body fluid secretionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 2Homo sapiens (human)
amine transportSolute carrier family 22 member 2Homo sapiens (human)
putrescine transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transportSolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 2Homo sapiens (human)
choline transportSolute carrier family 22 member 2Homo sapiens (human)
dopamine transportSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 2Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
histamine transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 2Homo sapiens (human)
histamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
amino acid import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
L-arginine import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
export across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
L-alpha-amino acid transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
detection of light stimulus involved in visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
histamine metabolic processSolute carrier family 22 member 3Homo sapiens (human)
organic cation transportSolute carrier family 22 member 3Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 3Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 3Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 3Homo sapiens (human)
serotonin transportSolute carrier family 22 member 3Homo sapiens (human)
organic cation transportSolute carrier family 22 member 3Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 3Homo sapiens (human)
organic anion transportSolute carrier family 22 member 3Homo sapiens (human)
monocarboxylic acid transportSolute carrier family 22 member 3Homo sapiens (human)
monoamine transportSolute carrier family 22 member 3Homo sapiens (human)
spermidine transportSolute carrier family 22 member 3Homo sapiens (human)
dopamine transportSolute carrier family 22 member 3Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 3Homo sapiens (human)
regulation of appetiteSolute carrier family 22 member 3Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 3Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 3Homo sapiens (human)
histamine transportSolute carrier family 22 member 3Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 3Homo sapiens (human)
histamine uptakeSolute carrier family 22 member 3Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 3Homo sapiens (human)
epinephrine uptakeSolute carrier family 22 member 3Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 3Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 3Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 3Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 3Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 3Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cellular response to copper ionMajor prion proteinHomo sapiens (human)
negative regulation of protein phosphorylationMajor prion proteinHomo sapiens (human)
intracellular copper ion homeostasisMajor prion proteinHomo sapiens (human)
response to oxidative stressMajor prion proteinHomo sapiens (human)
learning or memoryMajor prion proteinHomo sapiens (human)
long-term memoryMajor prion proteinHomo sapiens (human)
negative regulation of protein processingMajor prion proteinHomo sapiens (human)
protein destabilizationMajor prion proteinHomo sapiens (human)
negative regulation of type II interferon productionMajor prion proteinHomo sapiens (human)
negative regulation of interleukin-17 productionMajor prion proteinHomo sapiens (human)
negative regulation of interleukin-2 productionMajor prion proteinHomo sapiens (human)
negative regulation of apoptotic processMajor prion proteinHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityMajor prion proteinHomo sapiens (human)
positive regulation of neuron apoptotic processMajor prion proteinHomo sapiens (human)
negative regulation of activated T cell proliferationMajor prion proteinHomo sapiens (human)
response to cadmium ionMajor prion proteinHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationMajor prion proteinHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationMajor prion proteinHomo sapiens (human)
positive regulation of calcium-mediated signalingMajor prion proteinHomo sapiens (human)
negative regulation of T cell receptor signaling pathwayMajor prion proteinHomo sapiens (human)
protein homooligomerizationMajor prion proteinHomo sapiens (human)
regulation of cell cycleMajor prion proteinHomo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascadeMajor prion proteinHomo sapiens (human)
cellular response to xenobiotic stimulusMajor prion proteinHomo sapiens (human)
positive regulation of protein targeting to membraneMajor prion proteinHomo sapiens (human)
dendritic spine maintenanceMajor prion proteinHomo sapiens (human)
negative regulation of long-term synaptic potentiationMajor prion proteinHomo sapiens (human)
regulation of glutamate receptor signaling pathwayMajor prion proteinHomo sapiens (human)
positive regulation of glutamate receptor signaling pathwayMajor prion proteinHomo sapiens (human)
regulation of potassium ion transmembrane transportMajor prion proteinHomo sapiens (human)
negative regulation of amyloid-beta formationMajor prion proteinHomo sapiens (human)
negative regulation of dendritic spine maintenanceMajor prion proteinHomo sapiens (human)
negative regulation of amyloid precursor protein catabolic processMajor prion proteinHomo sapiens (human)
positive regulation of protein localization to plasma membraneMajor prion proteinHomo sapiens (human)
response to amyloid-betaMajor prion proteinHomo sapiens (human)
cellular response to amyloid-betaMajor prion proteinHomo sapiens (human)
regulation of calcium ion import across plasma membraneMajor prion proteinHomo sapiens (human)
neuron projection maintenanceMajor prion proteinHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
gamma-aminobutyric acid signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of serotonin secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of vasoconstriction5-hydroxytryptamine receptor 1AHomo sapiens (human)
exploration behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of dopamine metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of hormone secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1AHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
symbiont entry into host cellSphingomyelin phosphodiesteraseHomo sapiens (human)
symbiont entry into host cellSphingomyelin phosphodiesteraseHomo sapiens (human)
plasma membrane repairSphingomyelin phosphodiesteraseHomo sapiens (human)
sphingomyelin metabolic processSphingomyelin phosphodiesteraseHomo sapiens (human)
sphingomyelin catabolic processSphingomyelin phosphodiesteraseHomo sapiens (human)
signal transductionSphingomyelin phosphodiesteraseHomo sapiens (human)
nervous system developmentSphingomyelin phosphodiesteraseHomo sapiens (human)
cholesterol metabolic processSphingomyelin phosphodiesteraseHomo sapiens (human)
response to xenobiotic stimulusSphingomyelin phosphodiesteraseHomo sapiens (human)
response to virusSphingomyelin phosphodiesteraseHomo sapiens (human)
response to ionizing radiationSphingomyelin phosphodiesteraseHomo sapiens (human)
termination of signal transductionSphingomyelin phosphodiesteraseHomo sapiens (human)
response to type I interferonSphingomyelin phosphodiesteraseHomo sapiens (human)
response to tumor necrosis factorSphingomyelin phosphodiesteraseHomo sapiens (human)
cellular response to UVSphingomyelin phosphodiesteraseHomo sapiens (human)
positive regulation of protein dephosphorylationSphingomyelin phosphodiesteraseHomo sapiens (human)
wound healingSphingomyelin phosphodiesteraseHomo sapiens (human)
response to cocaineSphingomyelin phosphodiesteraseHomo sapiens (human)
positive regulation of apoptotic processSphingomyelin phosphodiesteraseHomo sapiens (human)
negative regulation of MAP kinase activitySphingomyelin phosphodiesteraseHomo sapiens (human)
positive regulation of endocytosisSphingomyelin phosphodiesteraseHomo sapiens (human)
glycosphingolipid catabolic processSphingomyelin phosphodiesteraseHomo sapiens (human)
ceramide biosynthetic processSphingomyelin phosphodiesteraseHomo sapiens (human)
positive regulation of viral entry into host cellSphingomyelin phosphodiesteraseHomo sapiens (human)
symbiont entry into host cellSphingomyelin phosphodiesteraseHomo sapiens (human)
response to interleukin-1Sphingomyelin phosphodiesteraseHomo sapiens (human)
cellular response to calcium ionSphingomyelin phosphodiesteraseHomo sapiens (human)
bilirubin conjugationUDP-glucuronosyltransferase 1A4Homo sapiens (human)
heme catabolic processUDP-glucuronosyltransferase 1A4Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A4Homo sapiens (human)
vitamin D3 metabolic processUDP-glucuronosyltransferase 1A4Homo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
smooth muscle contraction5-hydroxytryptamine receptor 7Homo sapiens (human)
circadian rhythm5-hydroxytryptamine receptor 7Homo sapiens (human)
blood circulation5-hydroxytryptamine receptor 7Homo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 7Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 7Homo sapiens (human)
inflammatory responseHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
memoryHistamine H1 receptorHomo sapiens (human)
visual learningHistamine H1 receptorHomo sapiens (human)
regulation of vascular permeabilityHistamine H1 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H1 receptorHomo sapiens (human)
regulation of synaptic plasticityHistamine H1 receptorHomo sapiens (human)
cellular response to histamineHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H1 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H1 receptorHomo sapiens (human)
sodium ion transportSodium channel protein type 1 subunit alphaHomo sapiens (human)
adult walking behaviorSodium channel protein type 1 subunit alphaHomo sapiens (human)
determination of adult lifespanSodium channel protein type 1 subunit alphaHomo sapiens (human)
neuronal action potential propagationSodium channel protein type 1 subunit alphaHomo sapiens (human)
neuronal action potentialSodium channel protein type 1 subunit alphaHomo sapiens (human)
nerve developmentSodium channel protein type 1 subunit alphaHomo sapiens (human)
neuromuscular process controlling postureSodium channel protein type 1 subunit alphaHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painSodium channel protein type 1 subunit alphaHomo sapiens (human)
establishment of localization in cellSodium channel protein type 1 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 1 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 1 subunit alphaHomo sapiens (human)
regulation of presynaptic membrane potentialSodium channel protein type 1 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 1 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 4 subunit alphaHomo sapiens (human)
muscle contractionSodium channel protein type 4 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 4 subunit alphaHomo sapiens (human)
regulation of skeletal muscle contraction by action potentialSodium channel protein type 4 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 4 subunit alphaHomo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 1A3Homo sapiens (human)
estrogen metabolic processUDP-glucuronosyltransferase 1A3Homo sapiens (human)
bile acid secretionUDP-glucuronosyltransferase 1A3Homo sapiens (human)
retinoic acid metabolic processUDP-glucuronosyltransferase 1A3Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A3Homo sapiens (human)
flavonoid glucuronidationUDP-glucuronosyltransferase 1A3Homo sapiens (human)
xenobiotic glucuronidationUDP-glucuronosyltransferase 1A3Homo sapiens (human)
vitamin D3 metabolic processUDP-glucuronosyltransferase 1A3Homo sapiens (human)
cerebral cortex cell migration5-hydroxytryptamine receptor 6Homo sapiens (human)
positive regulation of TOR signaling5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 6Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 6Homo sapiens (human)
fatty acid metabolic processCytochrome P450 2J2Homo sapiens (human)
icosanoid metabolic processCytochrome P450 2J2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2J2Homo sapiens (human)
regulation of heart contractionCytochrome P450 2J2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2J2Homo sapiens (human)
linoleic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
organic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
modulation of chemical synaptic transmissionVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
response to amyloid-betaVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
chemical synaptic transmissionVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
osmosensory signaling pathwaySodium channel protein type 7 subunit alphaHomo sapiens (human)
response to bacteriumSodium channel protein type 7 subunit alphaHomo sapiens (human)
cellular homeostasisSodium channel protein type 7 subunit alphaHomo sapiens (human)
sodium ion homeostasisSodium channel protein type 7 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 7 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 7 subunit alphaHomo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
sensory perception of soundVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion importVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transporter activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
monoamine transportSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent dopamine transporter Homo sapiens (human)
lactationSodium-dependent dopamine transporter Homo sapiens (human)
sensory perception of smellSodium-dependent dopamine transporter Homo sapiens (human)
locomotory behaviorSodium-dependent dopamine transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent dopamine transporter Homo sapiens (human)
response to iron ionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine transportSodium-dependent dopamine transporter Homo sapiens (human)
adenohypophysis developmentSodium-dependent dopamine transporter Homo sapiens (human)
response to nicotineSodium-dependent dopamine transporter Homo sapiens (human)
positive regulation of multicellular organism growthSodium-dependent dopamine transporter Homo sapiens (human)
regulation of dopamine metabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to cocaineSodium-dependent dopamine transporter Homo sapiens (human)
dopamine biosynthetic processSodium-dependent dopamine transporter Homo sapiens (human)
dopamine catabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to ethanolSodium-dependent dopamine transporter Homo sapiens (human)
cognitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent dopamine transporter Homo sapiens (human)
response to cAMPSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
prepulse inhibitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
hyaloid vascular plexus regressionSodium-dependent dopamine transporter Homo sapiens (human)
amino acid transportSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine transportSodium-dependent dopamine transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent dopamine transporter Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
skeletal system developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
extraocular skeletal muscle developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
striated muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
endoplasmic reticulum organizationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
myoblast fusionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
neuromuscular junction developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle adaptationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle fiber developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
release of sequestered calcium ion into cytosolVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cellular response to caffeineVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
immune system developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
heart developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
embryonic forelimb morphogenesisVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
camera-type eye developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transport into cytosolVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cell communication by electrical coupling involved in cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of ventricular cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rateSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac conduction system developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac ventricle developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
brainstem developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
response to denervation involved in regulation of muscle adaptationSodium channel protein type 5 subunit alphaHomo sapiens (human)
telencephalon developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cerebellum developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
odontogenesis of dentin-containing toothSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of epithelial cell proliferationSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cellular response to calcium ionSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of cardiac muscle cell contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
ventricular cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during Purkinje myocyte cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell to bundle of His cell communicationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of heart rate by cardiac conductionSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 9 subunit alphaHomo sapiens (human)
inflammatory responseSodium channel protein type 9 subunit alphaHomo sapiens (human)
circadian rhythmSodium channel protein type 9 subunit alphaHomo sapiens (human)
response to toxic substanceSodium channel protein type 9 subunit alphaHomo sapiens (human)
post-embryonic developmentSodium channel protein type 9 subunit alphaHomo sapiens (human)
sensory perception of painSodium channel protein type 9 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 9 subunit alphaHomo sapiens (human)
behavioral response to painSodium channel protein type 9 subunit alphaHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of painSodium channel protein type 9 subunit alphaHomo sapiens (human)
detection of mechanical stimulus involved in sensory perceptionSodium channel protein type 9 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 9 subunit alphaHomo sapiens (human)
organic cation transportMultidrug and toxin extrusion protein 2Homo sapiens (human)
transmembrane transportMultidrug and toxin extrusion protein 2Homo sapiens (human)
proton transmembrane transportMultidrug and toxin extrusion protein 2Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
amino acid import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-alpha-amino acid transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
proton transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
sodium ion transportSodium channel protein type 2 subunit alphaHomo sapiens (human)
nervous system developmentSodium channel protein type 2 subunit alphaHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to osmotic stressSodium channel protein type 2 subunit alphaHomo sapiens (human)
neuron apoptotic processSodium channel protein type 2 subunit alphaHomo sapiens (human)
memorySodium channel protein type 2 subunit alphaHomo sapiens (human)
determination of adult lifespanSodium channel protein type 2 subunit alphaHomo sapiens (human)
neuronal action potentialSodium channel protein type 2 subunit alphaHomo sapiens (human)
dentate gyrus developmentSodium channel protein type 2 subunit alphaHomo sapiens (human)
nerve developmentSodium channel protein type 2 subunit alphaHomo sapiens (human)
myelinationSodium channel protein type 2 subunit alphaHomo sapiens (human)
cellular response to hypoxiaSodium channel protein type 2 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 2 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 2 subunit alphaHomo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
sodium ion transportSodium channel protein type 3 subunit alphaHomo sapiens (human)
behavioral response to painSodium channel protein type 3 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 3 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 3 subunit alphaHomo sapiens (human)
thigmotaxisSodium channel protein type 11 subunit alphaHomo sapiens (human)
acute inflammatory responseSodium channel protein type 11 subunit alphaHomo sapiens (human)
chronic inflammatory responseSodium channel protein type 11 subunit alphaHomo sapiens (human)
axonogenesisSodium channel protein type 11 subunit alphaHomo sapiens (human)
circadian rhythmSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to heatSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to xenobiotic stimulusSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to toxic substanceSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to high light intensitySodium channel protein type 11 subunit alphaHomo sapiens (human)
protein kinase A signalingSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to auditory stimulusSodium channel protein type 11 subunit alphaHomo sapiens (human)
neuronal action potentialSodium channel protein type 11 subunit alphaHomo sapiens (human)
sensory perception of painSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to prostaglandin ESodium channel protein type 11 subunit alphaHomo sapiens (human)
thermosensory behaviorSodium channel protein type 11 subunit alphaHomo sapiens (human)
mast cell degranulationSodium channel protein type 11 subunit alphaHomo sapiens (human)
cell motilitySodium channel protein type 11 subunit alphaHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of painSodium channel protein type 11 subunit alphaHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painSodium channel protein type 11 subunit alphaHomo sapiens (human)
reflexSodium channel protein type 11 subunit alphaHomo sapiens (human)
micturitionSodium channel protein type 11 subunit alphaHomo sapiens (human)
skeletal muscle organ developmentSodium channel protein type 11 subunit alphaHomo sapiens (human)
artery developmentSodium channel protein type 11 subunit alphaHomo sapiens (human)
behavioral response to acetic acid induced painSodium channel protein type 11 subunit alphaHomo sapiens (human)
behavioral response to formalin induced painSodium channel protein type 11 subunit alphaHomo sapiens (human)
cellular response to coldSodium channel protein type 11 subunit alphaHomo sapiens (human)
calcium ion transmembrane transportSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to nitric oxideSodium channel protein type 11 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 11 subunit alphaHomo sapiens (human)
action potential initiationSodium channel protein type 11 subunit alphaHomo sapiens (human)
sensory perception of itchSodium channel protein type 11 subunit alphaHomo sapiens (human)
calcitonin gene-related peptide receptor signaling pathwaySodium channel protein type 11 subunit alphaHomo sapiens (human)
small intestine smooth muscle contractionSodium channel protein type 11 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 11 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 11 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 8 subunit alphaHomo sapiens (human)
nervous system developmentSodium channel protein type 8 subunit alphaHomo sapiens (human)
peripheral nervous system developmentSodium channel protein type 8 subunit alphaHomo sapiens (human)
neuronal action potentialSodium channel protein type 8 subunit alphaHomo sapiens (human)
optic nerve developmentSodium channel protein type 8 subunit alphaHomo sapiens (human)
myelinationSodium channel protein type 8 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 8 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 8 subunit alphaHomo sapiens (human)
regulation of heart rateSodium channel protein type 10 subunit alphaHomo sapiens (human)
sensory perceptionSodium channel protein type 10 subunit alphaHomo sapiens (human)
regulation of monoatomic ion transmembrane transportSodium channel protein type 10 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 10 subunit alphaHomo sapiens (human)
odontogenesis of dentin-containing toothSodium channel protein type 10 subunit alphaHomo sapiens (human)
regulation of cardiac muscle contractionSodium channel protein type 10 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane depolarizationSodium channel protein type 10 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 10 subunit alphaHomo sapiens (human)
AV node cell action potentialSodium channel protein type 10 subunit alphaHomo sapiens (human)
bundle of His cell action potentialSodium channel protein type 10 subunit alphaHomo sapiens (human)
regulation of presynaptic membrane potentialSodium channel protein type 10 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 10 subunit alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (206)

Processvia Protein(s)Taxonomy
amine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-amino acid transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
choline transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
efflux transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
protein bindingSolute carrier family 22 member 3Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
type 8 metabotropic glutamate receptor bindingMajor prion proteinHomo sapiens (human)
amyloid-beta bindingMajor prion proteinHomo sapiens (human)
protease bindingMajor prion proteinHomo sapiens (human)
copper ion bindingMajor prion proteinHomo sapiens (human)
protein bindingMajor prion proteinHomo sapiens (human)
lamin bindingMajor prion proteinHomo sapiens (human)
glycosaminoglycan bindingMajor prion proteinHomo sapiens (human)
microtubule bindingMajor prion proteinHomo sapiens (human)
tubulin bindingMajor prion proteinHomo sapiens (human)
aspartic-type endopeptidase inhibitor activityMajor prion proteinHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingMajor prion proteinHomo sapiens (human)
signaling receptor activityMajor prion proteinHomo sapiens (human)
identical protein bindingMajor prion proteinHomo sapiens (human)
ATP-dependent protein bindingMajor prion proteinHomo sapiens (human)
transmembrane transporter bindingMajor prion proteinHomo sapiens (human)
protein-containing complex bindingMajor prion proteinHomo sapiens (human)
protein-folding chaperone bindingMajor prion proteinHomo sapiens (human)
molecular adaptor activityMajor prion proteinHomo sapiens (human)
molecular function activator activityMajor prion proteinHomo sapiens (human)
molecular condensate scaffold activityMajor prion proteinHomo sapiens (human)
cupric ion bindingMajor prion proteinHomo sapiens (human)
cuprous ion bindingMajor prion proteinHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
receptor-receptor interaction5-hydroxytryptamine receptor 1AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
sphingomyelin phosphodiesterase activitySphingomyelin phosphodiesteraseHomo sapiens (human)
protein bindingSphingomyelin phosphodiesteraseHomo sapiens (human)
zinc ion bindingSphingomyelin phosphodiesteraseHomo sapiens (human)
hydrolase activity, acting on glycosyl bondsSphingomyelin phosphodiesteraseHomo sapiens (human)
phosphatidylcholine phospholipase C activitySphingomyelin phosphodiesteraseHomo sapiens (human)
acid sphingomyelin phosphodiesterase activitySphingomyelin phosphodiesteraseHomo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A4Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A4Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 7Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 7Homo sapiens (human)
histamine receptor activityHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H1 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H1 receptorHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 1 subunit alphaHomo sapiens (human)
voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialSodium channel protein type 1 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 4 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 4 subunit alphaHomo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A3Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A3Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A3Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A3Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A3Homo sapiens (human)
histamine receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 6Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
monooxygenase activityCytochrome P450 2J2Homo sapiens (human)
iron ion bindingCytochrome P450 2J2Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
isomerase activityCytochrome P450 2J2Homo sapiens (human)
linoleic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
hydroperoxy icosatetraenoate isomerase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 5,6-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
heme bindingCytochrome P450 2J2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2J2Homo sapiens (human)
amyloid-beta bindingVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
calcium ion bindingVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
protein bindingVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
ATP bindingVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
sodium channel activitySodium channel protein type 7 subunit alphaHomo sapiens (human)
transmembrane transporter bindingSodium channel protein type 7 subunit alphaHomo sapiens (human)
osmolarity-sensing monoatomic cation channel activitySodium channel protein type 7 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 7 subunit alphaHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
ankyrin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
protease bindingSodium-dependent dopamine transporter Homo sapiens (human)
signaling receptor bindingSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingSodium-dependent dopamine transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine bindingSodium-dependent dopamine transporter Homo sapiens (human)
amine bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein-containing complex bindingSodium-dependent dopamine transporter Homo sapiens (human)
metal ion bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein phosphatase 2A bindingSodium-dependent dopamine transporter Homo sapiens (human)
heterocyclic compound bindingSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
small molecule bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
molecular function activator activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 5 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
calmodulin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
fibroblast growth factor bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
enzyme bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein kinase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein domain specific bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ankyrin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ubiquitin protein ligase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
transmembrane transporter bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
nitric-oxide synthase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in Purkinje myocyte action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
scaffold protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 9 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 9 subunit alphaHomo sapiens (human)
organic cation transmembrane transporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
antiporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
transmembrane transporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
polyspecific organic cation:proton antiporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein bindingMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-amino acid transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
polyspecific organic cation:proton antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 2 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 2 subunit alphaHomo sapiens (human)
calmodulin bindingSodium channel protein type 2 subunit alphaHomo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 3 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 11 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 8 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 8 subunit alphaHomo sapiens (human)
ATP bindingSodium channel protein type 8 subunit alphaHomo sapiens (human)
sodium ion bindingSodium channel protein type 8 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 10 subunit alphaHomo sapiens (human)
transmembrane transporter bindingSodium channel protein type 10 subunit alphaHomo sapiens (human)
voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialSodium channel protein type 10 subunit alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (120)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
membraneSolute carrier family 22 member 2Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 2Homo sapiens (human)
presynapseSolute carrier family 22 member 2Homo sapiens (human)
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
photoreceptor outer segmentVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
nuclear outer membraneSolute carrier family 22 member 3Homo sapiens (human)
plasma membraneSolute carrier family 22 member 3Homo sapiens (human)
endomembrane systemSolute carrier family 22 member 3Homo sapiens (human)
membraneSolute carrier family 22 member 3Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 3Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 3Homo sapiens (human)
mitochondrial membraneSolute carrier family 22 member 3Homo sapiens (human)
neuronal cell bodySolute carrier family 22 member 3Homo sapiens (human)
presynapseSolute carrier family 22 member 3Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
dendriteMajor prion proteinHomo sapiens (human)
cytoplasmMajor prion proteinHomo sapiens (human)
endoplasmic reticulumMajor prion proteinHomo sapiens (human)
Golgi apparatusMajor prion proteinHomo sapiens (human)
cytosolMajor prion proteinHomo sapiens (human)
plasma membraneMajor prion proteinHomo sapiens (human)
external side of plasma membraneMajor prion proteinHomo sapiens (human)
cell surfaceMajor prion proteinHomo sapiens (human)
postsynaptic densityMajor prion proteinHomo sapiens (human)
inclusion bodyMajor prion proteinHomo sapiens (human)
extrinsic component of membraneMajor prion proteinHomo sapiens (human)
nuclear membraneMajor prion proteinHomo sapiens (human)
terminal boutonMajor prion proteinHomo sapiens (human)
intracellular membrane-bounded organelleMajor prion proteinHomo sapiens (human)
membrane raftMajor prion proteinHomo sapiens (human)
extracellular exosomeMajor prion proteinHomo sapiens (human)
postsynapseMajor prion proteinHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1AHomo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
extracellular spaceSphingomyelin phosphodiesteraseHomo sapiens (human)
lysosomeSphingomyelin phosphodiesteraseHomo sapiens (human)
extracellular spaceSphingomyelin phosphodiesteraseHomo sapiens (human)
lysosomeSphingomyelin phosphodiesteraseHomo sapiens (human)
endosomeSphingomyelin phosphodiesteraseHomo sapiens (human)
lipid dropletSphingomyelin phosphodiesteraseHomo sapiens (human)
plasma membraneSphingomyelin phosphodiesteraseHomo sapiens (human)
endolysosomeSphingomyelin phosphodiesteraseHomo sapiens (human)
lamellar bodySphingomyelin phosphodiesteraseHomo sapiens (human)
lysosomal lumenSphingomyelin phosphodiesteraseHomo sapiens (human)
extracellular exosomeSphingomyelin phosphodiesteraseHomo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A4Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A4Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A4Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
trans-Golgi network membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
synapse5-hydroxytryptamine receptor 7Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 7Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
cytosolHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
synapseHistamine H1 receptorHomo sapiens (human)
dendriteHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneSodium channel protein type 1 subunit alphaHomo sapiens (human)
nucleoplasmSodium channel protein type 1 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 1 subunit alphaHomo sapiens (human)
intercalated discSodium channel protein type 1 subunit alphaHomo sapiens (human)
nuclear bodySodium channel protein type 1 subunit alphaHomo sapiens (human)
Z discSodium channel protein type 1 subunit alphaHomo sapiens (human)
T-tubuleSodium channel protein type 1 subunit alphaHomo sapiens (human)
node of RanvierSodium channel protein type 1 subunit alphaHomo sapiens (human)
neuronal cell bodySodium channel protein type 1 subunit alphaHomo sapiens (human)
axon initial segmentSodium channel protein type 1 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 1 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 4 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 4 subunit alphaHomo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A3Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A3Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A3Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
cilium5-hydroxytryptamine receptor 6Homo sapiens (human)
synapse5-hydroxytryptamine receptor 6Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2J2Homo sapiens (human)
extracellular exosomeCytochrome P450 2J2Homo sapiens (human)
cytoplasmCytochrome P450 2J2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2J2Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
synapseVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
neuronal cell bodyVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
plasma membraneSodium channel protein type 7 subunit alphaHomo sapiens (human)
glial cell projectionSodium channel protein type 7 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 7 subunit alphaHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
cytoplasmSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
cell surfaceSodium-dependent dopamine transporter Homo sapiens (human)
membraneSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
neuron projectionSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell bodySodium-dependent dopamine transporter Homo sapiens (human)
axon terminusSodium-dependent dopamine transporter Homo sapiens (human)
membrane raftSodium-dependent dopamine transporter Homo sapiens (human)
postsynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
dopaminergic synapseSodium-dependent dopamine transporter Homo sapiens (human)
flotillin complexSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
presynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
sarcoplasmic reticulumVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
T-tubuleVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
I bandVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic densityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
dendriteVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic density membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleolusSodium channel protein type 5 subunit alphaHomo sapiens (human)
endoplasmic reticulumSodium channel protein type 5 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
cell surfaceSodium channel protein type 5 subunit alphaHomo sapiens (human)
intercalated discSodium channel protein type 5 subunit alphaHomo sapiens (human)
membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
lateral plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
Z discSodium channel protein type 5 subunit alphaHomo sapiens (human)
T-tubuleSodium channel protein type 5 subunit alphaHomo sapiens (human)
sarcolemmaSodium channel protein type 5 subunit alphaHomo sapiens (human)
perinuclear region of cytoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 5 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 9 subunit alphaHomo sapiens (human)
axonSodium channel protein type 9 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 9 subunit alphaHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
apical plasma membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
basolateral plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
apical plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
plasma membraneSodium channel protein type 2 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 2 subunit alphaHomo sapiens (human)
intercalated discSodium channel protein type 2 subunit alphaHomo sapiens (human)
T-tubuleSodium channel protein type 2 subunit alphaHomo sapiens (human)
axonSodium channel protein type 2 subunit alphaHomo sapiens (human)
node of RanvierSodium channel protein type 2 subunit alphaHomo sapiens (human)
paranode region of axonSodium channel protein type 2 subunit alphaHomo sapiens (human)
presynaptic membraneSodium channel protein type 2 subunit alphaHomo sapiens (human)
glutamatergic synapseSodium channel protein type 2 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 2 subunit alphaHomo sapiens (human)
membraneSodium channel protein type 2 subunit alphaHomo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
sarcoplasmSodium channel protein type 3 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 3 subunit alphaHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneSodium channel protein type 11 subunit alphaHomo sapiens (human)
axonSodium channel protein type 11 subunit alphaHomo sapiens (human)
neuronal cell bodySodium channel protein type 11 subunit alphaHomo sapiens (human)
axonal growth coneSodium channel protein type 11 subunit alphaHomo sapiens (human)
C-fiberSodium channel protein type 11 subunit alphaHomo sapiens (human)
extracellular exosomeSodium channel protein type 11 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 11 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 8 subunit alphaHomo sapiens (human)
membraneSodium channel protein type 8 subunit alphaHomo sapiens (human)
Z discSodium channel protein type 8 subunit alphaHomo sapiens (human)
cell junctionSodium channel protein type 8 subunit alphaHomo sapiens (human)
axonSodium channel protein type 8 subunit alphaHomo sapiens (human)
cytoplasmic vesicleSodium channel protein type 8 subunit alphaHomo sapiens (human)
node of RanvierSodium channel protein type 8 subunit alphaHomo sapiens (human)
axon initial segmentSodium channel protein type 8 subunit alphaHomo sapiens (human)
presynaptic active zone membraneSodium channel protein type 8 subunit alphaHomo sapiens (human)
parallel fiber to Purkinje cell synapseSodium channel protein type 8 subunit alphaHomo sapiens (human)
postsynaptic density membraneSodium channel protein type 8 subunit alphaHomo sapiens (human)
glutamatergic synapseSodium channel protein type 8 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 8 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 10 subunit alphaHomo sapiens (human)
axonSodium channel protein type 10 subunit alphaHomo sapiens (human)
presynaptic membraneSodium channel protein type 10 subunit alphaHomo sapiens (human)
extracellular exosomeSodium channel protein type 10 subunit alphaHomo sapiens (human)
glutamatergic synapseSodium channel protein type 10 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 10 subunit alphaHomo sapiens (human)
clathrin complexSodium channel protein type 10 subunit alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (919)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID111833Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 20 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID1211794Fraction unbound in blood (not specified)2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID349880Permeability across porcine brain lipid coated polyvinylidene fluoride membrane by PAMPA2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID1217711Metabolic activation in human liver microsomes assessed as [3H]GSH adduct formation rate measured per mg of protein at 100 uM by [3H]GSH trapping assay2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1147085Antidepressant activity in Swiss-Webster mouse assessed as prevention of reserpine-induced ptosis at 10 to 50 mg/kg, ip1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
3-Aminotetrahydrocarbazoles as a new series of central nervous system agents.
AID288190Permeability coefficient through artificial membrane in presence of stirred water layer at 100 rpm stirring speed2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID1211297Drug recovery in plasma (unknown origin)2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID16331Delta logPoct-cyc1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists.
AID90053Binding affinity towards histamine receptor by inhibiting specific binding of [3H]-mepyramine (3 nM) in vitro to membranes of rat brain without cerebellum1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
cis-1,3,4,6,7,11b-Hexahydro-2-methyl-7-phenyl-2H-pyrazino[2,1-a] isoquinoline: a new atypical antidepressant.
AID1217712Time dependent inhibition of CYP2C8 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1570001Permeability of compound at 100 ug/ml measured after dilution with PBS/EtOH (70:30) at pH 7.4 after 18 hrs by PAMPA-BBB assay2019European journal of medicinal chemistry, Oct-15, Volume: 180Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID221731Ability to kill 50% of the animals after 24h, when administered perorally1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants.
AID142503Binding affinity towards muscarinic acetylcholine receptor by inhibiting specific binding of [3H]quinuclidinyl benzilate (0.8 nM) in vitro to membranes of rat brain without cerebellum1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
cis-1,3,4,6,7,11b-Hexahydro-2-methyl-7-phenyl-2H-pyrazino[2,1-a] isoquinoline: a new atypical antidepressant.
AID218673Binding affinity towards alpha-1 adrenergic receptor1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID134376Acute toxicity was measured in mice after peroral administration (293-330)1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
1-Azacycloalkyl-1,4-benzodiazepin-2-ones with antianxiety-antidepressant actions.
AID23968logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID624610Specific activity of expressed human recombinant UGT1A72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID173926Potentiation of Methamphetamine effect for intracranial self stimulation(SS) in rats1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Pyrazolodiazepines. 3. 4-Aryl-1,6,7,8-tetrahydro-1,3-dialkylpyrazolo[3,4-e][1,4]diazepines as antidepressant agents.
AID648667Permeability of the compound in porcine brain lipid assessed as ratio of compound in acceptor plate to amount of compound in donor plate at 5 mg/ml after 10 hrs by PAMPA assay2012Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6
Novel oxoisoaporphine-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
AID449543Sedative activity in Swiss albino mouse assessed as reduction on spontaneous locomotor activity at 10 mg/kg, ip administered 30 mins before test measured for 30 mins2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis and preliminary pharmacological evaluation of imidazo[2,1-f]purine-2,4-dione derivatives.
AID255317Percent inhibition against 5-hydroxytryptamine transporter at 1 uM nonselective2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID1517867Permeability of compound by PAMPA-BBB assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
AID1212317Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning measured per 10'6 cells at 1 uM after 5 mins by LC-MS analysis in presence of ammonium chloride2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID1529186Binding affinity to human serum albumin assessed as change in dissociation constant pKa1 of compound in aqueous medium to presence of human serum albumin by UV-pH titration based spectrophotometric analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID679763TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: ? uM, Imipramine: 100 uM) in MDR1-expressing MDCKII cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
AID5945Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA).
AID1918194Lipophilicity, log D of the compound2022Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.
AID1212318Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM up to 10 mins by LC-MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID180113Inhibition of the 5-HT [14C]5-HT uptake by rat brain slices In vitro1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Synthesis and central nervous system properties of 2-[(alkoxycarbonyl)amino]-4(5)-phenyl-2-imidazolines.
AID1334754Permeability of the compound at 25 ug/ml after 18 hrs by PAMPA assay2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID112387The effect on excitement was measured in mice following oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Imine analogues of tricyclic antidepressants.
AID781328pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 20052014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID172614Amount of milk ingested after the 15 min methamphetamine-challenges, produced by the compound at 2.5 mg/kg in fasted rats1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Pyrazolodiazepines. 3. 4-Aryl-1,6,7,8-tetrahydro-1,3-dialkylpyrazolo[3,4-e][1,4]diazepines as antidepressant agents.
AID1131106Anticholinergic effect in sc dosed CFLP mouse assessed as inhibition of pilocarpine-induced salivation1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Substituted 3-amino-1,1-diaryl-2-propanols as potential antidepressant agents.
AID243189Inhibition of partially open human voltage-gated potassium channel subunit Kv11.1 (ERG K+ channel)2005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
A two-state homology model of the hERG K+ channel: application to ligand binding.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1436078Permeability of compound at 100 ug/ml after 18 hrs by PAMPA2017European journal of medicinal chemistry, Jan-27, Volume: 126Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
AID1571404Intrinsic clearance in rat liver microsomes measured up to 60 mins in presence of NADPH by LC-MS/MS analysis
AID590293Antidepressant activity in Swiss albino mouse assessed as decrease in immobility time at 30 mg/kg, ip measured for 6 mins by forced swim test2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Discovery and synthesis of novel 3-phenylcoumarin derivatives as antidepressant agents.
AID1776036Metabolic stability in CD1 mouse liver microsomes assessed as half life at 10 uM incubated for 4 hr by LC-MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds.
AID1144368Antidepressant activity in pargyline-pretreated mouse assessed as potentiation of DL-DOPA-induced jumping, fighting and squeaking at 100 mg/kg, po treated 4 hrs prior to DL-DOPA-challenge1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Novel analogs of tricyclic psychopharmacological agents.
AID681584TP_TRANSPORTER: inhibition of MPP+ uptake in OCT3-expressing HRPE cells2000American journal of physiology. Renal physiology, Sep, Volume: 279, Issue:3
Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID1601979Displacement of [3H]-citalopram from SERT in rat cortex tissue measured after 60 mins by microbeta scintillation counting analysis2019European journal of medicinal chemistry, Mar-15, Volume: 166Synthesis of novel pyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT
AID1144418Toxicity in po dosed Swiss mouse assessed as behavioral changes1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Basic derivatives of 6,7-dihydroindolo(1,7-ab)(1) benzazepine and 6H-indolo(7,1-cd)(1,5) benzoxazepine as potential antidepressant agents.
AID1625123Permeability of the compound in pH 7.4 PBS at 200 uL after 18 hrs by PAMPA-BBB assay2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID114386Analgesic activity for the inhibition of phenylquinone induced writhing (PQW) after subcutaneous administration to mice1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Tricyclics with analgesic and antidepressant activity. 1. [[(Alkylamino)ethyl]thio]dibenz[b,f]oxepins and 10,11-dihydro derivatives.
AID1217707Time dependent inhibition of CYP2C19 in human liver microsomes at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID28926Effective permeability corrected for ionization2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID1196338Displacement of [3H]imipramine from human SERT expressed in CHO cells2015European journal of medicinal chemistry, Mar-06, Volume: 92Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
AID23972logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1720746Metabolic stability in mouse microsome assessed as intrinsic clearance
AID1172092Effect on spontaneous locomotor activity in ip dosed mouse during 2 to 6 mins2015Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1
Antidepressant- and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1,3-dimethyl-purine-2,6-dione derivatives with diversified 5-HT₁A receptor functional profile.
AID1054435Antidepression-like activity in rat assessed as decrease in immobility time at 60 mg/kg, po by forced swimming test2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Identification and profiling of 3,5-dimethyl-isoxazole-4-carboxylic acid [2-methyl-4-((2S,3'S)-2-methyl-[1,3']bipyrrolidinyl-1'-yl)phenyl] amide as histamine H(3) receptor antagonist for the treatment of depression.
AID125386Effective dose (p.o.) required to inhibit monoamine oxidase, in vivo1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Synthetic CNS agents. 1. (+/-)-1,2,3,4,4a,5,10,10a-Octahydro-5,10[1',2'] -benzenobenz[g]isoquinoline hydrochloride. A new, highly potent, potential antidepressant.
AID1123530Neuroleptic activity in po dosed mouse assessed as inhibition of d-amphetamine sulfate-induced lethality administered for 0.5 hrs followed by d-amphetamine sulfate challenge measured after 24 hrs1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
10-(Alkylamino)-4H-thieno[3,4-b][1,5]benzodiazepines. A novel class of potential neuroleptic agents.
AID311934Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID603953In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID449475Sedative activity in Swiss albino mouse assessed as reduction on spontaneous locomotor activity at 30 mg/kg, ip administered 30 mins before test measured for 6 mins2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis and preliminary pharmacological evaluation of imidazo[2,1-f]purine-2,4-dione derivatives.
AID1144419Toxicity in po dosed Swiss mouse assessed as clonic convulsion1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Basic derivatives of 6,7-dihydroindolo(1,7-ab)(1) benzazepine and 6H-indolo(7,1-cd)(1,5) benzoxazepine as potential antidepressant agents.
AID203916Binding affinity towards serotonin S1 receptor at 1.0 uM1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID113644Effect on the antagonism of nicotine-induced death (D)1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
2,4-Dihydro-6-phenyl-1H-s-triazolo[4,3-a][1,4]benzoidiazepin-1-ones with antianxiety and antidepressant activity.
AID1212333Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of diclofenac2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID729812Induction of apoptosis in human HeLa cells assessed as decrease in cells at G2/M phase measured at 2.5 uM after 24 hrs by propidium iodide assay2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Basic N-interlinked imipramines show apoptotic activity against malignant cells including Burkitt's lymphoma.
AID1217709Time dependent inhibition of CYP3A4 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID147591Compound was tested for its inhibitory activity against Noradrenaline receptor1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID449542Sedative activity in Swiss albino mouse assessed as reduction on spontaneous locomotor activity at 10 mg/kg, ip administered 30 mins before test measured for 6 mins2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis and preliminary pharmacological evaluation of imidazo[2,1-f]purine-2,4-dione derivatives.
AID172474Amount of milk ingested after the 120 min methamphetamine-challenges, produced by the compound at 10 mg/kg in fasted rats1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Pyrazolodiazepines. 3. 4-Aryl-1,6,7,8-tetrahydro-1,3-dialkylpyrazolo[3,4-e][1,4]diazepines as antidepressant agents.
AID681985TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, Imipramine: 1000 uM) in OCT2A-expressing HEK293 cells2002Journal of the American Society of Nephrology : JASN, Jul, Volume: 13, Issue:7
cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney.
AID1442001Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1).
AID28234% absorbed in human GI-tract2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID773434Displacement of [3H]imipramin from human recombinant SERT over-expressed in HEK293 cells2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1357284Inhibition of mmLDL-stimulated acid sphingomyelinase in human PBMC lysates using 3H-sphingomyelin as substrate preincubated for 30 mins followed by mmLDL stimulation measured after 2 hrs by HPLC method2018European journal of medicinal chemistry, Jun-10, Volume: 153NB 06: From a simple lysosomotropic aSMase inhibitor to tools for elucidating the role of lysosomes in signaling apoptosis and LPS-induced inflammation.
AID1357285Dissociation constant, pKa of the compound2018European journal of medicinal chemistry, Jun-10, Volume: 153NB 06: From a simple lysosomotropic aSMase inhibitor to tools for elucidating the role of lysosomes in signaling apoptosis and LPS-induced inflammation.
AID1161578Permeability of the compound by PAMPA-BBB assay2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Shogaol-huprine hybrids: dual antioxidant and anticholinesterase agents with β-amyloid and tau anti-aggregating properties.
AID1336731Permeability of compound at 100 ug/ml after 18 hrs by PAMPA2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID113650Effect on the antagonism of pentylenetetrazole-induced clonic convulsions (P)1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
2,4-Dihydro-6-phenyl-1H-s-triazolo[4,3-a][1,4]benzoidiazepin-1-ones with antianxiety and antidepressant activity.
AID1211295Unbound fraction in plasma (unknown origin) at pH 7.63 after 6 hrs by equilibrium dialysis method in presence of 5% CO22011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID112624Compound was tested for antidepressant activity by determining the decreased exploratory activity in mice upon oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Imine analogues of tricyclic antidepressants.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1847247Antiviral activity against Ebola virus VLP infected in human HeLa cells assessed as reduction in viral infection preincubated for 1 hr followed by substrate addition and measured after 2 hrs by envision plate reader method2021European journal of medicinal chemistry, Nov-05, Volume: 223Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction.
AID271644Inhibition of protease-resistant scrapie prion protein activity in ScN2a cells2006Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22
A chimeric ligand approach leading to potent antiprion active acridine derivatives: design, synthesis, and biological investigations.
AID1557178Permeability of the compound at 100 ug/ml measured after compound dilution in PBS/EtOH buffer (70:30) by PAMPA-BBB assay2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID1299182Inhibition of human SERT I172M mutant expressed in HEK293 MSR cells assessed as [3H]-5-HT uptake preincubated for 30 mins followed addition of [3H]-5HT and compound for 10 mins by micro-scintillation counter2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Synthesis and inhibitory evaluation of 3-linked imipramines for the exploration of the S2 site of the human serotonin transporter.
AID624617Specific activity of expressed human recombinant UGT2B172000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1211792Hepatic clearance in human2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1255974Antidepressant activity in Swiss albino mouse assessed as decrease in immobility time at 10 mg/kg, po administered 60 mins before test measured for 6 mins by tail suspension test relative to control2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Design, synthesis, and biological evaluation of oxindole derivatives as antidepressive agents.
AID780294Effect on social seperation in chick anxiety-depression model assessed as attenuation of decline in distress vocalizations during depression-like phase at 5 mg/kg, ip 15 mins prior to behavioral testing measured after 30 to 45 mins2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.
AID598094Plasma concentration in mouse at 20 mg/kg, ip after 30 mins2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID643383Induction of phospholipidosis in bovine corneal fibroblasts assessed as lamellar inclusion bodies after 72 hrs by light microscopy2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
AID132963Effect on tetrabenazine-induced suppression of locomotor activity in the mouse after peroral administration1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
3,4-Diphenyl-1H-pyrazole-1-propanamine antidepressants.
AID1636423Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 21.3 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of N2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1496040Effective permeability of the compound in PBS/EtOH at 50 ug/mL after 18 hrs by PAMPA-BBB assay2018Bioorganic & medicinal chemistry letters, 06-15, Volume: 28, Issue:11
Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.
AID142220Binding affinity against Muscarinic acetylcholine receptor was determined in homogenized rat cortex tissue using [3H]N-methylscopolamine as radioligand1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Tricyclic compounds as selective antimuscarinics. 1. Structural requirements for selectivity toward the muscarinic acetylcholine receptor in a series of pirenzepine and imipramine analogues.
AID111827Compound was evaluated for the ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 10 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID581807Inhibition of Saccharomyces cerevisiae MKCDR1h multidrug transporter Cdr1p assessed as concentration required to threefold increase in rate of fluorescence signal relative to absence of inhibitor by fluorescein diacetate based high-throughput screening sp2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters.
AID676720Antidepressant activity in CF1 mouse assessed as reduction in immobility at 20 mg/kg, po measured after 60 mins by forced-swimming test2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Acylphloroglucinols from Elaphoglossum crassipes: antidepressant-like activity of crassipin A.
AID22538Half life period is estimated1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID1212316Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning measured per 10'6 cells at 1 uM after 5 mins by LC-MS analysis2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID1720745Metabolic stability in mouse microsome assessed as half life
AID1436079Permeability of compound at 25 ug/ml after 18 hrs by PAMPA2017European journal of medicinal chemistry, Jan-27, Volume: 126Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID161281Inhibition of human Potassium channel HERG expressed in mammalian cells2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
AID408340Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Support vector machines classification of hERG liabilities based on atom types.
AID1529182Protein binding in plasma (unknown origin)2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID211846Acute toxicity (p.o.) after 24 hr was determined in mouse1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Synthetic CNS agents. 1. (+/-)-1,2,3,4,4a,5,10,10a-Octahydro-5,10[1',2'] -benzenobenz[g]isoquinoline hydrochloride. A new, highly potent, potential antidepressant.
AID184683Minimal effective dose in an rat anti-immobility effect using behavioral despair test1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID135326BBB penetration classification2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID294618Antidepressant-like activity in Swiss Albino mouse at 10 mg/kg by forced swimming test2007Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8
Novel class of arylpiperazines containing N-acylated amino acids: their synthesis, 5-HT1A, 5-HT2A receptor affinity, and in vivo pharmacological evaluation.
AID184476Estimated oral dose depressing motor activity by 50% in rats(po)1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Derivatives of 11-(1-piperazinyl)-5H-pyrrolo[2,1-c][1,4]benzodiazepine as central nervous system agents.
AID1183278Permeability of the compound by PAMPA2014European journal of medicinal chemistry, Sep-12, Volume: 84Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β-amyloid, tau, and cholinesterase pathologies.
AID329204Inhibition of L-[3H]Leu uptake at Aquifex aeolicus sodium-coupled leucine transporter2007Nature, Aug-23, Volume: 448, Issue:7156
Antidepressant binding site in a bacterial homologue of neurotransmitter transporters.
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1150606Antidepressant activity in ip dosed rat assessed as prevention of tetrabenazine-induced ptosis1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Cycloalkanoindoles. 2. 1-Alkyl-1,2,3,4-tetrahydrocarbazole-1-ethanamines and related compounds. Potential antidepressants.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1332024Inhibition of human SERT expressed in CHO cell membranes assessed as reduction in [3H]serotonin uptake preincubated for 10 mins followed by [3H]serotonin addition measured after 20 mins by liquid scintillation counting method2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Discovery of SMP-304, a novel benzylpiperidine derivative with serotonin transporter inhibitory activity and 5-HT
AID134408Compound was evaluated for 50% lethal dose in mice; LD50 range 100-300 mg/kg1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Structure-activity studies on antidepressant 2,2-diarylethylamines.
AID1212332Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of propranolol2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID183628Effect of compound administered 60 min before the test in the forced swimming test in Rat (8 rats per group) at 40 mg/kg2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
New arylpiperazine 5-HT(1A) receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation.
AID134602Lethal dose in mouse p.o.1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
New bicyclic antidepressant agent. Synthesis and activity of napactadine and related compounds.
AID309520Antidepressant activity in Swiss Albino mouse assessed as immobility time during final 4 mins of 6 mins session at 20 mg/kg administered 30 mins before the test by forced-swimming test2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines.
AID172611Amount of milk ingested after the 15 min methamphetamine-challenges, produced by the compound at 0.625 mg/kg in fasted rats1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Pyrazolodiazepines. 3. 4-Aryl-1,6,7,8-tetrahydro-1,3-dialkylpyrazolo[3,4-e][1,4]diazepines as antidepressant agents.
AID114157Antidepressant activity was evaluated by measuring its ability to antagonize reserpine-induced ptosis in mice1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID1211296Unbound fraction in plasma (unknown origin) under normal atmospheric condition at pH 7.72 after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID288187Permeability coefficient through artificial membrane in presence of stirred water layer at 250 rpm stirring speed2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID180129Inhibition of uptake of 5-HT in rat brain slices1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Synthesis and antidepressant profiles of phenyl-substituted 2-amino- and 2-[(alkoxycarbonyl)amino]-1,4,5,6-tetrahydropyrimidines.
AID1211793Lipophilicity, log P of the compound2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1144378Antipsychotic activity in mouse assessed as change in methamphetamine-induced hyperactivity at 10 mg/kg, po relative to control1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Novel analogs of tricyclic psychopharmacological agents.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1150604Acute toxicity in ip dosed albino mouse assessed as mortality measured for 5 days1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Cycloalkanoindoles. 2. 1-Alkyl-1,2,3,4-tetrahydrocarbazole-1-ethanamines and related compounds. Potential antidepressants.
AID1517958Displacement of [3H]-imipramine from human serotonin transporter expressed in HEK293 cells membranes incubated for 30 mins by microbeta scintillation counting analysis
AID1209243Drug metabolism in assessed as human CYP3A4-mediated metabolism2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID692184Therapeutic index, ratio of Cmax in human to IC50 for human MATE2-K2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID180130Inhibition of uptake of Dopamine in rat brain slices1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Synthesis and antidepressant profiles of phenyl-substituted 2-amino- and 2-[(alkoxycarbonyl)amino]-1,4,5,6-tetrahydropyrimidines.
AID1209247Drug metabolism in human liver microsomes assessed as intrinsic clearance per mg protein by multiple depletion curves method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID1713987Effective permeability of the compound at 25 ug/ml after 18 hrs by UV plate reader based PAMPA-BBB assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease.
AID64630Binding affinity towards dopamine receptor D2 at 1.0 uM concentration1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID692193Inhibition of human OCT2 A270S mutant expressed in HEK-293-Flp-In cells incubated for 3 mins by ASP+ substrate uptake assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID179941Inhibition of Norepinephrine uptake from rat diencephalon-midbrain1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Orally active and potent inhibitors of gamma-aminobutyric acid uptake.
AID235625Therapeutic index administered intraperitoneally in mouse1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
New bicyclic antidepressant agent. Synthesis and activity of napactadine and related compounds.
AID1890389Metabolic stability in human liver microsomes assessed as intrinsic clearance2022European journal of medicinal chemistry, Apr-05, Volume: 233Design, synthesis, and behavioral evaluation of dual-acting compounds as phosphodiesterase type 10A (PDE10A) inhibitors and serotonin ligands targeting neuropsychiatric symptoms in dementia.
AID1091956Apparent hydrophobicity, log D of the compound in Octanol-buffer2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID26300log P values determined at pH 7.41999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID19006Calculated membrane partition coefficient (Kmemb)2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID692189Therapeutic index, ratio of Cmax in human to IC50 for human OCT2 A270S mutant2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID1545656Half-life in CD1 mouse liver microsomes by HPLC analysis2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Novel multitarget 5-arylidenehydantoins with arylpiperazinealkyl fragment: Pharmacological evaluation and investigation of cytotoxicity and metabolic stability.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID118917Compound was tested for lethality in mice at a dose 80 mg/kg intraperitoneally; L denotes lethal at this dose1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Cognition-activating properties of 3-(Aryloxy)pyridines.
AID692194Inhibition of human OCT1 expressed in HEK-293-Flp-In cells incubated for 3 mins by ASP+ substrate uptake assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID330659Effect on life span of Caenorhabditis elegans at 50 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID540237Phospholipidosis-positive literature compound observed in rat
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID172608Amount of milk ingested after the 120 min methamphetamine-challenges, produced by the compound at 2.5 mg/kg in fasted rats1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Pyrazolodiazepines. 3. 4-Aryl-1,6,7,8-tetrahydro-1,3-dialkylpyrazolo[3,4-e][1,4]diazepines as antidepressant agents.
AID179383Concentration of compound to inhibit 50% of [3H]norepinephrine neurotransmitter uptake in rat brain1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Conformationally restricted tricyclic antidepressants. 1. Octahydrodibenzazepinonaphthyridines as rigid imipramine analogues.
AID196059Inhibition of the uptake of tritiated dopamine (DA) in rat synaptosomes1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID180366The compound was tested for antidepressant activity by its ability to inhibit muricidal intraperitoneally1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Central nervous system activity of 7-substituted 1-azaphenoxathiin analogues and their oxidation products.
AID1597295Displacement of [3H] imipramine from human recombinant 5-HT transporter measured after 60 mins by scintillation counter method
AID1211795Dissociation constant, pKa of the compound2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID117217Lethal dose was evaluated against reserpine induced hypothermia in mice by intraperitoneal administration1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Design, synthesis, and pharmacological activities of 2-substituted 4-phenylquinolines as potential antidepressant drugs.
AID23708Partition coefficient (logP)1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID26296Partition coefficient (logD7.4)1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1625122Permeability of the compound in pH 7.4 PBS/EtOH at 100 ug/ml after 18 hrs by PAMPA-BBB assay2019Bioorganic & medicinal chemistry, 03-15, Volume: 27, Issue:6
Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
AID129179Antidepressant activity was determined to prevent tetrabenazine-induced ptosis(TBZ) after oral administration in mice1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Tricyclics with analgesic and antidepressant activity. 2. [[(Alkylamino)ethyl]thio]dibenzo[b,f]thiepins and 10,11-dihydro derivatives.
AID235738Therapeutic index as the ratio of LD50 to that of ED50 values.1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Design, synthesis, and pharmacological activities of 2-substituted 4-phenylquinolines as potential antidepressant drugs.
AID1285675Displacement of [3H]imipramine from human recombinant 5-HT transporter expressed in CHO cells2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
AID29812Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID118797Compound was tested for cognitive activity by measuring retention for passive avoidance learning in mice at dose 10 mg/kg1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Cognition-activating properties of 3-(Aryloxy)pyridines.
AID235626Therapeutic index administered perorally in mouse1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
New bicyclic antidepressant agent. Synthesis and activity of napactadine and related compounds.
AID114395Tested for antagonism of oxotremorine hypothermia (OX) in mice1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID476994Anxiolytic-like activity in Swiss albino mouse assessed as number of punished crossing of the light beam during 6 mins at 10 mg/kg, ip measured after 30 mins postdose by four-plate test (RVb = 94.8 +/- 4.1)2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity.
AID26362Ionization constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID476995Anxiolytic-like activity in Swiss albino mouse assessed as number of punished crossing of the light beam during 30 mins at 20 mg/kg, ip measured after 30 mins postdose by four-plate test (RVb = 94.8 +/- 4.1)2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity.
AID293491Antidepressant activity in Swiss mouse assessed as immobility time at 15 mg/kg, ip thrice a day by 5-mins swim test2007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
Antidepressant-like profile of action of two 4-amine derivatives of 10,11-dihydro-5H-dibenzo [a,d] cycloheptane in mice evaluated in the forced swimming test.
AID196031Inhibition of [3H]norepinephrine uptake into rat brain synaptosomes in vitro;Values ranges from: 0.01-0.071987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID1375645Antiviral activity against Ebolavirus like particle harboring EBOV VP40 assessed as inhibition of viral infection in human HeLa cells preincubated with host cells for 1 hrs followed by viral inoculation by beta-lactamse reporter assay2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Structures of Ebola Virus Glycoprotein Complexes with Tricyclic Antidepressant and Antipsychotic Drugs.
AID196028Inhibition of [3H]dopamine uptake into rat brain synaptosomes in vitro;Values ranges from: 0.09-0.181987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID427197Membrane permeability dissolved in PBS/EtOH (70:30) mixture by PAMPA-BBB assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
AID1209252Drug metabolism in assessed as human CYP2C19-mediated metabolism2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID294622Antidepressant-like activity in C57BL/6J mouse at 10 mg/kg by tail suspension test2007Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8
Novel class of arylpiperazines containing N-acylated amino acids: their synthesis, 5-HT1A, 5-HT2A receptor affinity, and in vivo pharmacological evaluation.
AID1514461Metabolic stability in human liver microsomes assessed as compound remaining at 1 uM after 60 mins in presence of G-6-P, G-6-PDH, MgCl2 and NADP+ by LC-MS/MS analysis (Rvb = 100%)2019Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1
Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety.
AID288186Permeability coefficient through artificial membrane in presence of stirred water layer at 200 rpm stirring speed2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID113415Compound was tested for total number of explored holes in 5 minutes after intraperitoneal administration of 37.5 mg/Kg in mice1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Pyrrolobenzodiazepines and related systems. 2. Synthesis and biological properties of isonoraptazepine derivatives.
AID134217Tested in vitro for serotonin(5-HT) neuronal uptake inhibition1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID112388Effect on pupil dilation was measured in mice upon oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Imine analogues of tricyclic antidepressants.
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1131083Antidepressant activity in ip dosed CD1 mouse assessed as inhibition of tetrabenazine methanesulfonate-induced reserpine like behavior administered 30 mins before tetrabenazine methanesulfonate challenge measured after 30 mins1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Synthesis of spiro[isobenzofuran-1(3H),4'-piperidines] as potential central nervous system agents. 5. Conformationally mobile analogues derived by furan ring opening.
AID1123529Neuroleptic activity in po dosed rat assessed as concentration required to cause 50% reduction of motor activity1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
10-(Alkylamino)-4H-thieno[3,4-b][1,5]benzodiazepines. A novel class of potential neuroleptic agents.
AID1144416Antispasmodic activity in guinea pig ileum assessed as inhibition of histamine-induced spasm1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Basic derivatives of 6,7-dihydroindolo(1,7-ab)(1) benzazepine and 6H-indolo(7,1-cd)(1,5) benzoxazepine as potential antidepressant agents.
AID1132844Analgesic activity in mouse assessed as inhibition of acetic acid-induced writhing response at 30 mg/kg, po administered 30 mins prior to acetic acid-challenge relative to control1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis of spiro[tetralin-2,2'-pyrrolidine] and spiro[indan-2,2'-pyrrolidine] derivatives as potential analgesics.
AID1223490Apparent permeability across human differentiated Caco2 cells2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID1363637Metabolic stability in mouse liver microsomes assessed as compound remaining at 25 uM after 1 hr in presence of NADPH by LC-MS analysis2018Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21
Synthesis, Receptor Affinity, and Antiallodynic Activity of Spirocyclic σ Receptor Ligands with Exocyclic Amino Moiety.
AID1144413Antidepressant activity in po dosed Swiss mouse assessed as reversal of reserpine-induced ptosis administered 1 hr prior to reserpine challenge1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Basic derivatives of 6,7-dihydroindolo(1,7-ab)(1) benzazepine and 6H-indolo(7,1-cd)(1,5) benzoxazepine as potential antidepressant agents.
AID110188Antagonism of tetrabenazine (TBZ)-induced depression in mice measured for ptosis1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID222712Effect on recovery time for coma induced in mice by cerebral concussion (treated group)2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1172091Antidepressant-like activity in mouse assessed as reduction in immobility time at 10 to 20 mg/kg, ip dosed 60 mins before test by forced swim test2015Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1
Antidepressant- and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1,3-dimethyl-purine-2,6-dione derivatives with diversified 5-HT₁A receptor functional profile.
AID134948Mouse behavior activity was determined; S-D=Stimulant-Depressant1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Synthesis and central nervous system properties of 2-[(alkoxycarbonyl)amino]-4(5)-phenyl-2-imidazolines.
AID288901Locomotor activity in Swiss Albino mouse assessed as number of crossings in 6 mins at 30 mg/kg, ip administered 30 mins before the test2007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
7-Arylpiperazinylalkyl and 7-tetrahydroisoquinolinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and some of their purine-2,6,8-trione analogs as 5-HT(1A), 5-HT(2A), and 5-HT(7) serotonin receptor ligands.
AID338160Displacement of [3H]citalopram from serotonin transporter1993Journal of natural products, Apr, Volume: 56, Issue:4
The role of receptor binding in drug discovery.
AID161627Half maximal inhibition of Prion protein PrPsc formation was assayed in ScN2a cells2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID178315Antidepressant activity was determined for potentiation of head twitching induced by 5-hydroxytryptophan-(5-HTP) after intraperitoneal administration in pargyline-pretreated rats1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Tricyclics with analgesic and antidepressant activity. 2. [[(Alkylamino)ethyl]thio]dibenzo[b,f]thiepins and 10,11-dihydro derivatives.
AID112136Effective dose required to potentiate yohimbine hydrochloride induced lethality in mice, administered intraperitoneally1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
New bicyclic antidepressant agent. Synthesis and activity of napactadine and related compounds.
AID1195628Antidepressant-like activity in mouse assessed as decrease in immobility time at 10 mg/kg, po by forced swimming test2015Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10
Pyridinic analog of the natural product (-)-spectaline as potential adjuvant for the treatment of central nervous system disorders.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID6418Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID225162Effect on Immobility Time in the Forced-Swimming Test in Mice at the dose of 10 mg/kg po for single administration2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID1752934Intrinsic clearance in mouse liver microsomes measured upto 40 mins by LC-MS/MS analysis
AID19419Partition coefficient (logD7.4)1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.
AID431484Inhibition of [3H]serotonin reuptake at serotonin transporter2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Synthesis of 1,1-[1-naphthyloxy-2-thiophenyl]-2-methylaminomethylcyclopropanes and their evaluation as inhibitors of serotonin, norepinephrine, and dopamine transporters.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1517957Displacement of [3H]-8-OH-DPAT from human 5HT1A receptor expressed in CHO-K1 cell membranes incubated for 60 mins by microbeta scintillation counting analysis
AID134601Lethal dose in mouse i.p.1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
New bicyclic antidepressant agent. Synthesis and activity of napactadine and related compounds.
AID1458670Toxicity in CD-1 mouse assessed as effect on spontaneous locomotory activity by measuring number of areas crossed administered for 30 mins measured every 1 min for first 5 mins2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID196063Inhibition the uptake of tritiated serotonin (5-HT) by the serotonin transporter SERT in rat synaptosomes1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1319973Permeability of the compound by PAMPA assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID129955Antidepressant activity measured by effects on tetrabenzidine (TBZ) inhibited exploratory activity.1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Structure-activity studies on antidepressant 2,2-diarylethylamines.
AID729820Reduction in cell viability of human DG75 cells after 24 hrs by Alamar blue viability assay2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Basic N-interlinked imipramines show apoptotic activity against malignant cells including Burkitt's lymphoma.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1818858Antidepressant activity in Wistar rat model of scopolamine-induced depressive like behavior assessed as increased swimming time at 1 mg/kg measured after 24 hrs by forced swimming test2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Designed Peptide Inhibitors of STEP Phosphatase-GluA2 AMPA Receptor Interaction Enhance the Cognitive Performance in Rats.
AID692183Protein binding in human plasma2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID780297Effect on isolation-stressor in chick anxiety-depression model assessed as attenuation of decline in distress vocalizations during depression-like phase at 5 mg/kg, ip 15 mins prior to behavioral testing measured after 5 to 60 mins2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.
AID288894Antidepressant activity in Swiss Albino mouse assessed as immobility time during final 4 mins of 6 mins session at 20 mg/kg, ip administered 30 mins before the test in forced-swimming test2007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
7-Arylpiperazinylalkyl and 7-tetrahydroisoquinolinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and some of their purine-2,6,8-trione analogs as 5-HT(1A), 5-HT(2A), and 5-HT(7) serotonin receptor ligands.
AID114920Compound was evaluated after 24 hr for physostigmine induced lethality upon oral administration 60 min before intraperitoneal injection of physostigmine (0.9 mg/kg) in mice at 25 mg/kg1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
New dibenzothiadiazepine derivatives with antidepressant activities.
AID310931Partition coefficient, log P of the compound2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID392739Antidepressant activity against Swiss-Webster mouse assessed as reduction in duration of immobility at 10 mg/kg, ip after 1 hr by tail suspension behavioral despair test relative to control2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
1-Malonyl-1,4-dihydropyridine as a novel carrier for specific delivery of drugs to the brain.
AID123344Percentage of total immobility time after an intraperitoneal dose of 1.5 (mg/kg) in porsolt's test2002Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23
New pyridobenzodiazepine derivatives: modifications of the basic side chain differentially modulate binding to dopamine (D(4.2), D(2L)) and serotonin (5-HT(2A)) receptors.
AID1071344Permeability of the compound by BBB-PAMPA2014European journal of medicinal chemistry, Feb-12, Volume: 731,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-midgorge-site inhibitors of acetylcholinesterase: synthesis, pharmacological evaluation and mechanistic studies.
AID185200Time-related potentiation of methamphetamine-induced anorexia in rats at the lowest active dose.1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Pyrazolodiazepines. 3. 4-Aryl-1,6,7,8-tetrahydro-1,3-dialkylpyrazolo[3,4-e][1,4]diazepines as antidepressant agents.
AID1334753Permeability of the compound at 100 ug/ml after 18 hrs by PAMPA assay2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
AID1211294Unbound fraction in plasma (unknown origin) at pH 7.4 after 6 hrs by equilibrium dialysis method in presence of 5% CO22011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID178370Effective dose (p.o.) required to reverse ptosis induced by tetrabenazine in rat1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Synthetic CNS agents. 1. (+/-)-1,2,3,4,4a,5,10,10a-Octahydro-5,10[1',2'] -benzenobenz[g]isoquinoline hydrochloride. A new, highly potent, potential antidepressant.
AID181669In vitro inhibition of norepinephrine uptake in rat brain synaptosomes using [3H]NE1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antidepressant activity of 4-aryltetrahydrothieno[2,3-c]pyridine derivatives.
AID1352675Effective permeability at 25 ug/ml after 18 hrs by PAMPA2018European journal of medicinal chemistry, Feb-25, Volume: 146Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID1255970Antidepressant activity in Swiss albino mouse assessed as decrease in immobility time at 10 mg/kg, po administered 60 mins before test measured for 6 mins by forced swimming test relative to control2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Design, synthesis, and biological evaluation of oxindole derivatives as antidepressive agents.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID132108In vivo effect on Tetrabenazine ptosis activity in mice following i.p. administration.1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID183627Effect of compound administered 60 min before the test in the forced swimming test in Rat (8 rats per group) at 30 mg/kg2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
New arylpiperazine 5-HT(1A) receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID692185Cmax in human2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID119457Dose required to reduce reserpine induced hypothermia was measured after sc administration of reserpine at 2.5 mg/kg, 18 hr before the rectal-temperature recording in mice1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
New dibenzothiadiazepine derivatives with antidepressant activities.
AID1264447Permeability of the compound by PAMPA method2015European journal of medicinal chemistry, Nov-13, Volume: 105Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity.
AID214939Binding affinity against human UDP Glucuronosyltransferase 1A4 (UGT1A4)2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Pharmacophore and quantitative structure-activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity.
AID127795In vitro activity for the ability to inhibit the uptake of Serotonin into mouse cortical slices.1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Tetracyclic pyridazines as potential psychopharmacological agents.
AID309530Effect on locomotor activity in Swiss Albino mouse assessed as number of crossings in 30 mins at 20 mg/kg administered 30 mins before the test2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID692196Inhibition of human MATE2-K expressed in HEK-293-Flp-In cells incubated for 3 mins by ASP+ substrate uptake assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID476996Anxiolytic-like activity in Swiss albino mouse assessed as number of punished crossing of the light beam during 30 mins at 10 mg/kg, ip measured after 30 mins postdose by four-plate test (RVb = 210.7 +/- 17.7)2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity.
AID678719Metabolic stability in human liver microsomes assessed as medium signal/noise ratio (S/N of 10 to 100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID119219Rotation number in mice was determined at 9 minutes after a dose of 10 mg/Kg1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Pyrrolobenzodiazepines and related systems. 2. Synthesis and biological properties of isonoraptazepine derivatives.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID114407Anticonvulsant activity to prevent pentamethylenetetrazole (MTZ) induced lethality in mice after oral administration1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Tricyclics with analgesic and antidepressant activity. 1. [[(Alkylamino)ethyl]thio]dibenz[b,f]oxepins and 10,11-dihydro derivatives.
AID222068Effect on the sleeping time of mice anesthetized with halothane (treated group);NT means not tested2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID351894Inhibition of [3H]norepinephrine uptake at human NET expressed in HEK293 cells2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.
AID180151Inhibitory activity against uptake of [3H]norepinephrine into rat brain synaptosomes.1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
1-Azacycloalkyl-1,4-benzodiazepin-2-ones with antianxiety-antidepressant actions.
AID1123532Antidepressant activity in po dosed mouse assessed as inhibition of tetrabenazine hexamate-induced depression administered 1 hr followed by tetrabenazine hexamate challenge measured after 30 mins1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
10-(Alkylamino)-4H-thieno[3,4-b][1,5]benzodiazepines. A novel class of potential neuroleptic agents.
AID1570058Displacement of [3H]-citalopram from SERT in rat cortex tissue incubated for 60 mins by microbeta scintillation counting method2019European journal of medicinal chemistry, Oct-15, Volume: 180Synthesis of new 5,6,7,8-tetrahydropyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT
AID496020Plasma protein binding in human after 30 min by ultrafiltration2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID1144417Acute toxicity in po dosed Swiss mouse assessed as mortality after 7 days1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Basic derivatives of 6,7-dihydroindolo(1,7-ab)(1) benzazepine and 6H-indolo(7,1-cd)(1,5) benzoxazepine as potential antidepressant agents.
AID130125Compound was evaluated for maximal electroshock antagonism (MES) against mice1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Synthesis and central nervous system properties of 2-[(alkoxycarbonyl)amino]-4(5)-phenyl-2-imidazolines.
AID361986Lipophilicity, log D of compound at pH 7.4 by shake flask method2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Determination of log D via automated microfluidic liquid-liquid extraction.
AID113875Intraperitoneal dose required for antagonism of d-amphetamine lethality in grouped mice (GAL).; inact means compound is inactive at 20 mg/kg dose.1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Derivatives of 11-(1-piperazinyl)-5H-pyrrolo[2,1-c][1,4]benzodiazepine as central nervous system agents.
AID114488Inhibition of reserpine (5 mg/kg i.p.) induced hypothermia in mice 2 hr after i.p. administration.1983Journal of medicinal chemistry, May, Volume: 26, Issue:5
Antidepressant activity of 5-aryl-2,3,5,6-tetrahydroimidazo[2,1-a]isoquinolin-5-ols.
AID1458668Toxicity in Swiss albino mouse assessed as effect on spontaneous locomotory activity measuring number of areas crossed administered for 30 mins measured every 2 mins up to 6 mins2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID184473Reduction in motor activity in rats following p.o. administration.1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Thiophene systems. 5. Thieno[3,4-b][1,5]benzoxazepines, thieno[3,4-b][1,5]benzothiazepines, and thieno[3,4-b][1,4]benzodiazepines as potential central nervous system agents.
AID478691Antidepressant activity in rat assessed as immobility time at 20 mg/kg, po by forced swimming test (Rvb = 150.3 +/- 11.1 sec)2010Journal of natural products, May-28, Volume: 73, Issue:5
Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
AID681986TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, Imipramine: 1000 uM) in OCT2-expressing HEK293 cells2002Journal of the American Society of Nephrology : JASN, Jul, Volume: 13, Issue:7
cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney.
AID127858Evaluated in vivo for reserpine hypothermia after oral administration in mouse. Minimum active dose was reported1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Synthesis and central nervous system properties of 2-[(alkoxycarbonyl)amino]-4(5)-phenyl-2-imidazolines.
AID113655Effect on the potentiation of gamma-butyrolactone-induced sleep (gamma-B)1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
2,4-Dihydro-6-phenyl-1H-s-triazolo[4,3-a][1,4]benzoidiazepin-1-ones with antianxiety and antidepressant activity.
AID351887Inhibition of [3H]5HT uptake at human SERT expressed in HEK293 cells2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1211293Unbound fraction in plasma (unknown origin) under normal atmospheric condition at pH 7.22 after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID1514445Metabolic stability in human liver microsomes assessed as compound remaining at 1 uM after 15 mins in presence of G-6-P, G-6-PDH, MgCl2 and NADP+ by LC-MS/MS analysis (Rvb = 100%)2019Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1
Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety.
AID449471Antidepressant activity in Swiss albino mouse assessed as reduction of immobility time at 20 mg/kg, ip administered 30 mins before test by forced swimming test2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis and preliminary pharmacological evaluation of imidazo[2,1-f]purine-2,4-dione derivatives.
AID181621Antimuricide effect was observed in the olfactory bulb removed rats; antimuricide effect at 30 mg/kg; + = 31 - 50%1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antidepressant activity of substituted (omega-aminoalkoxy)benzene derivatives.
AID1739433Metabolic stability in human liver microsomes assessed as half life at 100 uM measured upto 30 mins2020European journal of medicinal chemistry, Aug-15, Volume: 200Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
AID179763In vitro inhibitory activity against [3H]5-HT uptake into crude synaptosomes from whole rat brain.1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
3,4-Diphenyl-1H-pyrazole-1-propanamine antidepressants.
AID1192730Permeability of the compound by PAMPA2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
AID294621Antidepressant-like activity in C57BL/6J mouse at 5 mg/kg by tail suspension test2007Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8
Novel class of arylpiperazines containing N-acylated amino acids: their synthesis, 5-HT1A, 5-HT2A receptor affinity, and in vivo pharmacological evaluation.
AID28921Partition coefficient (logP) (hexadecane)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID5444Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene.
AID476989Antidepressant-like activity in Swiss mouse assessed as immobilization time at 20 mg/kg, ip after 30 mins by forced swim test (RVb = 167.1 +/- 6.7 s)2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity.
AID112385The effect on electroshock protection in mice following oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Imine analogues of tricyclic antidepressants.
AID427196Membrane permeability by PAMPA-BBB assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
AID611034Antidepressant activity in Swiss mouse assessed as reduction of immobility duration at 10 mg/kg, ip administered 30 mins prior test measured during last 4 mins of 6 mins observation period by forced-swimming test (Rvb = 0 %)2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Synthesis and antidepressant-like activity evaluation of sulphonamides and sulphonyl-hydrazones.
AID1222793Dissociation constant, pKa of the compound2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Which metabolites circulate?
AID114393Tested for antagonism of nicotine-induced death (D) in mice1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID1382495Half life in human liver microsomes at 0.1 uM preincubated for 5 mins followed by NDAPH addition measured up to 60 mins by HPLC-MS/MS analysis2018European journal of medicinal chemistry, Mar-25, Volume: 148Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA).
AID1285689Half life in mouse liver microsomes at 20 uM preincubated for 15 mins followed by addition of NADPH-regenerating system measured after 5 to 90 mins by UPLC/MC analysis2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1207660Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID624633Drug glucuronidation reaction catalyzed by human recombinant UGT1A42005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID1470712Anti-depressant like activity in Swiss albino mouse assessed as reduction in immobility time at 60 mg/kg, po administered 60 mins prior to test measured for 5 mins by forced swim test relative to control2017European journal of medicinal chemistry, May-26, Volume: 132Novel aryl piperazines for alleviation of 'andropause' associated prostatic disorders and depression.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID204217Binding affinity to Serotonin transporter using [3H]-paroxetine as radioligand in stably transfected NIH3T3 cells2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene.
AID1144379Antipsychotic activity in mouse assessed as change in methamphetamine-induced hyperactivity at 20 mg/kg, po relative to control1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Novel analogs of tricyclic psychopharmacological agents.
AID288192Partition coefficient, log P of the compound2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID751835Binding affinity to human 5-HT transporter by radioligand displacement assay2013European journal of medicinal chemistry, May, Volume: 63Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.
AID1777550Displacement of SGRG-K(Ac)-GG-K(Ac)-GLG-K(Ac)-GGA-K(Ac)-RHRKVGG-K(Biotin) from Europium chelated human BRD4 bromodomain 2 (342 to 460 residues) measured after 2 hrs by TR-FRET assay2021Bioorganic & medicinal chemistry, 09-01, Volume: 45Identification of isoform/domain-selective fragments from the selection of DNA-encoded dynamic library.
AID1384014Effective permeability of the compound dissolved in PBS at 100 uM after 3 to 6 hrs by PAMPA2018European journal of medicinal chemistry, Apr-25, Volume: 150The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer's disease.
AID373867Hepatic clearance in human hepatocytes in absence of fetal calf serum2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
AID5679Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene.
AID114565Tested for stereotyped gnawing and licking behavior of mice pretreated with apomorphine (AG)1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID1382494Intrinsic clearance in human liver microsomes at 0.1 uM preincubated for 5 mins followed by NDAPH addition measured up to 60 mins by HPLC-MS/MS analysis2018European journal of medicinal chemistry, Mar-25, Volume: 148Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA).
AID1823847Anti-antidepressant like activity in Wistar rat assessed as reduction in locomotor activity by measuring total immobility time by Forced swim test
AID1514446Metabolic stability in human liver microsomes assessed as compound remaining at 1 uM after 30 mins in presence of G-6-P, G-6-PDH, MgCl2 and NADP+ by LC-MS/MS analysis (Rvb = 100%)2019Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1
Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety.
AID493410Antidepressant activity in Swiss albino mouse assessed as reduction of immobility duration at 30 mg/kg, ip administered 3 times for 24 hrs measured after 1 hr last post dose by tail suspension test2010Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15
Synthesis, antidepressant evaluation and QSAR studies of novel 2-(5H-[1,2,4]triazino[5,6-b]indol-3-ylthio)-N-(substituted phenyl)acetamides.
AID1718151Displacement of [3H]DTG from sigma 2 receptor in Sprague-Dawley rat brain membranes in presence of (+)-pentazocine by scintillation counting method2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
AID624632Drug glucuronidation reaction catalyzed by human recombinant UGT1A32005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID1212329Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of dextromethorphan2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID288897Locomotor activity in Swiss Albino mouse assessed as number of crossings in 6 mins at 10 mg/kg, ip administered 30 mins before the test2007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
7-Arylpiperazinylalkyl and 7-tetrahydroisoquinolinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and some of their purine-2,6,8-trione analogs as 5-HT(1A), 5-HT(2A), and 5-HT(7) serotonin receptor ligands.
AID222711Effect on recovery time for coma induced in mice by cerebral concussion (control group)2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID1585850Effective permeability of the compound in PBS/EtOH at 100 ug/ml after 18 hrs by PAMPA2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID114396Tested for antagonism of pentylenetetrazole-induced clonic convulsions (P) in mice1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID729814Induction of apoptosis in human MUTU-I cells assessed as decrease in cells at G2/M phase measured at 2.5 uM after 24 hrs by propidium iodide assay2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Basic N-interlinked imipramines show apoptotic activity against malignant cells including Burkitt's lymphoma.
AID28923Effective permeability measured with Caco-2 cells2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID288893Antidepressant activity in Swiss Albino mouse assessed as immobility time during final 4 mins of 6 mins session at 10 mg/kg, ip administered 30 mins before the test in forced-swimming test2007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
7-Arylpiperazinylalkyl and 7-tetrahydroisoquinolinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and some of their purine-2,6,8-trione analogs as 5-HT(1A), 5-HT(2A), and 5-HT(7) serotonin receptor ligands.
AID145696Binding affinity to Norepinephrine transporter using [3H]-nisoxatine as radioligand in stably transfected NIH3T3 cells2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene.
AID114738Delay in response to noxious heat stimuli in mice by tail flick method after subcutaneous administration1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Tricyclics with analgesic and antidepressant activity. 1. [[(Alkylamino)ethyl]thio]dibenz[b,f]oxepins and 10,11-dihydro derivatives.
AID1353530Antidepressant like activity in Swiss albino mouse assessed as immobility time at 10 mg/kg, ip administered 30 mins prior to test and measured last 4 mins of 6 mins test by forced swimming test (Rvb = 162.71 +/- 6.8 secs)2018European journal of medicinal chemistry, Mar-10, Volume: 147Computer-aided insights into receptor-ligand interaction for novel 5-arylhydantoin derivatives as serotonin 5-HT
AID132665In vitro inhibition of accumulation of (-)-[3H]Norepinephrine (NA) in mouse brain slices1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis of pyridylallylamines related to zimelidine and their inhibition of neuronal monoamine uptake.
AID181670In vitro inhibition of 5-HT uptake in rat brain synaptosomes using [3H]- 5-hydroxytryptamine1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antidepressant activity of 4-aryltetrahydrothieno[2,3-c]pyridine derivatives.
AID1091957Apparent permeability of the compound by PAMPA2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID624618Specific activity of expressed human recombinant UGT2B42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1144367Antidepressant activity in pargyline-pretreated mouse assessed as potentiation of DL-DOPA-induced jumping, fighting and squeaking at 25 mg/kg, po treated 4 hrs prior to DL-DOPA-challenge1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Novel analogs of tricyclic psychopharmacological agents.
AID223128Ability to kill 50% of the animals (administered orally), after sublethal dose of yohimbine (25 mg/Kg) when given subcutaneously.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants.
AID114043Muscle relaxant effect was measured as ED50 which is the dose that causes muscle relaxation in 50% of the mice, po1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antidepressant activity of substituted (omega-aminoalkoxy)benzene derivatives.
AID183074Inhibition of GABA uptake from rat diencephalon-midbrain at 100 uM concentration1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
Orally active and potent inhibitors of gamma-aminobutyric acid uptake.
AID1465314Effective permeability of the compound by PAMPA2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID681116TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
AID1480942Permeability of the compound at pH 7.4 at 1 mg/ml after 4 hrs by PAMPA-BBB assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
AID1514463Metabolic stability in human liver microsomes assessed as compound remaining at 1 uM after 120 mins by LC-MS/MS analysis (Rvb = 100%)2019Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1
Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety.
AID680295TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 uM, Imipramine: 20 uM) in MDR1-expressing NIH-3T3 cells2004Biochemical and biophysical research communications, Mar-19, Volume: 315, Issue:4
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
AID1212319Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM measured at 10 mins by LC-MS analysis in presence of ammonium chloride2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID1703748Intrinsic clearance in human liver microsomes at 0.1 uM in presence of NADPH measured upto 60 mins by LC/MS/MS analysis2020European journal of medicinal chemistry, Sep-15, Volume: 202Evaluation of N-phenyl-2-aminothiazoles for treatment of multi-drug resistant and intracellular Staphylococcus aureus infections.
AID1557184Permeability of the compound at 25 ug/ml by PAMPA-BBB assay2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID692186Therapeutic index, ratio of Cmax in human to IC50 for human OCT12011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID87513Compound tested for its inhibitory activity against Histamine H1 receptor1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID48901Evaluated for its relative defibrillating activity in male cats 10 min after injection at concentration 2 mg/Kg2001Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22
A new class of antiarrhythmic-defibrillatory agents.
AID180114Inhibition of the NE [3H]Norepinephrine uptake by rat brain slices In vitro1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Synthesis and central nervous system properties of 2-[(alkoxycarbonyl)amino]-4(5)-phenyl-2-imidazolines.
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID1568822Effective permeability of the compound at 25 ug/ml incubated for 18 hrs by PAMPA-BBB assay2019European journal of medicinal chemistry, Sep-15, Volume: 178Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID223123Potentiation of 5-hydroxytryptophan-induced head twitch in mice after oral administration1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants.
AID112642Antidepressant activity by determining the reversal of tetrabenazine-induced ptosis upon oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Imine analogues of tricyclic antidepressants.
AID178876Compound was tested for the inhibition of tetrabenazine-induced sedation in rat, after peroral administration1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
(2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol: a novel antidepressant agent and selective inhibitor of norepinephrine uptake.
AID692187Therapeutic index, ratio of Cmax in human to IC50 for human MATE12011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID288194Intrinsic artificial membrane permeability coefficient, log P0 of the compound2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1427527Effective permeability of the compound at pH 7.4 after 18 hrs by PAMPA2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID218807Binding affinity towards alpha-2 adrenergic receptor1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID590299Antidepressant activity in Swiss albino mouse assessed as decrease in immobility duration at 30 mg/kg, ip administered 30 mins prior to test measured after 30 mins by tail suspension test (Rvb = 79.9%)2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Discovery and synthesis of novel 3-phenylcoumarin derivatives as antidepressant agents.
AID625277FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID23960logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID449476Sedative activity in Swiss albino mouse assessed as reduction on spontaneous locomotor activity at 30 mg/kg, ip administered 30 mins before test measured for 30 mins2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis and preliminary pharmacological evaluation of imidazo[2,1-f]purine-2,4-dione derivatives.
AID180132Inhibition of uptake of tritiated norepinephrine (NE) into rat brain synaptosomes1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: synthesis and antidepressant activity.
AID1390040Effective permeability of the compound at 100 ug/ml after 18 hrs by PAMPA-BBB assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID1517838Permeability of the compound in pH 7.4 PBS/EtOH at 25 ug/ml after 18 hrs by PAMPA-BBB assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1212314Drug uptake in lysosomes of human Fa2N-4 cells assessed as inhibition of LysoTracker Red fluorescence after 30 mins2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID1132845Analgesic activity in mouse by hot-plate test1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis of spiro[tetralin-2,2'-pyrrolidine] and spiro[indan-2,2'-pyrrolidine] derivatives as potential analgesics.
AID112984Compound was tested for the inhibition of tetrabenazine-induced sedation in mice, after peroral administration1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
(2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol: a novel antidepressant agent and selective inhibitor of norepinephrine uptake.
AID1357283Inhibition of TNFalpha-stimulated apoptosis in human PBMC assessed as apoptotic cells at 2 uM preincubated for 30 mins followed by TNFalpha stimulation measured after 4 hrs by YO-PRO-1/Hoechst 33342 staining based assay relative to control2018European journal of medicinal chemistry, Jun-10, Volume: 153NB 06: From a simple lysosomotropic aSMase inhibitor to tools for elucidating the role of lysosomes in signaling apoptosis and LPS-induced inflammation.
AID449474Sedative activity in Swiss albino mouse assessed as reduction on spontaneous locomotor activity at 20 mg/kg, ip administered 30 mins before test measured for 30 mins2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis and preliminary pharmacological evaluation of imidazo[2,1-f]purine-2,4-dione derivatives.
AID132117Tested in vivo for head twitches antagonizing activity in mice1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID288902Locomotor activity in Swiss Albino mouse assessed as number of crossings in 30 mins at 5 mg/kg, ip administered 30 mins before the test2007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
7-Arylpiperazinylalkyl and 7-tetrahydroisoquinolinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and some of their purine-2,6,8-trione analogs as 5-HT(1A), 5-HT(2A), and 5-HT(7) serotonin receptor ligands.
AID5355Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA).
AID107473Compound was tested for total number of falls in 100 seconds after intraperitoneal administration of 37.5 mg/Kg in mice by rotarod test1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Pyrrolobenzodiazepines and related systems. 2. Synthesis and biological properties of isonoraptazepine derivatives.
AID288907Locomotor activity in Swiss Albino mouse assessed as number of crossings in 30 mins at 30 mg/kg, ip administered 30 mins before the test2007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
7-Arylpiperazinylalkyl and 7-tetrahydroisoquinolinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and some of their purine-2,6,8-trione analogs as 5-HT(1A), 5-HT(2A), and 5-HT(7) serotonin receptor ligands.
AID22345Therapeutic plasma levels for the compound was evaluated.1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID63979Binding affinity towards dopamine receptor D2 using [3H]spiperone as radioligand2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA).
AID1150605Antidepressant activity in ip dosed mouse assessed as prevention of reserpine-induced ptosis1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Cycloalkanoindoles. 2. 1-Alkyl-1,2,3,4-tetrahydrocarbazole-1-ethanamines and related compounds. Potential antidepressants.
AID131890Effective dose required to antagonise clonidine-induced antinociception(ACA) in mouse by peroral administration; NT is Not Tested1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID1545657Intrinsic clearance in CD1 mouse liver microsomes by HPLC analysis2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Novel multitarget 5-arylidenehydantoins with arylpiperazinealkyl fragment: Pharmacological evaluation and investigation of cytotoxicity and metabolic stability.
AID1374214Effective permeability of the compound in pH 7.4 buffer after 18 hrs by PAMPA-BBB assay2018Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID91721Inhibition of binding of [3H]imipramine to imipramine receptor in rat brain1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: synthesis and antidepressant activity.
AID112987Compound was tested for the neuroleptic activity as measured by it's antagonism of d-amphetamine induced lethality in grouped mice(GAL) when administered perorally1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Thiophene systems. 5. Thieno[3,4-b][1,5]benzoxazepines, thieno[3,4-b][1,5]benzothiazepines, and thieno[3,4-b][1,4]benzodiazepines as potential central nervous system agents.
AID112381The effect on 24-hour mortality in mice following oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Imine analogues of tricyclic antidepressants.
AID118792Compound was tested for cognitive activity by measuring retention for passive avoidance learning in mice at dose 40 mg/kg1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Cognition-activating properties of 3-(Aryloxy)pyridines.
AID131526Effective dose against tetrabenazine induced ptosis in mice administered orally1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
1-Azacycloalkyl-1,4-benzodiazepin-2-ones with antianxiety-antidepressant actions.
AID29423HPLC capacity factor (k')2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1713986Effective permeability of the compound in PBS/ethanol buffer (9:1) at 25 ug/ml after 10 hrs by UV plate reader based PAMPA-BBB assay2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease.
AID180468In vitro inhibitory activity against [3H]-5-HT uptake into crude synaptosomes from whole rat brain.1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
3,4-Diphenyl-1H-pyrazole-1-propanamine antidepressants.
AID351888Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.
AID343685Ratio of drug level in brain to blood in Wistar rat2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Toward prediction of alkane/water partition coefficients.
AID133113Prevention of reserpine-induced ptosis in the mouse after peroral administration1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
3,4-Diphenyl-1H-pyrazole-1-propanamine antidepressants.
AID433879Antidepressant activity in Swiss-Webster mouse assessed as reduction in duration of immobility time at 10 mg/kg, ip by tail suspension behavioral despair test2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Synthesis of novel pyrazole derivatives and evaluation of their antidepressant and anticonvulsant activities.
AID1675412Binding affinity to H1 receptor (unknown origin)2020Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21
Synthesis, crystal structure and biological activity of novel analogues of tricyclic drugs.
AID1264455Permeability of the compound by high throughput PAMPA method2015European journal of medicinal chemistry, Nov-13, Volume: 105Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity.
AID183626Effect of compound administered 60 min before the test in the forced swimming test in Rat (8 rats per group) at 20 mg/kg2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
New arylpiperazine 5-HT(1A) receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation.
AID420669Lipophilicity, log D at pH 7.02009European journal of medicinal chemistry, May, Volume: 44, Issue:5
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID23962logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1752938Half life in mouse liver microsomes measured upto 40 mins by LC-MS/MS analysis
AID729821Reduction in cell viability of human MUTU-I cells after 24 hrs by Alamar blue viability assay2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Basic N-interlinked imipramines show apoptotic activity against malignant cells including Burkitt's lymphoma.
AID179990Tested in vivo for serotonin syndrome antagonizing activity in rat1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID360444Displacement of [3H]RTI82 from DAT in rat striatal membrane2007The Journal of biological chemistry, Mar-23, Volume: 282, Issue:12
Localization of cocaine analog [125I]RTI 82 irreversible binding to transmembrane domain 6 of the dopamine transporter.
AID130699In vivo inhibition of accumulation of (-)-[3H]Norepinephrine (NA) in mouse brain slices after intraperitoneal administration1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis of pyridylallylamines related to zimelidine and their inhibition of neuronal monoamine uptake.
AID1458675Inhibition of SERT expressed in rat brain synaptosomes assessed as decrease in incorporation of [3H]serotonin measured after 15 mins by scintillation counting method2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID1750323Half life in human liver microsomes at 1 uM measured up to 60 mins in presence of NADPH by HPLC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity.
AID184234Maximum inhibition of immobility in the rat (Expressed as percentage of immobility observed in vehicle controls)1999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
Novel derivatives of 2-pyridinemethylamine as selective, potent, and orally active agonists at 5-HT1A receptors.
AID129177Antidepressant activity measured by maximal electroshock seizure threshold (MEST) assay in untreated mice after ip administration1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Structure-activity studies on antidepressant 2,2-diarylethylamines.
AID1384013Effective permeability of the compound dissolved in PBS containing 1% F-127 at 100 uM after 3 to 6 hrs by PAMPA2018European journal of medicinal chemistry, Apr-25, Volume: 150The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer's disease.
AID1374552Antidepressant-like activity in Wistar rat assessed as decrease in immobility time at 30 mg/kg, ip administered 30 mins prior to test measured for 5 mins by forced swim test2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
MF-8, a novel promising arylpiperazine-hydantoin based 5-HT
AID449473Sedative activity in Swiss albino mouse assessed as reduction on spontaneous locomotor activity at 20 mg/kg, ip administered 30 mins before test measured for 6 mins2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis and preliminary pharmacological evaluation of imidazo[2,1-f]purine-2,4-dione derivatives.
AID1437174Permeability of the compound in PBS/EtOH at 100 ug/ml after 18 hrs by PAMPA2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
AID180133Inhibition of uptake of tritiated serotonin (5-HT) into rat brain synaptosomes1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: synthesis and antidepressant activity.
AID60003Inhibition of the response to phenethylamine was measured1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Synthetic CNS agents. 1. (+/-)-1,2,3,4,4a,5,10,10a-Octahydro-5,10[1',2'] -benzenobenz[g]isoquinoline hydrochloride. A new, highly potent, potential antidepressant.
AID681443TP_TRANSPORTER: inhibition of TEA uptake by Imipramine at 1mM in Octn1-HRPE cells2000Biochimica et biophysica acta, Jun-01, Volume: 1466, Issue:1-2
Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta.
AID288184Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID1336374Displacement of [3H]imipramine from human recombinant 5HT transporter expressed in CHO cells measured after 60 mins by scintillation counting method2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
AID1192731Permeability of the compound in PBS/EtOH buffer at 100 ug/ml by PAMPA2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
AID1132846Antidepressant activity in mouse assessed as reversal of reserpine-induced hypothermia measured as cumulative temperature rise at 30 mg/kg administered 17 hrs post reserpine-challenge1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Synthesis of spiro[tetralin-2,2'-pyrrolidine] and spiro[indan-2,2'-pyrrolidine] derivatives as potential analgesics.
AID225164Effect on Immobility Time in the Forced-Swimming Test in Mice at the dose of 30 mg/kg po for repeated administration2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID12234881-Octanol-water distribution coefficient, log D of the compound at pH 7.42012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID26515Partition coefficient (logD7.4)1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID129450Anti-tetrabenazine (TBZ) activity, ability to prevent TBZ-induced ptosis in mice1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Synthesis and antidepressant activity of 4-aryltetrahydrothieno[2,3-c]pyridine derivatives.
AID48900Evaluated for its relative defibrillating activity in male cats 10 min after injection at concentration 1 mg/Kg2001Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22
A new class of antiarrhythmic-defibrillatory agents.
AID1458656Displacement of [3H]-imipramine from human serotonin transporter expressed in HEK-293 cell membranes after 30 mins by scintillation counting2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID112481Compound was tested for antidepressant activity against reserpine induced ptosis in mice after intraperitoneal administration.; value ranges from 2.2-2.41989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
3-aminopyridazine derivatives with atypical antidepressant, serotonergic, and dopaminergic activities.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID114561Tested for potentiation of gamma-butyrolactone induced sleep (gamma-B) in mice1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID1212335Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of atorvastatin2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID1375641Binding affinity to EBOV Mayinga, Zaire, 1976 envelope glycoprotein extracellular domain H613A mutant tagged with His/foldon trimerization sequence from the bacteriophage T4 fibritin at C terminal expressed in HEK293T cells at pH 5.2 by SYPRO orange dye-b2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Structures of Ebola Virus Glycoprotein Complexes with Tricyclic Antidepressant and Antipsychotic Drugs.
AID394126Antidepressive activity in Albino Swiss mouse assessed as total immobility time at 15 mg/kg, ip after 30 mins measured for 4 mins by forced swimming test2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Synthesis and serotonin receptor activity of the arylpiperazine alkyl/propoxy derivatives of new azatricycloundecanes.
AID222978Antagonism of tetrabenazine-induced ptosis in mice was evaluated after oral administration1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants.
AID204880Binding affinity towards Serotonin transporter using [3H]paroxetine as radioligand2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA).
AID1728286Metabolic stability in mouse liver microsomes assessed as parent compound remaining measured after 90 mins in presence of NADPH2021European journal of medicinal chemistry, Jan-15, Volume: 210Novel σ
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1496041Effective permeability of the compound by PAMPA-BBB assay2018Bioorganic & medicinal chemistry letters, 06-15, Volume: 28, Issue:11
Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.
AID114394Tested for antagonism of nicotine-induced tonic extensor convulsions (TE) in mice1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID294617Antidepressant-like activity in Swiss Albino mouse at 5 mg/kg by forced swimming test2007Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8
Novel class of arylpiperazines containing N-acylated amino acids: their synthesis, 5-HT1A, 5-HT2A receptor affinity, and in vivo pharmacological evaluation.
AID28925Highest effective permeability across hexadecane membrane (pH 4-8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID1352674Effective permeability at 25 ug/ml after 16 hrs by PAMPA2018European journal of medicinal chemistry, Feb-25, Volume: 146Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease.
AID1863562Antiviral activity against pseudotyped Ebola virus assessed as inhibition of viral entry2022European journal of medicinal chemistry, Oct-05, Volume: 240Discovery of potent ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold.
AID1211791Fraction unbound in human hepatocytes2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID179154Effect of compound administered 60 min before the test in the forced swimming test in Rat (8 rats per group) at 30 mg/kg2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
New arylpiperazine 5-HT(1A) receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation.
AID330661Effect on life span of Caenorhabditis elegans at 200 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID598090Antidepressant-like activity in mouse assessed as immobility time at 20 mg/kg, ip after 30 mins by forced swim test2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.
AID681345TP_TRANSPORTER: inhibition of TEA uptake (TEA: 50 uM) in OCT2-expressing MDCK cells2001Pharmaceutical research, Nov, Volume: 18, Issue:11
Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules.
AID293501Effect on motor co-ordination in Swiss mouse assessed as number of falls at 15 mg/kg, ip after 10 days by Rota-rod test2007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
Antidepressant-like profile of action of two 4-amine derivatives of 10,11-dihydro-5H-dibenzo [a,d] cycloheptane in mice evaluated in the forced swimming test.
AID1175702Antidepressant-like activity in Swiss albino mouse assessed as decrease in immobility time at 0.5 mg/kg, ip measured for 5 mins by tail suspension test relative to control2015Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
Design and synthesis of new series of coumarin-aminopyran derivatives possessing potential anti-depressant-like activity.
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1777549Displacement of SGRG-K(Ac)-GG-K(Ac)-GLG-K(Ac)-GGA-K(Ac)-RHRKVGG-K(Biotin) from Europium chelated human BRD4 bromodomain 1 (49 to 170 residues) measured after 2 hrs by TR-FRET assay2021Bioorganic & medicinal chemistry, 09-01, Volume: 45Identification of isoform/domain-selective fragments from the selection of DNA-encoded dynamic library.
AID19257Logarithm of partition coefficient of the neutral form of compound given for chloroform/water solvent system1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists.
AID25866Protonation constant of the compound.1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID111841Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 5 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID729813Induction of apoptosis in human DG75 cells assessed as decrease in cells at G2/M phase measured at 2.5 uM after 24 hrs by propidium iodide assay2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Basic N-interlinked imipramines show apoptotic activity against malignant cells including Burkitt's lymphoma.
AID581672Inhibition of Pdr5p-mediated rhodamine 6G transport in Saccharomyces cerevisiae MKPDR5h plasma membrane by spectrofluorometric assay2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters.
AID478701Antidepressant activity in rat assessed as immobility time at 20 mg/kg, po by forced swimming test (Rvb = 138.6 +/- 12 sec)2010Journal of natural products, May-28, Volume: 73, Issue:5
Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
AID1144415Antispasmodic activity in guinea pig ileum assessed as inhibition of acetylcholine-induced spasm1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Basic derivatives of 6,7-dihydroindolo(1,7-ab)(1) benzazepine and 6H-indolo(7,1-cd)(1,5) benzoxazepine as potential antidepressant agents.
AID1453097Effective permeability of the compound at 100 ug/ml incubated for 18 hrs by PAMPA-BBB assay2017Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12
Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
AID1209251Drug metabolism in human liver microsomes by optimal design approach2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID123350Percentage of total immobility time after an intraperitoneal dose of 7.5 (mg/kg) in porsolt's test2002Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23
New pyridobenzodiazepine derivatives: modifications of the basic side chain differentially modulate binding to dopamine (D(4.2), D(2L)) and serotonin (5-HT(2A)) receptors.
AID172615Amount of milk ingested after the 15 min methamphetamine-challenges, produced by the compound at 5 mg/kg in fasted rats1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Pyrazolodiazepines. 3. 4-Aryl-1,6,7,8-tetrahydro-1,3-dialkylpyrazolo[3,4-e][1,4]diazepines as antidepressant agents.
AID346472Displacement of radiolabeled imipramine from human SERT2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
AID1211797Intrinsic clearance in cryopreserved human hepatocytes cells assessed per 10'6 cells by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID114156Antidepressant activity was evaluated by measuring its ability to antagonize RO 4-1284-induced hypothermia in mice1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID395325Lipophilicity, log P by microemulsion electrokinetic chromatography2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID1091958Hydrophobicity, log P of the compound in octanol-water by shaking-flask method2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID111839Compound was evaluated for the ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 40.0 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID141547Concentration of compound for 50% displacement of [3H]QNB from Muscarinic acetylcholine receptor in rat brain1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Conformationally restricted tricyclic antidepressants. 1. Octahydrodibenzazepinonaphthyridines as rigid imipramine analogues.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1647892Antidepressant activity in Wistar rat assessed as immobility time at 45 mg/kg, ip measured for 5 mins by forced swim test (Rvb = 271.9 +/- 7.2 sec)2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane Hydrochloride (SUVN-911): A Novel, Potent, Selective, and Orally Active Neuronal Nicotinic Acetylcholine α4β2 Receptor Antagonist for the Treatment of Depression.
AID131880Effective dose required for inhibition of tetrabenazine-induced ptosis in mouse by peroral administration;Values ranges from: 1.8-9.31987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID612016Displacement of [3H]imipramine from human 5HT transporter2011Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15
Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.
AID1054121Binding affinity to histamine H1 receptor (unknown origin) by radioligand binding assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Polypharmacology - foe or friend?
AID113292Dose of compound required to reduce apomorphine-induced hypothermia by 50% in mice by hypothermia (Apo 16)test1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
New dibenzothiadiazepine derivatives with antidepressant activities.
AID131528Effective dose against tetrabenazine induced ptosis in mice administered subcutaneously1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
1-Azacycloalkyl-1,4-benzodiazepin-2-ones with antianxiety-antidepressant actions.
AID130716In vivo inhibition of uptake of nor epinephrine in mouse heart; value ranges from 3.1-14.61985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Synthesis and antidepressant profiles of phenyl-substituted 2-amino- and 2-[(alkoxycarbonyl)amino]-1,4,5,6-tetrahydropyrimidines.
AID172472Amount of milk ingested after the 120 min methamphetamine-challenges, produced by the compound at 0.625 mg/kg in fasted rats1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Pyrazolodiazepines. 3. 4-Aryl-1,6,7,8-tetrahydro-1,3-dialkylpyrazolo[3,4-e][1,4]diazepines as antidepressant agents.
AID118790Retention for passive avoidance learning in mice at dose 20 mg/kg1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Cognition-activating properties of 3-(Aryloxy)pyridines.
AID1091955Dissociation constant, pKa of the compound at pH 7.32011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID1568812Permeability of the compound in pH 7.4 PBS/EtOH at 100 ug/ml by PAMPA-BBB assay2019European journal of medicinal chemistry, Sep-15, Volume: 178Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID118210Ability to prevent the reserpine induced hypothermia in mice relative to amitriptyline1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antidepressant activity of substituted (omega-aminoalkoxy)benzene derivatives.
AID128147Ability to inhibit the uptake of Serotonin into mouse cortical slices 1 hour after intraperitoneal injection ex vivo1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Tetracyclic pyridazines as potential psychopharmacological agents.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1209248Drug metabolism in human liver microsomes assessed as intrinsic clearance per mg protein by optimal design approach2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID1636268Permeability of the compound at pH 7.4 after 18 hrs by PAMPA-BBB assay2016Bioorganic & medicinal chemistry, 10-15, Volume: 24, Issue:20
Design, synthesis and biological evaluation of N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors.
AID288193Flux ionization constant, pKa of the membrane permeability coefficient of the compound2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID729819Reduction in cell viability of human HeLa cells after 24 hrs by Alamar blue viability assay2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Basic N-interlinked imipramines show apoptotic activity against malignant cells including Burkitt's lymphoma.
AID1299180Inhibition of human SERT W103A mutant expressed in HEK293 MSR cells assessed as [3H]-5-HT uptake preincubated for 30 mins followed addition of [3H]-5HT and compound for 10 mins by micro-scintillation counter2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Synthesis and inhibitory evaluation of 3-linked imipramines for the exploration of the S2 site of the human serotonin transporter.
AID225165Effect on Immobility Time in the Forced-Swimming Test in Mice at the dose of 30 mg/kg po for single administration2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID180131Inhibition of uptake of nor epinephrine in rat brain slices1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Synthesis and antidepressant profiles of phenyl-substituted 2-amino- and 2-[(alkoxycarbonyl)amino]-1,4,5,6-tetrahydropyrimidines.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID130700In vivo inhibition of accumulation of [14C]5-HT (5-HT) in mouse brain slices after intraperitoneal administration1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis of pyridylallylamines related to zimelidine and their inhibition of neuronal monoamine uptake.
AID128659Analgesic activity was determined for inhibition of phenyl-p-quinone-induced writhing (PQW) after subcutaneous administration in mice1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Tricyclics with analgesic and antidepressant activity. 2. [[(Alkylamino)ethyl]thio]dibenzo[b,f]thiepins and 10,11-dihydro derivatives.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1129361Unbound fraction in HEK293 cell homogenate at 0.1 uM by equilibrium dialysis based UPLC-MS/MS analysis2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
AID714926Antidepressant activity in Swiss albino mouse assessed as mean immobility time measured during 6 mins period at 20 mg/kg, po administered 30 mins before test by tail suspension test (Rvb = 185.7 +/- 5.33 secs)2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Synthesis, characterization, antidepressant and antioxidant activity of novel piperamides bearing piperidine and piperazine analogues.
AID1211798Intrinsic clearance in human using well stirred liver model by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID123347Percentage of total immobility time after an intraperitoneal dose of 30 (mg/kg) in porsolt's test2002Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23
New pyridobenzodiazepine derivatives: modifications of the basic side chain differentially modulate binding to dopamine (D(4.2), D(2L)) and serotonin (5-HT(2A)) receptors.
AID1465293Effective permeability of the compound at 100 ug/ml by PAMPA-BBB assay2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
AID1444094Permeability of the compound in PBS/EtOH at 100 ug/ml after 18 hrs by PAMPA-BBB assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
AID476988Antidepressant-like activity in Swiss mouse assessed as immobilization time at 10 mg/kg, ip after 30 mins by forced swim test (RVb = 167.1 +/- 6.7 s)2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity.
AID118793Retention for passive avoidance learning in mice at dose 5 mg/kg1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Cognition-activating properties of 3-(Aryloxy)pyridines.
AID176472Potency to produce a significant inhibition of immobility in rat1999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
Novel derivatives of 2-pyridinemethylamine as selective, potent, and orally active agonists at 5-HT1A receptors.
AID1890429Metabolic stability in human liver microsomes assessed as half life2022European journal of medicinal chemistry, Apr-05, Volume: 233Design, synthesis, and behavioral evaluation of dual-acting compounds as phosphodiesterase type 10A (PDE10A) inhibitors and serotonin ligands targeting neuropsychiatric symptoms in dementia.
AID113656Effect on the potentiation of yohimbine-induced toxicity (Y) in aggregated mice1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
2,4-Dihydro-6-phenyl-1H-s-triazolo[4,3-a][1,4]benzoidiazepin-1-ones with antianxiety and antidepressant activity.
AID307535Antidepressant effect in mouse at 10 mg/kg, ip assessed as reduction in immobility duration after 30 mins by forced swimming test relative to control2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Design and synthesis of novel hydantoin-containing melanin-concentrating hormone receptor antagonists.
AID1209255Drug metabolism in assessed as human CYP1A2-mediated intrinsic clearance per mg protein2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID179153Effect of compound administered 60 min before the test in the forced swimming test in Rat (8 rats per group) at 20 mg/kg2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
New arylpiperazine 5-HT(1A) receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation.
AID1909448Permeability of the compound by PAMPA-BBB assay2022European journal of medicinal chemistry, Jun-05, Volume: 236Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
AID1285690Intrinsic clearance in mouse liver microsomes at 20 uM preincubated for 15 mins followed by addition of NADPH-regenerating system measured after 5 to 90 mins by UPLC/MC analysiS2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
AID780292Effect on social seperation in chick anxiety-depression model assessed as attenuation of decline in distress vocalizations during depression-like phase at 5 mg/kg, ip 15 mins prior to behavioral testing measured after 45 to 60 mins2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
In vitro structure-activity relationships of aplysinopsin analogs and their in vivo evaluation in the chick anxiety-depression model.
AID288185Permeability coefficient through artificial membrane in presence of stirred water layer2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID195890In vitro inhibition of dopamine (DA) uptake in synaptosomal preparation of rat brain1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
(2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol: a novel antidepressant agent and selective inhibitor of norepinephrine uptake.
AID1458659Antidepressant activity in Swiss albino mouse assessed as decrease in immobility time administered for 30 mins measured last 4 mins of 6 mins test by forced swimming test2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID172613Amount of milk ingested after the 15 min methamphetamine-challenges, produced by the compound at 10 mg/kg in fasted rats1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Pyrazolodiazepines. 3. 4-Aryl-1,6,7,8-tetrahydro-1,3-dialkylpyrazolo[3,4-e][1,4]diazepines as antidepressant agents.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID363880Neurotoxicity in albino mouse assessed as animal in lateral position at 10 mg/kg, ip administered 1 hr prior to ethanol challenge measured after 30 mins2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
Syntheses and anti-depressant activity of 5-amino-1, 3, 4-thiadiazole-2-thiol imines and thiobenzyl derivatives.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1823851Sedative activity in ip dosed Wistar rat assessed as effect on spontaneous locomotor activity measured for 10 mins by social interaction test
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID144767Inhibition of [3H]MK-801 binding to NMDA receptor of rat cerebral cortical synaptic membrane1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
(+/-)-(Z)-2-(aminomethyl)-1-phenylcyclopropanecarboxamide derivatives as a new prototype of NMDA receptor antagonists.
AID114415Antipsychotic activity to prevent amphetamine induced lethality in mice after oral administration1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Tricyclics with analgesic and antidepressant activity. 1. [[(Alkylamino)ethyl]thio]dibenz[b,f]oxepins and 10,11-dihydro derivatives.
AID1332035Ratio of IC50 for human SERT expressed in CHO cell membranes assessed as reduction in [3H]serotonin uptake to Ki for [3H]citalopram from human SERT expressed in HEK293 cell membranes2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Discovery of SMP-304, a novel benzylpiperidine derivative with serotonin transporter inhibitory activity and 5-HT
AID29925Volume of distribution in man (IV dose)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1421886Effective permeability of the compound at 25 ug/ml after 18 hrs by BBB-PAMPA method2018European journal of medicinal chemistry, Oct-05, Volume: 158Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1571403Half life in rat liver microsomes in presence of NADPH by LC-MS/MS analysis
AID1718178Inhibition of SERT (unknown origin)2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
AID1212326Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of nigericin and monensin2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID124991Writhing number was determined against clonidine induced analgesia by the compound at an intraperitoneal dose of 10 mg/Kg in mice1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Pyrrolobenzodiazepines and related systems. 2. Synthesis and biological properties of isonoraptazepine derivatives.
AID1305711Half life in mouse liver microsomes at 0.1 uM2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Coumarin carboxylic acids as monocarboxylate transporter 1 inhibitors: In vitro and in vivo studies as potential anticancer agents.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID193219Percentage decrease in immobility time, after acute administration (intraperitoneally) in rat dosed at 20 mg/kg2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Synthesis of 2-amino-5-sulfanyl-1,3,4-thiadiazole derivatives and evaluation of their antidepressant and anxiolytic activity.
AID131702Effective dose (p.o.) required to reverse ptosis induced by tetrabenazine in mouse1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Synthetic CNS agents. 1. (+/-)-1,2,3,4,4a,5,10,10a-Octahydro-5,10[1',2'] -benzenobenz[g]isoquinoline hydrochloride. A new, highly potent, potential antidepressant.
AID1458667Anxiolytic-like activity in Swiss albino mouse assessed as suppression of movement administered for 30 mins by four-plate test2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.
AID1212328Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of astemizole2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID611038Antidepressant activity in Swiss mouse assessed as immobility duration at 10 mg/kg, ip administered 30 mins prior test measured during last 4 mins of 6 mins observation period by forced-swimming test (Rvb = 166 +/- 12.23 to 218.54 +/- 8.11 Secs)2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Synthesis and antidepressant-like activity evaluation of sulphonamides and sulphonyl-hydrazones.
AID1718165Displacement of [3H]-(+)-pentazocine from sigma 1 receptor in Sprague-Dawley rat brain membranes by scintillation counting method2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
AID386625Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID1144366Antidepressant activity in pargyline-pretreated mouse assessed as potentiation of DL-DOPA-induced jumping, fighting and squeaking at 20 mg/kg, po treated 4 hrs prior to DL-DOPA-challenge1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Novel analogs of tricyclic psychopharmacological agents.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID624615Specific activity of expressed human recombinant UGT2B102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID467611Dissociation constant, pKa of the compound2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID196036Inhibition of [3H]5-HT uptake into rat brain synaptosomes in vitro;Values ranges from: 0.14-0.221987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1144414Antidepressant activity in po dosed Swiss mouse assessed as reversal of reserpine-induced hypothermia measured over 5 hrs1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Basic derivatives of 6,7-dihydroindolo(1,7-ab)(1) benzazepine and 6H-indolo(7,1-cd)(1,5) benzoxazepine as potential antidepressant agents.
AID1212325Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of ammonium chloride2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID1374215Effective permeability of the compound in PBS/EtOH at 100 ug/ml after 18 hrs by PAMPA-BBB assay2018Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
AID1209246Drug metabolism in assessed as human CYP2C19-mediated maximum rate of reaction per mg protein2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID1210069Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID34292Compound was tested for its binding affinity towards brain (Hippocampus) Adenylate cyclase1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID179973Inhibition of norepinephrine uptake in synaptosomal preparation fro rat hypothalamus, using [3H]norepinephrine1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Nontricyclic antidepressant agents derived from cis- and trans-1-amino-4-aryltetralins.
AID436830Antidepressant-like activity in NMRI mouse assessed as reduction in immobility time at 16 mg/kg, ip by forced swimming test relative to control2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Tetrahydroisoquinolines as dopaminergic ligands: 1-Butyl-7-chloro-6-hydroxy-tetrahydroisoquinoline, a new compound with antidepressant-like activity in mice.
AID23973Partition coefficient (logD, measured by HPLC, log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID172473Amount of milk ingested after the 120 min methamphetamine-challenges, produced by the compound at 1.25 mg/kg in fasted rats1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Pyrazolodiazepines. 3. 4-Aryl-1,6,7,8-tetrahydro-1,3-dialkylpyrazolo[3,4-e][1,4]diazepines as antidepressant agents.
AID1750324Intrinsic clearance in human liver microsomes at 1 uM measured up to 60 mins in presence of NADPH by HPLC-MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity.
AID714927Antidepressant activity in Swiss albino mouse assessed as mean immobility time measured during last 4 mins of single 6 mins test session at 20 mg/kg, po by forced swim test (Rvb = 75.33 +/- 3.35 secs)2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Synthesis, characterization, antidepressant and antioxidant activity of novel piperamides bearing piperidine and piperazine analogues.
AID1739434Metabolic stability in human liver microsomes assessed as intrinsic clearance at 100 uM measured per mg protein upto 30 mins2020European journal of medicinal chemistry, Aug-15, Volume: 200Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID114489Inhibition of reserpine (5 mg/kg i.p.) induced hypothermia in mice 4 hr after i.p. administration.1983Journal of medicinal chemistry, May, Volume: 26, Issue:5
Antidepressant activity of 5-aryl-2,3,5,6-tetrahydroimidazo[2,1-a]isoquinolin-5-ols.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID196022In vitro inhibition of norepinephrine (NE) uptake in synaptosomal preparation of rat brain1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
(2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol: a novel antidepressant agent and selective inhibitor of norepinephrine uptake.
AID225159Effect on Immobility Time in the Forced-Swimming Test in Mice at the dose of 0 mg/kg po for single administration2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID26538log K was measured potentiometrically in Brij35 medium1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID28679Partition coefficient (logD6.8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID112146Effective dose required to prevent reserpine ptosis in mice, administered intraperitoneally1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
New bicyclic antidepressant agent. Synthesis and activity of napactadine and related compounds.
AID20050Human absorption A (%)1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1442006Ratio of Kii for human OCT1-ASP+-inhibitor complex to Kis for human OCT1-inhibitor complex by Lineweaver-Burk plot analysis2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1).
AID1375643Antiviral activity against Ebolavirus like particle harboring full length EBOV Zaire wt/GIN/2014/ Kissidougou-C15 envelope glycoprotein and Influenzae virus envelope assessed as inhibition of viral infection in MDCK-SIAT1 cells after 48 hrs by e-GFP-based2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Structures of Ebola Virus Glycoprotein Complexes with Tricyclic Antidepressant and Antipsychotic Drugs.
AID113648Effect on the antagonism of oxotremorine-induced hypothermia (OX)1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
2,4-Dihydro-6-phenyl-1H-s-triazolo[4,3-a][1,4]benzoidiazepin-1-ones with antianxiety and antidepressant activity.
AID1832393Microsomal stability in human liver microsome assessed as half life at 0.1 mg/ml2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of Novel Acetamide-Based Heme Oxygenase-1 Inhibitors with Potent
AID130904Inhibition of radioactive NE [3H]norepinephrine uptake into mouse heart1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Synthesis and central nervous system properties of 2-[(alkoxycarbonyl)amino]-4(5)-phenyl-2-imidazolines.
AID1217728Intrinsic clearance for reactive metabolites formation per mg of protein based on cytochrome P450 (unknown origin) inactivation rate by TDI assay2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1818860Antidepressant activity in Wistar rat model of scopolamine-induced depressive like behavior assessed as decrease in immobility time at 1 mg/kg measured after 24 hrs by forced swimming test2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Designed Peptide Inhibitors of STEP Phosphatase-GluA2 AMPA Receptor Interaction Enhance the Cognitive Performance in Rats.
AID61054Binding affinity to Dopamine receptor D2 using [3H]spiperone as radioligand in stably transfected NIH3T3 cells2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Influence of chain length and N-alkylation on the selective serotonin receptor ligand 9-(aminomethyl)-9,10-dihydroanthracene.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID225158Effect on Immobility Time in the Forced-Swimming Test in Mice at the dose of 0 mg/kg po for repeated administration2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID114392Tested for antagonism of bicuculline-induced tonic-extensor convulsions (B) in mice1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID288898Locomotor activity in Swiss Albino mouse assessed as number of crossings in 6 mins at 20 mg/kg, ip administered 30 mins before the test2007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
7-Arylpiperazinylalkyl and 7-tetrahydroisoquinolinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and some of their purine-2,6,8-trione analogs as 5-HT(1A), 5-HT(2A), and 5-HT(7) serotonin receptor ligands.
AID309522Effect on locomotor activity in Swiss Albino mouse assessed as number of crossings in 30 mins at 5 mg/kg administered 30 mins before the test2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines.
AID420787Antagonist activity at human 5HT3A receptor expressed in HEK293 cells assessed as inhibition of serotonin-induced inward Na+ current at >= 10 uM2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Molecular properties of psychopharmacological drugs determining non-competitive inhibition of 5-HT3A receptors.
AID692192Inhibition of human OCT2 expressed in HEK-293-Flp-In cells incubated for 3 mins by ASP+ substrate uptake assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID34293Compound was tested for its binding affinity towards brain (neocortex) Adenylate cyclase1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID1357282Inhibition of mmLDL-stimulated apoptosis in human PBMC assessed as apoptotic cells at 2 uM preincubated for 30 mins followed by mmLDL stimulation measured after 4 hrs by YO-PRO-1/Hoechst 33342 staining based assay (Rvb = 100%)2018European journal of medicinal chemistry, Jun-10, Volume: 153NB 06: From a simple lysosomotropic aSMase inhibitor to tools for elucidating the role of lysosomes in signaling apoptosis and LPS-induced inflammation.
AID1147092Antipsychotic activity in Sprague-Dawley rat assessed as prevention of d-amphetamine-induced stereotyped behavior at 32 mg/kg, po measured for 1 min after 90, 100, and 110 mins injection of amphetamine1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
3-Aminotetrahydrocarbazoles as a new series of central nervous system agents.
AID134216Tested in vitro for norepinephrine (NE) neuronal uptake inhibition1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID103232Anti MDR activity was expressed as MDR ratio or MDR fold reversal in doxorubicin resistant human breast carcinoma tumor cell line MCF-7/DOX1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: a comparative molecular field analysis study.
AID1131107Anticholinergic effect in sc dosed CFLP mouse assessed as inhibition of pilocarpine-induced mydriasis1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Substituted 3-amino-1,1-diaryl-2-propanols as potential antidepressant agents.
AID205267Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID193220Percentage decrease in immobility time, after subchronic administration (intraperitoneally) in rat dosed at 20 mg/kg2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Synthesis of 2-amino-5-sulfanyl-1,3,4-thiadiazole derivatives and evaluation of their antidepressant and anxiolytic activity.
AID116867Compound at an intraperitoneal dose of 10 mg/Kg was tested for the inhibition of abdominal constriction in mice1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Pyrrolobenzodiazepines and related systems. 2. Synthesis and biological properties of isonoraptazepine derivatives.
AID1901321Drug uptake in mouse liver microsomes incubated for 90 mins in presence of NAPDH
AID22432Volume of distribution in the plasma fluid was determined1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID1131104Antidepressant activity against reserpine-induced hypothermia CFLP mouse model assessed as change in esophageal temperature at 20 mg/kg, po treated before 2 to 24 hrs of reserpine challenge1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Substituted 3-amino-1,1-diaryl-2-propanols as potential antidepressant agents.
AID581806Inhibition of Saccharomyces cerevisiae MKPDR5h multidrug transporter Pdr5p assessed as concentration required to threefold increase in rate of fluorescence signal relative to absence of inhibitor by fluorescein diacetate based high-throughput screening sp2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters.
AID1212330Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of chloroquine2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID1528959Antidepressant-like activity in Swiss mouse assessed as reduction in immobility time at 30 mg/kg, ip administered as single dose for 30 mins prior to testing measured for last 4 mins of 6 mins test by tail suspension test
AID681348TP_TRANSPORTER: inhibition of TEA uptake (TEA: 50 uM) in OCT1-expressing MDCK cells2001Pharmaceutical research, Nov, Volume: 18, Issue:11
Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules.
AID1255968Antidepressant activity in Swiss albino mouse assessed as immobility at 10 mg/kg, po administered 60 mins before test measured for 6 mins by forced swimming test relative to control2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Design, synthesis, and biological evaluation of oxindole derivatives as antidepressive agents.
AID598130Drug level in mouse brain at 20 mg/kg, ip after 30 mins2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.
AID114327Antiphysostigmine effect was measured as ED50,po1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antidepressant activity of substituted (omega-aminoalkoxy)benzene derivatives.
AID176192Effective dose to block muricidal behavior in rat when administered ip1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Synthesis of some 5-phenylhexahydroazepino[4,5-b]indoles as potential neuroleptic agents.
AID1299179Inhibition of wild-type human SERT expressed in HEK293 MSR cells assessed as [3H]-5-HT uptake preincubated for 30 mins followed addition of [3H]-5HT and compound for 10 mins by micro-scintillation counter2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Synthesis and inhibitory evaluation of 3-linked imipramines for the exploration of the S2 site of the human serotonin transporter.
AID420668Inhibition of human ERG in MCF7 cells2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID1292332Permeability of the compound at 25 ug/ml after 18 hrs by PAMPA-BBB assay2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1319976Permeability of the compound at 25 ug/ml at 7.4 pH after 18 hrs by PAMPA2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents.
AID363879Neurotoxicity in albino mouse assessed as animal remained on the revolving rod at 10 mg/kg, ip after 30 mins by rotarod test.2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
Syntheses and anti-depressant activity of 5-amino-1, 3, 4-thiadiazole-2-thiol imines and thiobenzyl derivatives.
AID598134Ratio of drug level in brain to plasma in mouse at 20 mg/kg, ip after 30 mins2011Bioorganic & medicinal chemistry letters, Jun-01, Volume: 21, Issue:11
2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.
AID1292330Permeability of the compound at 100 ug/ml after 18 hrs by PAMPA-BBB assay2016Bioorganic & medicinal chemistry, 05-15, Volume: 24, Issue:10
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID129961Antidepressant activity measured by tetrabenazine (TBZ) induced ptosis in mice after intraperitoneal administration1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Structure-activity studies on antidepressant 2,2-diarylethylamines.
AID145895Binding affinity towards Norepinephrine transporter using [3H]nisoxitine as radioligand2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA).
AID1217729Intrinsic clearance for reactive metabolites formation assessed as summation of [3H]GSH adduct formation rate-based reactive metabolites formation and cytochrome P450 (unknown origin) inactivation rate-based reactive metabolites formation2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1131108Anticholinergic effect in guinea pig ileum assessed as inhibition of acetylcholine-induced contraction1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Substituted 3-amino-1,1-diaryl-2-propanols as potential antidepressant agents.
AID729797Inhibition of human SERT expressed in HEK293-MSR cells by 5-HT uptake assay2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Basic N-interlinked imipramines show apoptotic activity against malignant cells including Burkitt's lymphoma.
AID1212327Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of ammonium chloride, nigericin and monensin2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID1217727Intrinsic clearance for reactive metabolites formation per mg of protein in human liver microsomes based on [3H]GSH adduct formation rate at 100 uM by [3H]GSH trapping assay2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1217705Time dependent inhibition of CYP2B6 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1322339Antidepressant-like activity in mouse assessed as immobility time at 10 mg/kg, ip by tail suspension test (Rvb = 154.2 +/- 10.2 sec)
AID112383The effect on ataxia in mice following oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Imine analogues of tricyclic antidepressants.
AID1144365Antidepressant activity in pargyline-pretreated mouse assessed as potentiation of DL-DOPA-induced jumping, fighting and squeaking at 10 mg/kg, po treated 4 hrs prior to DL-DOPA-challenge1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Novel analogs of tricyclic psychopharmacological agents.
AID51930K+ channel blocking activity in Chinese hamster ovary cells expressing HERG Kv11.12002Journal of medicinal chemistry, Aug-29, Volume: 45, Issue:18
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
AID113652Effect of test compound on the potentiation of apomorphine-induced gnawing (AG) in aggregated mice1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
2,4-Dihydro-6-phenyl-1H-s-triazolo[4,3-a][1,4]benzoidiazepin-1-ones with antianxiety and antidepressant activity.
AID116717Acute cytotoxicity was evaluated as LD50 in mice (ip)1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID122478Compound was tested for myorelaxant action (time in seconds on the horizontal wire with forelegs) after intraperitoneal administration of 37.5 mg/Kg in mice by traction test1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Pyrrolobenzodiazepines and related systems. 2. Synthesis and biological properties of isonoraptazepine derivatives.
AID28235Unbound fraction (plasma)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1702354Antidepressant-like activity in Wistar rat assessed as minimum effective dose causing reduction in immobility time administered intraperitoneally with compound 60 mins prior to testing and measured for 5 mins test period by Porsolt-forced swim test
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID692195Inhibition of human MATE1 expressed in HEK-293-Flp-In cells incubated for 3 mins by ASP+ substrate uptake assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID196062Inhibition of uptake of tritiated norepinephrine (NE) in rat synaptosomes1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID1134043Antitetrabenazine activity in ip dosed CD1 mouse assessed as inhibition of tetrabenazine-induced ptosis challenged with tetrabenazine after 30 mins later and after another 30 mins of drug treatment1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Synthesis of spiro[isobenzofuran-1(3H),4'-piperidines] as potential central nervous system agents. 2. Compounds containing a heteroatom attached to nitrogen.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID78164Concentration required to reducing the histamine induced contraction by 50% was measured1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antidepressant activity of substituted (omega-aminoalkoxy)benzene derivatives.
AID1421885Effective permeability of the compound at 1 mg/ml after 4 hrs by BBB-PAMPA method2018European journal of medicinal chemistry, Oct-05, Volume: 158Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID132666In vitro inhibition of accumulation of [14C]5-HT (5-HT) in mouse brain slices1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis of pyridylallylamines related to zimelidine and their inhibition of neuronal monoamine uptake.
AID127789In vitro activity for the ability to inhibit the uptake of Norepinephrine into mouse cortical slices.1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Tetracyclic pyridazines as potential psychopharmacological agents.
AID131997Evaluated for antagonism of reserpine induced hypothermia1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Synthesis and central nervous system properties of 2-[(alkoxycarbonyl)amino]-4(5)-phenyl-2-imidazolines.
AID19424Partition coefficient (logD7.4)2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID172609Amount of milk ingested after the 120 min methamphetamine-challenges, produced by the compound at 5 mg/kg in fasted rats1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Pyrazolodiazepines. 3. 4-Aryl-1,6,7,8-tetrahydro-1,3-dialkylpyrazolo[3,4-e][1,4]diazepines as antidepressant agents.
AID1299181Inhibition of human SERT I179C mutant expressed in HEK293 MSR cells assessed as [3H]-5-HT uptake preincubated for 30 mins followed addition of [3H]-5HT and compound for 10 mins by micro-scintillation counter2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Synthesis and inhibitory evaluation of 3-linked imipramines for the exploration of the S2 site of the human serotonin transporter.
AID271645Antiprion activity in ScN2a cells assessed as complete reduction of protease-resistant scrapie prion protein2006Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22
A chimeric ligand approach leading to potent antiprion active acridine derivatives: design, synthesis, and biological investigations.
AID1353531Antidepressant like activity in Swiss albino mouse assessed as immobility time at 20 mg/kg, ip administered 30 mins prior to test and measured last 4 mins of 6 mins test by forced swimming test (Rvb = 162.71 +/- 6.8 secs)2018European journal of medicinal chemistry, Mar-10, Volume: 147Computer-aided insights into receptor-ligand interaction for novel 5-arylhydantoin derivatives as serotonin 5-HT
AID1519022Metabolic stability in C57BL/6 mouse liver microsomes assessed as parent compound remaining at 25 uM incubated for 90 mins in presence of NADPH by LC-qTOF/MS analysis
AID179384Concentration of compound to inhibit 50% of [3H]-5-HT neurotransmitter uptake in rat brain1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Conformationally restricted tricyclic antidepressants. 1. Octahydrodibenzazepinonaphthyridines as rigid imipramine analogues.
AID1152645Displacement of [3H]imipramine from human recombinant SERT expressed in CHO cells2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
AID1918193Dissociation constant, pKa of the compound2022Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.
AID243422log (1/Km) value for human liver microsome cytochrome P450 3A42005Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
AID1675411Binding affinity to SERT (unknown origin)2020Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21
Synthesis, crystal structure and biological activity of novel analogues of tricyclic drugs.
AID28928Intrinsic permeability of the compound2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID1832394Microsomal stability in human liver microsome assessed as intrinsic clearance at 0.1 mg/ml incubated upto 1 hour2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Discovery of Novel Acetamide-Based Heme Oxygenase-1 Inhibitors with Potent
AID196023In vitro inhibition of serotonin uptake in synaptosomal preparation of rat brain1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
(2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol: a novel antidepressant agent and selective inhibitor of norepinephrine uptake.
AID1217706Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1217704Time dependent inhibition of CYP1A2 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1129953Toxicity in Kunming mouse assessed as locomotor activity at 10 mg/kg, po measured for 10 mins (Rvb = 1165 +/- 263 cm)2014Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7
Synthesis and biological evaluation of a series of benzoxazole/benzothiazole-containing 2,3-dihydrobenzo[b][1,4]dioxine derivatives as potential antidepressants.
AID377489Antidepressant activity in CF1 mouse assessed as decrease in duration of immobility at 15 mg/kg during final 4 mins of the 6 mins session by forced swimming test2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID427198Membrane permeability dissolved in PBS/EtOH (80:20) mixture by PAMPA-BBB assay2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
AID469403Permeability across PAMPA membrane 2009Journal of medicinal chemistry, Nov-26, Volume: 52, Issue:22
Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
AID1529184Protein binding in immobilized human serum albumin by HPLC analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID1207659Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID229207Binding affinity for sigma receptors was evaluated by the inhibitory effect on [3H]DTG to rat whole brain membranes;NT means not tested.2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID311935Partition coefficient, log P of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID179960Inhibition of dopamine uptake in synaptosomal preparation in rat corpus striatum, using [3H]dopamine1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Nontricyclic antidepressant agents derived from cis- and trans-1-amino-4-aryltetralins.
AID1648400Metabolic stability in Sprague-Dawley rat liver microsomes assessed as parent compound remaining at 20 uM measured for 60 mins by HPLC/MS analysis2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Regiospecific Introduction of Halogens on the 2-Aminobiphenyl Subunit Leading to Highly Potent and Selective M3 Muscarinic Acetylcholine Receptor Antagonists and Weak Inverse Agonists.
AID288895Antidepressant activity in Swiss Albino mouse assessed as immobility time during final 4 mins of 6 mins session at 30 mg/kg, ip administered 30 mins before the test in forced-swimming test2007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
7-Arylpiperazinylalkyl and 7-tetrahydroisoquinolinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and some of their purine-2,6,8-trione analogs as 5-HT(1A), 5-HT(2A), and 5-HT(7) serotonin receptor ligands.
AID28924Effective permeability (Pe) across a hexadecane membrane (pH 6.8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID36851Concentration of compound for 50% displacement of [3H]WB-4101 from Alpha-1 adrenergic receptor of rat brain1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Conformationally restricted tricyclic antidepressants. 1. Octahydrodibenzazepinonaphthyridines as rigid imipramine analogues.
AID478685Antidepressant activity in rat assessed as immobility time at 20 mg/kg, po by forced swimming test (Rvb = 169.6 +/- 19 sec)2010Journal of natural products, May-28, Volume: 73, Issue:5
Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
AID113642Effect on the antagonism of bicuculline-induced tonic-extensor convulsions (B)1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
2,4-Dihydro-6-phenyl-1H-s-triazolo[4,3-a][1,4]benzoidiazepin-1-ones with antianxiety and antidepressant activity.
AID1209253Drug metabolism in assessed as human CYP1A2-mediated metabolism2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID23975logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID132403Electrical shock aggression was evaluated in mice, administered intraperitoneally1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
New bicyclic antidepressant agent. Synthesis and activity of napactadine and related compounds.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1514462Metabolic stability in human liver microsomes assessed as compound remaining at 1 uM after 120 mins in presence of G-6-P, G-6-PDH, MgCl2 and NADP+ by LC-MS/MS analysis (Rvb = 100%)2019Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1
Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety.
AID1470742Anti-depressant like activity in Swiss albino mouse assessed as reduction in immobility time at 60 mg/kg, po measured for 5 mins by tail suspension test2017European journal of medicinal chemistry, May-26, Volume: 132Novel aryl piperazines for alleviation of 'andropause' associated prostatic disorders and depression.
AID1850268Inhibition of endogenous human CaV2.2 in human SH-SY5Y cells in presence of nifedipine by Calcium 4 dye based calcium influx fluorescence-imaging assay2022RSC medicinal chemistry, Feb-23, Volume: 13, Issue:2
Inhibition of N-type calcium ion channels by tricyclic antidepressants - experimental and theoretical justification for their use for neuropathic pain.
AID119216Rotation number in mice was determined at 15 minutes after a dose of 10 mg/Kg1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Pyrrolobenzodiazepines and related systems. 2. Synthesis and biological properties of isonoraptazepine derivatives.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID309524Effect on locomotor activity in Swiss Albino mouse assessed as number of crossings in 30 mins at 10 mg/kg administered 30 mins before the test2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines.
AID1285114Half life in human liver microsomes at 0.1 uM up to 60 mins by HPLC-MS/MS analysis2016European journal of medicinal chemistry, Apr-13, Volume: 112Three stories on Eph kinase inhibitors: From in silico discovery to in vivo validation.
AID26310Partition coefficient (logD7.4)1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID476997Anxiolytic-like activity in Swiss albino mouse assessed as number of punished crossing of the light beam during 30 mins at 20 mg/kg, ip measured after 30 mins postdose by four-plate test (RVb = 210.7 +/- 17.7)2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity.
AID1211796Intrinsic clearance in cryopreserved human HepaRG cells assessed per 10'6 cells by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID289402Displacement of [3H]leucine from Aquifex aeolicus His-LeuT expressed in Escherichia coli by scintillation proximity assay2007Science (New York, N.Y.), Sep-07, Volume: 317, Issue:5843
LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake.
AID1375640Binding affinity to EBOV Mayinga, Zaire, 1976 envelope glycoprotein extracellular domain H613A mutant tagged with His/foldon trimerization sequence from the bacteriophage T4 fibritin at C terminal expressed in HEK293T cells assessed as decrease in melting2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Structures of Ebola Virus Glycoprotein Complexes with Tricyclic Antidepressant and Antipsychotic Drugs.
AID293504Effect on motor co-ordination in Swiss mouse assessed as time on rotating bar at 15 mg/kg, ip after 10 days by Rota-rod test2007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
Antidepressant-like profile of action of two 4-amine derivatives of 10,11-dihydro-5H-dibenzo [a,d] cycloheptane in mice evaluated in the forced swimming test.
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1585851Effective permeability of the compound by PAMPA2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID112145Effective dose required to prevent reserpine ptosis in mice, administered (po)orally1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
New bicyclic antidepressant agent. Synthesis and activity of napactadine and related compounds.
AID1209242Drug metabolism in assessed as human CYP3A4-mediated maximum rate of reaction per mg protein2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1207218Inhibition of hERG K channel2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID1636367Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 74.4 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of N2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID131718Effective dose against oxotremorine induced lacrimation1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Synthetic CNS agents. 1. (+/-)-1,2,3,4,4a,5,10,10a-Octahydro-5,10[1',2'] -benzenobenz[g]isoquinoline hydrochloride. A new, highly potent, potential antidepressant.
AID117244Toxicity was measured as LD50,po1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Synthesis and antidepressant activity of substituted (omega-aminoalkoxy)benzene derivatives.
AID137278Reserpine hypothermia antagonism in mouse administered perorally with 5 mg/kg of reserpine 2 hour prior to test compound administration1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Synthesis and central nervous system properties of 2-[(alkoxycarbonyl)amino]-4(5)-phenyl-2-imidazolines.
AID114412Antidepressant activity to prevent tetrabenazine induced ptosis (TBZ) in mice after intraperitoneal administration1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Tricyclics with analgesic and antidepressant activity. 1. [[(Alkylamino)ethyl]thio]dibenz[b,f]oxepins and 10,11-dihydro derivatives.
AID1209241Drug metabolism in assessed as human CYP3A4-mediated intrinsic clearance per mg protein2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID775111Antidepressant activity in ICR mouse assessed as immobility time at 20 mg/kg, ip by tail suspension test2013Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21
2-Amino-6-chloro-3,4-dihydroquinazoline: A novel 5-HT3 receptor antagonist with antidepressant character.
AID1217708Time dependent inhibition of CYP2D6 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID128144Ability to inhibit the uptake of Norepinephrine into mouse cortical slices 1 hour after intraperitoneal injection ex vivo1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Tetracyclic pyridazines as potential psychopharmacological agents.
AID1332036Displacement of [3H]citalopram from human SERT expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting method2017Bioorganic & medicinal chemistry, 01-01, Volume: 25, Issue:1
Discovery of SMP-304, a novel benzylpiperidine derivative with serotonin transporter inhibitory activity and 5-HT
AID1480943Permeability of the compound at pH 7.4 at 5 mg/ml after 18 hrs by PAMPA-BBB assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
AID1437175Permeability of the compound by PAMPA2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
AID1511118Permeability of the compound measured after compound dilution in PBS/EtOH buffer (70:30) by PAMPA-BBB assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
AID119032Percentage protection against NMDA-induced lethality in mice by the compound at 20 mg/Kg administered ip 60 mins before iv administration of NMDA in the lethal dose of 90 mg/Kg.1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
(+/-)-(Z)-2-(aminomethyl)-1-phenylcyclopropanecarboxamide derivatives as a new prototype of NMDA receptor antagonists.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID449472Antidepressant activity in Swiss albino mouse assessed as reduction of immobility time at 30 mg/kg, ip administered 30 mins before test by forced swimming test2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis and preliminary pharmacological evaluation of imidazo[2,1-f]purine-2,4-dione derivatives.
AID1144364Antidepressant activity in pargyline-pretreated mouse assessed as potentiation of DL-DOPA-induced jumping, fighting and squeaking at 5 mg/kg, po treated 4 hrs prior to DL-DOPA-challenge1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Novel analogs of tricyclic psychopharmacological agents.
AID179927Inhibition of 5-HT uptake in synaptosomal preparation from rat corpus striatum, using [3H]5-HT1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Nontricyclic antidepressant agents derived from cis- and trans-1-amino-4-aryltetralins.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID179155Effect of compound administered 60 min before the test in the forced swimming test in Rat (8 rats per group) at 40 mg/kg2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
New arylpiperazine 5-HT(1A) receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation.
AID222070Effect on the sleeping time of mice before halothane load (control group);NT means not tested2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID131719Effective dose against oxotremorine induced tremor1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Synthetic CNS agents. 1. (+/-)-1,2,3,4,4a,5,10,10a-Octahydro-5,10[1',2'] -benzenobenz[g]isoquinoline hydrochloride. A new, highly potent, potential antidepressant.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID288191Membrane retention in permeability experiment with artificial membrane2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID28236Unbound fraction (tissues)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID119033Percentage protection against NMDA-induced lethality in mice by the compound at 40 mg/Kg administered ip 60 mins before iv administration of NMDA in the lethal dose of 90 mg/Kg.1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
(+/-)-(Z)-2-(aminomethyl)-1-phenylcyclopropanecarboxamide derivatives as a new prototype of NMDA receptor antagonists.
AID114562Tested for potentiation of yohimbine toxicity in aggregated mice(Y)1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID134215Tested in vitro for dopamine(DA) neuronal uptake inhibition1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID115619Minimum effective dose causing antagonism of tetrabenazine induced depression in mice was determined when administered perorally1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Thiophene systems. 5. Thieno[3,4-b][1,5]benzoxazepines, thieno[3,4-b][1,5]benzothiazepines, and thieno[3,4-b][1,4]benzodiazepines as potential central nervous system agents.
AID752199Binding affinity to human serotonin 5-HT transporter by radioligand displacement assay2013Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.
AID1511119Permeability of the compound at 25 ug/ml by PAMPA-BBB assay2019European journal of medicinal chemistry, Oct-15, Volume: 180A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
AID1212341Cytotoxicity against human Fa2N-4 cells by lactate dehydrogenase assay2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID395328Lipophilicity, log P of the compound2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID112169Effective dose to reverse tetrabenazine ptosis in mouse when administered po1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Synthesis of some 5-phenylhexahydroazepino[4,5-b]indoles as potential neuroleptic agents.
AID1207188Inhibition of voltage-gated L-type Ca channel (species unknown)2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID309529Effect on locomotor activity in Swiss Albino mouse assessed as number of crossings in 6 mins at 20 mg/kg administered 30 mins before the test2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines.
AID1209256Drug metabolism in assessed as human CYP1A2-mediated maximum rate of reaction per mg protein2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID15708Plasma clearance for the compound was determined.1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID294623Antidepressant-like activity in C57BL/6J mouse at 20 mg/kg by tail suspension test2007Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8
Novel class of arylpiperazines containing N-acylated amino acids: their synthesis, 5-HT1A, 5-HT2A receptor affinity, and in vivo pharmacological evaluation.
AID1627333Antidepressant activity in CD1(ICR) mouse assessed as decrease in immobility time at 60 mg/kg, po after 1 hr by tail suspension test2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Synthesis, structure-activity relationships and biological evaluation of 4,5,6,7-tetrahydropyrazolopyrazines as metabotropic glutamate receptor 5 negative allosteric modulators.
AID129176Antidepressant activity measured by maximal electroshock seizure threshold (MEST) assay in TBZ treated mice after ip administration1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Structure-activity studies on antidepressant 2,2-diarylethylamines.
AID1209259Drug metabolism in human liver microsomes assessed as maximum rate of reaction per mg protein by optimal design approach2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID1444095Effective permeability of the compound at pH 7.4 at 25 ug/ml after 18 hrs by PAMPA-BBB assay2017European journal of medicinal chemistry, Apr-21, Volume: 130Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
AID1703749Half life in human liver microsomes at 0.1 uM in presence of NADPH by LC/MS/MS analysis2020European journal of medicinal chemistry, Sep-15, Volume: 202Evaluation of N-phenyl-2-aminothiazoles for treatment of multi-drug resistant and intracellular Staphylococcus aureus infections.
AID1054118Binding affinity to SERT (unknown origin) by radioligand binding assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Polypharmacology - foe or friend?
AID225960Minimum effective dose required for inhibition of serotonin uptake was determined by PCA method in rat by peroral administration1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID478679Antidepressant activity in rat assessed as immobility time at 20 mg/kg, po by forced swimming test (Rvb = 158.7 +/- 8.9 sec)2010Journal of natural products, May-28, Volume: 73, Issue:5
Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
AID1374547Antidepressant-like activity in Swiss albino mouse assessed as decrease in immobility time at 10 to 20 mg/kg, ip administered 30 mins prior to test measured for last 4 mins of 6 mins observation by forced swim test2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
MF-8, a novel promising arylpiperazine-hydantoin based 5-HT
AID23976logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID19260Logarithm of partition coefficient of the neutral form of compound given for octanol/water solvent system1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists.
AID128658Analgesic activity was determined for delay in response to noxious heat stimuli after subcutaneous administration in mice, in tail flick assay1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Tricyclics with analgesic and antidepressant activity. 2. [[(Alkylamino)ethyl]thio]dibenzo[b,f]thiepins and 10,11-dihydro derivatives.
AID294619Antidepressant-like activity in Swiss Albino mouse at 20 mg/kg by forced swimming test2007Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8
Novel class of arylpiperazines containing N-acylated amino acids: their synthesis, 5-HT1A, 5-HT2A receptor affinity, and in vivo pharmacological evaluation.
AID293498Antidepressant activity in Swiss mouse assessed as immobility time at 15 mg/kg/day, ip after 10 days by 5-mins swim test2007Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4
Antidepressant-like profile of action of two 4-amine derivatives of 10,11-dihydro-5H-dibenzo [a,d] cycloheptane in mice evaluated in the forced swimming test.
AID91833Binding affinity against imipramine receptor was determined in homogenized rat cortex tissue using [3H]-imipramine as radioligand1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Tricyclic compounds as selective antimuscarinics. 1. Structural requirements for selectivity toward the muscarinic acetylcholine receptor in a series of pirenzepine and imipramine analogues.
AID1211298Dissociation constant, pKa of the compound2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID1054120Binding affinity to dopamine D2 receptor (unknown origin) by radioligand binding assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Polypharmacology - foe or friend?
AID1772562n-Octanol/PBS buffer distribution coefficient, logD of the compound at pH 7.42021European journal of medicinal chemistry, Nov-05, Volume: 223Non-carboxylic acid inhibitors of aldose reductase based on N-substituted thiazolidinedione derivatives.
AID224550Percent increase of the diameter of the test pupil (% mydriasis) in comparison with that of the control pupil.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants.
AID566273Inhibition of human 5-HT transporter2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
AID681118TP_TRANSPORTER: transepithelial transport in Caco-2 cells2003International journal of pharmaceutics, Sep-16, Volume: 263, Issue:1-2
Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs.
AID28233Fraction ionized (pH 7.4)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1209254Drug metabolism in assessed as human CYP2C19-mediated intrinsic clearance per mg protein2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID112173Effective dose was evaluated for its antagonism to reserpine induced hypothermia in mice by intraperitoneal administration1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Design, synthesis, and pharmacological activities of 2-substituted 4-phenylquinolines as potential antidepressant drugs.
AID115594Ability to modify turning behavior of mice after intraperitoneal administration1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
3-aminopyridazine derivatives with atypical antidepressant, serotonergic, and dopaminergic activities.
AID243151Inhibitory concentration against potassium channel HERG2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
AID48902Evaluated for its relative defibrillating activity in male cats 10 min after injection at concentration 3 mg/Kg2001Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22
A new class of antiarrhythmic-defibrillatory agents.
AID1054119Binding affinity to 5HT2A receptor (unknown origin) by radioligand binding assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Polypharmacology - foe or friend?
AID113658Effect on the prolongation of hypoxic survival time (HS)1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
2,4-Dihydro-6-phenyl-1H-s-triazolo[4,3-a][1,4]benzoidiazepin-1-ones with antianxiety and antidepressant activity.
AID1217710Covalent binding in human liver microsomes measured per mg of protein using radiolabelled compound at 10 uM after 1 hr incubation by liquid scintillation counting2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID363878Antidepressant activity in albino mouse assessed as decrease in immobility time at 10 mg/kg, ip after 60 mins by forced-swimming test relative to untreated control2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
Syntheses and anti-depressant activity of 5-amino-1, 3, 4-thiadiazole-2-thiol imines and thiobenzyl derivatives.
AID330664Effect on life span of Caenorhabditis elegans at 10 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID112365The compound was tested for antidepressant activity by its ability to reverse tetrabenazine induced ptosis in mice, perorally1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Central nervous system activity of 7-substituted 1-azaphenoxathiin analogues and their oxidation products.
AID1636481Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 51.1 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of N2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID361985Lipophilicity, log D of compound at pH 7.4 by microfluidic liquid-liquid extraction method2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Determination of log D via automated microfluidic liquid-liquid extraction.
AID114563Prolongation of hypoxic survival time (HS) in mice1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
1-(Aminoalkyl)-6-aryl-4-H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity.
AID581808Inhibition of Saccharomyces cerevisiae MKSNQ2h multidrug transporter Snq2p assessed as concentration required to threefold increase in rate of fluorescence signal relative to absence of inhibitor by fluorescein diacetate based high-throughput screening sp2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters.
AID1658711Metabolic stability in Sprague-Dawley rat liver microsomes assessed as CYP450-mediated drug degradation at 20 uM measured up to 60 mins in presence of NADPH by LC-MS analysis2020ACS medicinal chemistry letters, Jun-11, Volume: 11, Issue:6
Discovery of Novel Nonpeptidic PAR2 Ligands.
AID624607Specific activity of expressed human recombinant UGT1A32000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID134420Lethal dose in mouse, in groups of ten1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Synthesis and central nervous system properties of 2-[(alkoxycarbonyl)amino]-4(5)-phenyl-2-imidazolines.
AID1322338Antidepressant-like activity in mouse assessed as immobility time at 5 mg/kg, ip by tail suspension test (Rvb = 154.2 +/- 10.2 sec)
AID639368Permeability of the compound by PAMPA assay2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
AID132107In vivo effect on Tetrabenazine motor activity in mice following i.p. administration.1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID29337Ionisation constant (pKa)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
AID24179logBB, log(C brain/C blood)1996Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24
Computation of brain-blood partitioning of organic solutes via free energy calculations.
AID119877Compound was tested for total number of movements in 5 minutes after intraperitoneal administration of 37.5 mg/Kg in mice1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Pyrrolobenzodiazepines and related systems. 2. Synthesis and biological properties of isonoraptazepine derivatives.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1209258Drug metabolism in human liver microsomes assessed as maximum rate of reaction per mg protein by multiple depletion curves method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID1305710Half life in human liver microsomes at 0.1 uM2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Coumarin carboxylic acids as monocarboxylate transporter 1 inhibitors: In vitro and in vivo studies as potential anticancer agents.
AID91481Binding constant against human serum albumin (HSA)2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Cheminformatic models to predict binding affinities to human serum albumin.
AID87880Inhibitory activity against brain adenylate cyclase Histamine H2 receptor1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID114922Compound was evaluated after 24 hr for physostigmine induced lethality upon oral administration 60 min before intraperitoneal injection of physostigmine (0.9 mg/kg) in mice at 50 mg/kg1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
New dibenzothiadiazepine derivatives with antidepressant activities.
AID692188Therapeutic index, ratio of Cmax in human to IC50 for human OCT22011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
AID5241Binding affinity towards 5-hydroxytryptamine 2 receptor1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID1677624Antidepressant activity in mouse assessed as total mean swimming time at 15 mg/kg (Rvb = 2.98 min)2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Synthesis and biological evaluation of imidazoline derivatives as potential CNS and CVS agents.
AID449470Antidepressant activity in Swiss albino mouse assessed as reduction of immobility time at 10 mg/kg, ip administered 30 mins before test by forced swimming test2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis and preliminary pharmacological evaluation of imidazo[2,1-f]purine-2,4-dione derivatives.
AID1209250Drug metabolism in human liver microsomes by multiple depletion curves method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
AID1702358Antidepressant-like activity in Wistar rat assessed as reduction in immobility time at 10 mg/kg, ip administered 60 mins prior to testing and measured for 5 mins test period by Porsolt-forced swim test
AID1212334Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of rifampin2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID115754Minimum effective dose was measured orally by antagonism of tetrabenazine-induced depression in mice(po)1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
Derivatives of 11-(1-piperazinyl)-5H-pyrrolo[2,1-c][1,4]benzodiazepine as central nervous system agents.
AID225161Effect on Immobility Time in the Forced-Swimming Test in Mice at the dose of 10 mg/kg po for repeated administration2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID1171393Oxidative metabolism in human liver microsomes assessed as protein covalent binding measured per mg protein at 10 uM after 1 hr in presence of NADPH2014ACS medicinal chemistry letters, Nov-13, Volume: 5, Issue:11
Synthesis, in Vitro Covalent Binding Evaluation, and Metabolism of (14)C-Labeled Inhibitors of 11β-HSD1.
AID309514Antidepressant activity in Swiss Albino mouse assessed as immobility time during final 4 mins of 6 mins session at 10 mg/kg administered 30 mins before the test by forced-swimming test2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID125388In vitro inhibitory concentration against monoamine oxidase with 5-HT as substrate1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Synthetic CNS agents. 1. (+/-)-1,2,3,4,4a,5,10,10a-Octahydro-5,10[1',2'] -benzenobenz[g]isoquinoline hydrochloride. A new, highly potent, potential antidepressant.
AID113646Effect on the antagonism of nicotine-induced tonic-extensor convulsions (TE) in mice1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
2,4-Dihydro-6-phenyl-1H-s-triazolo[4,3-a][1,4]benzoidiazepin-1-ones with antianxiety and antidepressant activity.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID110071Antagonism of tetrabenazine (TBZ)-induced depression measured in mice by motor activity1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID1255972Antidepressant activity in Swiss albino mouse assessed as immobility at 10 mg/kg, po administered 60 mins before test measured for 6 mins by tail suspension test relative to control2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Design, synthesis, and biological evaluation of oxindole derivatives as antidepressive agents.
AID338197Displacement of [3H]citalopram from serotonin transporter assessed as specific binding relative to total binding1993Journal of natural products, Apr, Volume: 56, Issue:4
The role of receptor binding in drug discovery.
AID1144381Antipsychotic activity in mouse assessed as change in methamphetamine-induced hyperactivity at 5 mg/kg, po relative to control1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Novel analogs of tricyclic psychopharmacological agents.
AID288903Locomotor activity in Swiss Albino mouse assessed as number of crossings in 30 mins at 10 mg/kg, ip administered 30 mins before the test2007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
7-Arylpiperazinylalkyl and 7-tetrahydroisoquinolinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and some of their purine-2,6,8-trione analogs as 5-HT(1A), 5-HT(2A), and 5-HT(7) serotonin receptor ligands.
AID1207159Inhibition of Na channel (species unknown)2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID1207249Effective free therapeutic plasma concentration (EFTPC): the concentration of unbound compund in the blood plasma at therapeutic dose (mean of range)2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1390042Effective permeability of the compound at 25 ug/ml after 18 hrs by PAMPA-BBB assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID620399Permeability of the compound by PAMPA2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Hybrids of oxoisoaporphine-tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation inhibitors.
AID23970logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID27361Dose of compound required in mg/kg to induce lethality in 50% of mice after 14 days1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
New dibenzothiadiazepine derivatives with antidepressant activities.
AID62860Concentration of compound for 50% displacement of [3H]spiperone from Dopamine receptor in rat brain1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Conformationally restricted tricyclic antidepressants. 1. Octahydrodibenzazepinonaphthyridines as rigid imipramine analogues.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID268084Metabolic stability in rat liver microsomes2006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
Dipeptidyl nitriles as human dipeptidyl peptidase I inhibitors.
AID134634Antagonism of reserpine-induced hypothermia in mice1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Synthesis and antidepressant profiles of phenyl-substituted 2-amino- and 2-[(alkoxycarbonyl)amino]-1,4,5,6-tetrahydropyrimidines.
AID1427528Permeability of the compound at 100 ug/ml after 18 hrs by PAMPA2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
AID119097Rotation number in mice was determined at 12 minutes after a dose of 10 mg/Kg1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Pyrrolobenzodiazepines and related systems. 2. Synthesis and biological properties of isonoraptazepine derivatives.
AID596125Antidepressant activity in Swiss Sprague-Dawley rat assessed as reduction of immobility time at 15 mg/kg, ip administered 30 mins before test by forced swimming test2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Further structure-activity relationship studies on 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents.
AID172612Amount of milk ingested after the 15 min methamphetamine-challenges, produced by the compound at 1.25 mg/kg in fasted rats1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Pyrazolodiazepines. 3. 4-Aryl-1,6,7,8-tetrahydro-1,3-dialkylpyrazolo[3,4-e][1,4]diazepines as antidepressant agents.
AID1173449Effective permeability of the compound by PAMPA assay2014Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23
Synthesis and antiprotozoal activity of oligomethylene- and p-phenylene-bis(methylene)-linked bis(+)-huprines.
AID1353529Antidepressant like activity in Swiss albino mouse assessed as immobility time at 5 mg/kg, ip administered 30 mins prior to test and measured last 4 mins of 6 mins test by forced swimming test (Rvb = 162.71 +/- 6.8 secs)2018European journal of medicinal chemistry, Mar-10, Volume: 147Computer-aided insights into receptor-ligand interaction for novel 5-arylhydantoin derivatives as serotonin 5-HT
AID60027Potentiation of the response to norepinephrine was measured1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Synthetic CNS agents. 1. (+/-)-1,2,3,4,4a,5,10,10a-Octahydro-5,10[1',2'] -benzenobenz[g]isoquinoline hydrochloride. A new, highly potent, potential antidepressant.
AID114237Serotonergic activity was determined by measuring the potentiation of 5-hydroxytryptophan in mice upon ip administration1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
3-aminopyridazine derivatives with atypical antidepressant, serotonergic, and dopaminergic activities.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1346943Human SERT (Monoamine transporter subfamily)1993Journal of natural products, Apr, Volume: 56, Issue:4
The role of receptor binding in drug discovery.
AID1345326Human M2 receptor (Acetylcholine receptors (muscarinic))1998The Journal of pharmacology and experimental therapeutics, Feb, Volume: 284, Issue:2
Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line.
AID1346501Mouse Kir3.2 (Inwardly rectifying potassium channels)2004Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Oct, Volume: 29, Issue:10
Inhibition of G protein-activated inwardly rectifying K+ channels by various antidepressant drugs.
AID1346535Mouse Kir3.4 (Inwardly rectifying potassium channels)2004Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Oct, Volume: 29, Issue:10
Inhibition of G protein-activated inwardly rectifying K+ channels by various antidepressant drugs.
AID1346732Human Kv10.1 (Voltage-gated potassium channels)2004The Journal of general physiology, Oct, Volume: 124, Issue:4
Mechanism of block of hEag1 K+ channels by imipramine and astemizole.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1801081Radioligand Binding Assays from Article 10.1111/cbdd.12394: \\Synthesis and evaluation of antidepressant-like activity of some 4-substituted 1-(2-methoxyphenyl)piperazine derivatives.\\2015Chemical biology & drug design, Mar, Volume: 85, Issue:3
Synthesis and evaluation of antidepressant-like activity of some 4-substituted 1-(2-methoxyphenyl)piperazine derivatives.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID493017Wombat Data for BeliefDocking2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9,485)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906027 (63.54)18.7374
1990's1586 (16.72)18.2507
2000's963 (10.15)29.6817
2010's762 (8.03)24.3611
2020's147 (1.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 100.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index100.94 (24.57)
Research Supply Index9.37 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index190.92 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (100.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1,359 (13.17%)5.53%
Reviews485 (4.70%)6.00%
Case Studies536 (5.19%)4.05%
Observational1 (0.01%)0.25%
Other7,939 (76.93%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (34)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain [NCT01179828]Phase 3150 participants (Actual)Interventional2010-07-31Completed
A Phase II, Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma [NCT04863950]Phase 225 participants (Anticipated)Interventional2022-05-25Recruiting
Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Sandoz Inc. and Tyco Healthcare (Tofranil) 50 mg Imipramine Hydrochloride Tablets In Healthy Adults Volunteers Under Fasting Conditions [NCT00946764]Phase 148 participants (Actual)Interventional2005-07-31Completed
Continuation Electroconvulsive Therapy Associated With Pharmacotherapy Versus Pharmacotherapy Alone for Relapse Prevention in Major Depression. A Clinical, Controlled, Prospective and Randomized Trial [NCT01305707]Phase 4104 participants (Actual)Interventional2009-07-31Terminated(stopped due to Difficulties in recruiting)
Medication Effects on Periurethral Sensation, Urethral Sphincter Activity and Pressure Flow Parameters [NCT01028014]56 participants (Actual)Interventional2010-04-30Completed
Comparisons of the Impact of Duloxetine Versus Imipramine on Therapeutic Efficacy, Psychological Distress, Sexual Function, Urethral and Bladder Wall Structure and Blood Flow in Women With Stress Urinary Incontinence: a Randomized Controlled Study [NCT04412876]Phase 30 participants (Actual)Interventional2020-05-31Withdrawn(stopped due to Failed to pass the Ministry of Science and Technology.)
Treatment of Multi-organ Bodily Distress Syndrome. A Double-blinded Placebo Controlled Trial of the Effects of Imipramine (Stress-3) [NCT01518634]Phase 2138 participants (Actual)Interventional2012-01-31Completed
The Role of Zinc in Therapy of Unipolar Depression [NCT00693680]60 participants (Actual)Interventional2005-01-31Completed
Dichotic Listening as a Predictor of Medication Response in Depression [NCT00404755]Phase 417 participants (Actual)Interventional2006-07-31Completed
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Imipramine Pamoate Capsules, 75 mg, Under Fasted Conditions [NCT01107353]39 participants (Actual)Interventional2008-08-31Completed
Dichotic Listening as a Predictor of Placebo and Medication Response in Depression [NCT00296725]Phase 1/Phase 225 participants (Actual)Interventional1994-04-30Completed
[NCT00000504]Phase 20 participants Interventional1982-09-30Completed
Randomised, Double-blind, Placebo-controlled Trial of the Effect of the Combination of Imipramine and Pregabalin for the Treatment of Painful Polyneuropathy [NCT01047488]Phase 475 participants (Anticipated)Interventional2010-02-28Not yet recruiting
Maintenance Therapies in Recurrent Depression-Study I [NCT00227955]Phase 4200 participants Interventional1987-12-31Completed
Pilot Studies Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects [NCT04520217]Phase 140 participants (Anticipated)Interventional2022-06-06Recruiting
[NCT00000390]Phase 20 participants InterventionalCompleted
Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder - Results From a Long-term Nation-wide Population-based Study Emulating a Randomized Trial [NCT05952713]73,336 participants (Actual)Observational2022-10-01Completed
The Efficacy of Imipramine in Treatment of Functional Dyspepsia: A Double Blind Randomized Placebo Controlled Trial [NCT00164775]Phase 3107 participants (Actual)Interventional2005-06-30Completed
Early Information Processing in Healthy Controls: Studies on the Relation Between Two Different Paradigms (PPI and P50ERP) and Effects of Pharmacological Interventions [NCT00206999]20 participants (Actual)Interventional2004-09-30Completed
[NCT00000464]Phase 30 participants Interventional1987-04-30Completed
[NCT00000518]Phase 30 participants Interventional1985-07-31Completed
Photodynamic Therapy and Microvesicles [NCT03960125]Early Phase 10 participants (Actual)Interventional2021-03-29Withdrawn(stopped due to The PI decided to move in another direction with his research.)
Medication Treatment Following Neuropsychologic, Dichotic and f-MRI Tests in Depressed Outpatients With Repeat f-MRI Following Treatment [NCT00296777]Phase 428 participants (Actual)Interventional2004-12-31Completed
Efficacy of Imipramine for Treatment of Patients With Esophageal [NCT01753128]Phase 383 participants (Actual)Interventional2012-12-31Completed
Pilot Studies Testing the Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy [NCT05688904]Phase 124 participants (Anticipated)Interventional2023-01-19Recruiting
Effect of Single Dose Imipramine on the Urethral and Anal Sphincter in Healthy Women Measured With Urethral Pressure Reflectometry (UPR) and Anal Acoustic Reflectometry (AAR) [NCT03102645]Phase 116 participants (Actual)Interventional2017-05-16Completed
A Pre-Surgical Window of Opportunity Trial Investigating the Effect of Imipramine on Previously Untreated Breast Cancer (CTMS# 17-0037) [NCT03122444]Early Phase 117 participants (Actual)Interventional2019-07-05Completed
[NCT00004834]326 participants Interventional1998-05-31Completed
Efficacy of Interpersonal Psychotherapy in Treatment Resistant Depression [NCT01896349]74 participants (Anticipated)Interventional2013-04-30Recruiting
Comparisons of the Impact of Duloxetine Versus Imipramine on Therapeutic Efficacy in Women With Stress Urinary Incontinence: a Randomized Controlled Study. [NCT05677295]Phase 390 participants (Anticipated)Interventional2023-04-18Recruiting
A Clinical Approach to Validate the Biological Significance of LPC16:0 as a Discriminating and Pathogenic Biomarker of Fibromyalgia [NCT04832100]400 participants (Anticipated)Observational2017-08-01Recruiting
Efficacy of Hydroxyzine Versus Treatment as Usual for Panic Disorder: An Eight-Week, Open Label, Pilot, Randomized Controlled Trial. [NCT05737511]Phase 480 participants (Anticipated)Interventional2023-12-30Not yet recruiting
Psychophysiological Interactions in Non-Cardiac Chest Pain [NCT00005575]Phase 30 participants Interventional1999-01-31Completed
Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567]Phase 3407 participants (Actual)Interventional2015-01-31Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00296725 (2) [back to overview]Hamilton Depression Scale (HAM-D)
NCT00296725 (2) [back to overview]Number of Participants With Positive Response as Assessed by the Clinical Global Impression -Global Improvement Scale (CGI-I)
NCT00404755 (2) [back to overview]Clinical Global Impression Scale (CGI)
NCT00404755 (2) [back to overview]Hamilton Depression Scale (HAM-D)
NCT01028014 (3) [back to overview]Difference (Pre - Post) in Amplitude (Microvolts) of Urethral Sphincter Activity as Measured by Quantitative Concentric Needle EMG
NCT01028014 (3) [back to overview]Difference (Pre - Post) in Maximum Urine Flow Rate (Qmax) (Milliliters Per Second) as Measured by Pressure Flowmetry
NCT01028014 (3) [back to overview]Difference (Pre - Post) in Urethral Sensation (Milliamps) as Measured by Current Perception Threshold Testing.
NCT01107353 (1) [back to overview]Bioequivalence Determined by Statistical Comparison Cmax
NCT03102645 (2) [back to overview]Anal Opening Pressure (AOP)
NCT03102645 (2) [back to overview]Urethral Opening Pressure (UOP)

Hamilton Depression Scale (HAM-D)

"The HAM-D is a commonly used measure of the severity of depression. While several versions exist consisting of different numbers of items, virtually all include the original 17. Each item is scored from on a 3 or 5 point scale (so, from 0-2 or 0-4), with 0 indicating the item is not present and the highest item score indicating it is present nearly all the time to the severest extent. Item scores are added to obtain a total HAM-D score. Minimum possible score is 0 (indicating none of the 17 items is present), maximal possible score is 52. By convention, scores of <=7 are accepted as indicating remission and scores that have decreased >= 50% from pre-treatment indicate positive response. Higher scores indicate worse depression, while lower scores indicate milder depression or lack of depressive symptoms." (NCT00296725)
Timeframe: 6 weeks

Interventionscore on a scale (Mean)
Fluoxetine10
Imipramine9

[back to top]

Number of Participants With Positive Response as Assessed by the Clinical Global Impression -Global Improvement Scale (CGI-I)

"The CGI consists of two ratings: 1) Global Severity (CGI-S) and 2) Global Improvement (CGI-I), both having seven possible ratings, each from 1-7. Ratings on the CGI-S are: 1=No psychopathology 2=Minimal psychopathology 3=Mild psychopathology 4=Moderate psychopathology 5=Moderately severe psychopathology 6=Severe psychopathology 7 Extreme psychopathology. CGI-I ratings are rated for how the past week's psychopathology compares to the week immediately prior to start of treatment and includes: 1=Very much improved 2=much improved 3=minimally improved 4=Unchanged 5=minimally worse 6=much worse 7=very much worse. Scores on both thus range from 1-7 with lower scores indicating less psychopathology/greater improvement, respectively, and higher scores indicating more psychopathology/less improvement, respectively. We define response as a CGI-I of 1 or 2; nonresponse is all other ratings (i.e., CGI-I = 3 or higher." (NCT00296725)
Timeframe: 6 weeks.

InterventionParticipants (Count of Participants)
Fluoxetine7
Imipramine4

[back to top]

Clinical Global Impression Scale (CGI)

"The CGI is a standard measure of global psychopathology. CGI-severity scores rated on a 7-point scale, with the severity of illness scale using a range of responses from~1 (normal) through to 7 (amongst the most severely ill patients). CGI-improvement scores range from 1 (very much improved) through to 7 (very much worse)." (NCT00404755)
Timeframe: 6 weeks or last visit in Phase

Interventionunits on a scale (Mean)
Bupropion2.65
Escitalopram2.73
Imipramine2.67

[back to top]

Hamilton Depression Scale (HAM-D)

Hamilton Depression Scale, 21 item version Summary of all 21 items and higher score means worse depression. Scores range from 0 to a maximum of 63. (NCT00404755)
Timeframe: 6 weeks or last visit in Phase

Interventionunits on a scale (Mean)
Bupropion11.2
Escitalopram9.7
Imipramine11.3

[back to top]

Difference (Pre - Post) in Amplitude (Microvolts) of Urethral Sphincter Activity as Measured by Quantitative Concentric Needle EMG

Concentric needle EMG was used to measure urethral sphincter activity at 2-3 sites around the urethral meatus before and after 2 weeks of therapy with one of 6 randomly assigned medications. Two methods of quantitative electromyography were performed on all subjects. (1) Multi-Motor Unit Action Potential (MUP) analysis, which has been shown to be the most sensitive technique in distinguishing neuropathic from control muscles; and (2) interference pattern analysis (IPA) which reflects changes in MUP recruitment from weak effort to maximal contraction. (NCT01028014)
Timeframe: 2 weeks

Interventionmicrovolts (Median)
Pseudoephedrine 120mg ER Daily-18
Solifenacin 5mg Daily10
Tamsulosin 0.4mg Daily11
Imipramine 25mg Daily-15
Cyclobenzaprine 10mg Daily12
Lactose Capsules, One Daily36

[back to top]

Difference (Pre - Post) in Maximum Urine Flow Rate (Qmax) (Milliliters Per Second) as Measured by Pressure Flowmetry

Pressure Flowmetry was used to measure maximum urine flow rate (Qmax)before and after 2 weeks of therapy with one of 6 randomly assigned medications. A 300 cc bladder fill was performed through the catheter, the catheter was removed, and transurethral and transrectal pressure transducers were placed for the pressure flow study. Voiding was performed in the seated position. Information obtained for the database included Qmax, average flow rate, time to Qmax, detrusor pressure at maximum flow rate, voided volume, and a calculated post-void residual. (NCT01028014)
Timeframe: 2 weeks

Interventionmilliliters per second (Median)
Pseudoephedrine 120mg ER Daily-7.3
Solifenacin 5mg Daily5.0
Tamsulosin 0.4mg Daily-5.6
Imipramine 25mg Daily-6.6
Cyclobenzaprine 10mg Daily10.3
Lactose Capsules, One Daily10.4

[back to top]

Difference (Pre - Post) in Urethral Sensation (Milliamps) as Measured by Current Perception Threshold Testing.

Current Perception Threshold testing was used to measure urethral sensation before and after 2 weeks of therapy with one of 6 randomly assigned medications. We performed CPT testing in the urethra using a Neurometer®, which is a constant current stimulator capable of delivering sine wave electrical stimuli at 3 frequencies (2000 Hz, 250 Hz and 5 Hz). At all 3 frequencies, the stimulus intensity was gradually increased until first perceived, and then decreased until no longer perceptible. CPT values were obtained using a semi-automated forced choice paradigm. (NCT01028014)
Timeframe: 2 weeks

InterventionMilliamps (Median)
Pseudoephedrine 120mg ER Daily0.06
Solifenacin 5mg Daily0.06
Tamsulosin 0.4mg Daily-0.8
Imipramine 25mg Daily-0.12
Cyclobenzaprine 10mg Daily0.0
Lactose Capsules, One Daily0.03

[back to top]

Bioequivalence Determined by Statistical Comparison Cmax

Blood samples were collected pre-dose and at intervals over 120 hours after each dose (NCT01107353)
Timeframe: 33 Days

Interventionng/mL (Mean)
First Imipramine Pamoate, Then Tofranil-PM11.5
First Tofranil PM, Then Imipramine Pamoate11.3

[back to top]

Anal Opening Pressure (AOP)

Mean change in AOP (baseline and 1 hour after drug administration). Measured with Anal Acoustic Reflectometry (AAR). (NCT03102645)
Timeframe: Immediately before drug/placebo administration (baseline) and 1 hour after drug/placebo administration on both study days.

InterventioncmH2O (Mean)
Imipramine12.11873
Placebo-2.989054

[back to top]

Urethral Opening Pressure (UOP)

Mean change in UOP (baseline and 1 hour after drug administration). Measured with Urethral Pressure Reflectometry (UPR). (NCT03102645)
Timeframe: Immediately before drug/placebo administration (baseline) and 1 hour after drug/placebo administration on both study days.

InterventioncmH2O (Mean)
Imipramine2.90411
Placebo-3.623431

[back to top]